

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|--|-----------|--|
| <p>(51) International Patent Classification ⁶ : C07K 7/00, 7/06, 7/08, 14/00, A61K 38/08, 38/10, 38/16</p> | <p>A1</p> | <p>(11) International Publication Number: WO 95/17420 (43) International Publication Date: 29 June 1995 (29.06.95)</p> |
| <p>(21) International Application Number: PCT/US94/13885 (22) International Filing Date: 2 December 1994 (02.12.94) (30) Priority Data: 172,002 22 December 1993 (22.12.93) US (60) Parent Application or Grant (63) Related by Continuation US 08/172,002 (CON) Filed on 22 December 1993 (22.12.93) (71) Applicants (for all designated States except US): TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION [US/US]; Broad Street and Montgomery Avenue, Philadelphia, PA 19122 (US). THOMAS JEFFERSON UNIVERSITY [US/US]; 1020 Locust Street, Philadelphia, PA 19107 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): WALSH, Peter, N. [US/US]; 544 West Hortter Street, Philadelphia, PA 19119 (US). BAGLIA, Frank, A. [US/US]; 306 Marplewoods Drive, Springfield, PA 19140 (US). JAMESON, Bradford,</p> | | <p>A. [US/US]; 810 West Sedgewick Street, Philadelphia, PA 19119 (US). (74) Agent: MONACO, Daniel, A.; Seidel, Gonda, Lavorgna & Monaco, P.C., Suite 1800, 2 Penn Center Plaza, Philadel- phia, PA 19102 (US). (81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KP, KR, KZ, LK, LR, LT, LU, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ). Published <i>With international search report.</i></p> |
| <p>(54) Title: PEPTIDE ANALOGS OF THE ACTIVATED PLATELET BINDING SITE ON FACTOR XI (57) Abstract Synthetic peptide analogs of human factor XI are provided which are conformationally restricted by means of intramolecular bonding</p> | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|--|----|--------------------------|
| AT | Austria | GB | United Kingdom | MR | Mauritania |
| AU | Australia | GE | Georgia | MW | Malawi |
| BB | Barbados | GN | Guinea | NE | Niger |
| BE | Belgium | GR | Greece | NL | Netherlands |
| BF | Burkina Faso | HU | Hungary | NO | Norway |
| BG | Bulgaria | IE | Ireland | NZ | New Zealand |
| BJ | Benin | IT | Italy | PL | Poland |
| BR | Brazil | JP | Japan | PT | Portugal |
| BY | Belarus | KE | Kenya | RO | Romania |
| CA | Canada | KG | Kyrgyzstan | RU | Russian Federation |
| CF | Central African Republic | KP | Democratic People's Republic of Korea | SD | Sudan |
| CG | Congo | KR | Republic of Korea | SE | Sweden |
| CH | Switzerland | KZ | Kazakhstan | SI | Slovenia |
| CI | Côte d'Ivoire | LJ | Liechtenstein | SK | Slovakia |
| CM | Cameroon | LK | Sri Lanka | SN | Senegal |
| CN | China | LU | Luxembourg | TD | Chad |
| CS | Czechoslovakia | LV | Latvia | TG | Togo |
| CZ | Czech Republic | MC | Monaco | TJ | Tajikistan |
| DE | Germany | MD | Republic of Moldova | TT | Trinidad and Tobago |
| DK | Denmark | MG | Madagascar | UA | Ukraine |
| ES | Spain | ML | Mali | US | United States of America |
| FI | Finland | | | UZ | Uzbekistan |

- 1 -

PEPTIDE ANALOGS OF THE ACTIVATED PLATELET BINDING
SITE ON FACTOR XI

Field of the Invention

5 The invention relates to synthetic peptide analogs
of factor XI heavy chain.

Background of the Invention

Factor XI.

10 Human factor XI is a plasma glycoprotein that
participates in the contact phase of blood coagulation.
Fujikawa et al., Biochemistry 25, 2417-2424 (1986) (incorpo-
rated herein by reference) disclose the amino acid sequence
of factor XI, deduced from the sequence of a cDNA insert
15 coding for factor XI.

Factor XI circulates in plasma as a complex with
its nonenzymatic cofactor, high molecular weight kininogen.
The complex of factor XI and kininogen can become bound to
an anionic surface, where factor XI can be activated by
20 factor XIIa. An example of an anionic surface to which the
complex can become bound is an activated platelet surface.
When zinc ions are present, the complex binds specifically
to high affinity, saturable receptors on activated platelets.

If factor XI of the complex becomes bound to an
25 activated platelet, rates of factor XI activation by XIIa can

The heavy chain contains four tandem repeat sequences (designated A1, A2, A3 and A4), comprising four separate domains. Factor XIa of the complex remains bound to the activated platelet site and recognizes factor IX as its normal macromolecular substrate. Factor XIa catalyzes the activation of factor IX, which can lead to intrinsic coagulation.

Analysis of rates of factor IX activation by platelet-bound and unbound factor XIa indicates that these reaction rates are nearly identical. However, platelet-bound factor XIa is protected from inhibition by both plasma and platelet derived inhibitors.

Two inhibitors of factor XIa enzymatic activity in human plasma are the serpins, α -1-proteinase inhibitor and antithrombin III. Two other inhibitors are protease nexin II, which is a truncated form of the transmembrane Alzheimer's amyloid β -protein precursor, and platelet inhibitor of factor XI (PIXI), which is a low molecular weight 8,500 Da protein from platelets. None of these four inhibitors significantly inhibit platelet-bound factor XI.

Activated factor IX (factor IXa) can be produced by factor XIa enzymatic activity and can bind to a factor IX/IXa binding site on the platelet surface. Importantly, the binding of factors IX/IXa and VIIIa to their respective sites on the platelet membrane results in a twenty million-fold acceleration in the catalytic efficiency of factor X activation. Thus, platelet surface-localized factor IX activation results in enhanced intrinsic coagulation results.

The activation of factor XI and sustained expression of its enzymatic activity at the platelet surface are key biological events in hemostasis. Moreover, the binding of factor XI to the platelet surface protects it from inactivation by both plasma and platelet derived inhibitors. Bound, activated factor XI will continue its protected enzymatic activity at the platelet surface irrespective of the presence of factor XIa inhibitors. Since high molecular weight kininogen is necessary for factor XI to be efficiently bound to platelets (Sinha, *et al.* J. Clin. Invest. **73** 1550-1556, at page 1551, col. 2, ¶3, and page 1552, col. 2, ¶2 (1984)), it has been postulated that factor XI binds indi-

rectly to platelets through kininogen. See, Greengard *et al.* Biochem., 25, 3884-3890 (1986). The high molecular weight kininogen binding site on domain A1 of the factor XI heavy chain has been characterized by Baglia *et al.*, J. Biolog. Chem. 267, 4247-4252 (1992); and Baglia *et al.*, J. Biolog. Chem. 265, 4149-4154 (1990) (each incorporated herein by reference). A computer structural model useful for producing constrained peptides capable of inhibiting the binding of factor XI to high molecular weight kininogen, was also characterized. Artificially constrained peptides according to the computer model were synthesized, which correspond to amino acids 44 (Thr) to 86 (Ser) in the A1 domain of the intact factor XI heavy chain. See, Baglia *et al.* J. Biolog. Chem. 267, 4247-4252 (1992). The peptides are capable of inhibiting the binding of factor XI to high molecular weight kininogen. Examples of such peptides are SEQ ID NOS: 13, and 17-22.

Since high molecular weight kininogen is required for platelets to efficiently bind factor XI, it was not known prior to the present invention that a direct binding site for activated platelets exists in the heavy chain of factor XI. Also, the location of the site of interaction between the heavy chain of factor XI and the platelet surface has not been defined until the present invention.

Antithrombotic Therapy.

Existing methods of preventing or treating arterial and venous thrombosis involve inhibiting the blood coagulation cascade with oral anticoagulants, heparin or other anticoagulants, or alternatively by pharmacologically inhibiting platelets. For example, oral anticoagulants such as coumarin-like drugs are used to inhibit the synthesis of vitamin K-dependent proteins. They block many coagulation reactions, involving proteins such as prothrombin, factor VII, factor IX and factor X. Heparin, by potentiating the action of antithrombin III, accelerates inactivation of thrombin, factor Xa and a variety of other plasma serine proteases.

These therapeutic approaches are nonselective and inhibit coagulation reactions involved in the development of venous and arterial thrombosis while at the same time inhibiting reactions which are essential for the maintenance of normal hemostasis. Similarly, most platelet inhibitor drugs block a wide variety of platelet responses. Thus, while some drugs may be effective in preventing thrombotic processes, they can enhance the risk of bleeding. What is needed is a therapeutic agent which specifically interferes with intrinsic coagulation reactions leading to the activation of factors XI or IX, while leaving extrinsic coagulation reactions intact. This will permit normal hemostatic plug formation at sites of vascular injury, thereby minimizing the risk of bleeding during the antithrombotic therapy.

Prevention of factor XI binding to activated platelets would limit the biologically important platelet contribution to coagulation reactions. Accordingly, there is a need for antithrombotic agents which inhibit the binding of factor XI and/or factor XIa to surfaces of activated platelets.

Summary of the Invention

A synthetic peptide is provided comprising an amino acid sequence corresponding to a portion of the sequence of the binding site for activated platelets on the heavy chain of XI. The peptide has an artificially restricted conformation and the ability to inhibit the binding of factor XI to activated platelet surfaces.

In another embodiment, the invention is directed to a method of designing a peptide analog to the binding site for activated platelets on the factor XI heavy chain. The distance between two parts of a molecular model of the substrate binding site is determined at conformational equilibrium. The primary structure of the binding site is then modified to restrict that distance to the determined distance. A peptide comprising the modified primary structure is then synthesized.

- 5 -

In yet another embodiment of the invention, a method of producing a peptide having a restricted conformation is provided. Accordingly, a peptide having an amino acid sequence corresponding to a portion of the sequence of the binding site for activated platelets on the factor XI heavy chain is provided. The conformational equilibrium of that portion of the factor XI heavy chain is determined. A covalent modification is introduced into the peptide to restrict a distance between two parts of it to a distance between corresponding parts of the peptide in the equilibrium confirmation determined.

The invention further provides pharmaceutical compositions comprising one or more of the peptides according to the invention corresponding to a portion of the sequence of the binding site for activated platelets on the factor XI heavy chain, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier. Preferred pharmaceutical compositions further comprise a second synthetic peptide having an amino acid sequence corresponding to a portion of the sequence of the binding site for high molecular weight kininogen on the heavy chain of XI, or a pharmaceutically acceptable salt of the second peptide; wherein the second peptide has an artificially restricted conformation and the ability to inhibit the binding of factor XI to high molecular weight kininogen.

The invention also provides a method of inhibiting the binding of factor XI to activated platelets and factor XIa-induced activation of factor IX on a platelet surface. The activated platelets are contacted with one or more peptides of the invention, corresponding to a portion of the sequence of the binding site for activated platelets on the factor XI heavy chain, which peptide competes with factor XI in the binding of the activated platelets. Activation of factor IX on the platelet surface is thus indirectly inhibited by the peptides of the invention. Inhibition of factor IX activation on the platelet surface in turn inhibits factor IX's coagulant activity. Thus, the peptides of the invention are potent anticoagulants, having antithrombotic utility.

A preferred method for inhibiting the binding of factor XI to activated platelets and preventing the factor XIa-induced activation of factor IX on a platelet surface also comprises contacting activated platelets with a second synthetic peptide corresponding to a portion of the sequence of the binding site for high molecular weight kininogen on the heavy chain of XI, or a pharmaceutically acceptable salt of said peptide; wherein the second peptide has an artificially restricted conformation and the ability to inhibit the binding of factor XI to high molecular weight kininogen.

By "platelet binding site" or "activated platelet binding site" on factor XI heavy chain is meant the region of the intact factor XI polypeptide chain comprising from about amino acid 193 (Ala) to about amino acid 266 (Arg) of the mature polypeptide, corresponding to amino acid 13 (Ala) to amino acid 86 (Arg) of SEQ ID NO:1.

By "high molecular weight kininogen binding site" on factor XI heavy chain is meant the region of the intact factor XI polypeptide chain comprising from about amino acid 44 (Thr) to about amino acid 86 (Ser) of the mature polypeptide, corresponding to SEQ ID NO:22.

By "sequence corresponds to a portion of an identified binding site" on the factor XI heavy chain is meant a sequence which comprises a sequence segment identical to a portion of the identified binding site sequence or a sequence segment derived from a three-dimensional model of a portion of the identified binding site sequence.

Description of the Figures

A3 Domain-Derived Peptides

Figure 1 is a graph showing the effect of synthetic factor XI domain A3-derived peptides according to the invention on the binding of radio labelled factor XI to activated platelets in the presence of ZnCl_2 (25 μM), CaCl_2 (2 mM), and high molecular weight kininogen (42 nM). The binding of ^{125}I -factor XI was compared to control binding in the absence of competing peptides. The percentage of factor XI binding was then plotted against the concentration of the

synthetic peptide. The experimental protocol is set forth in detail in Example 13(d) below.

Figure 2 is a graph showing the effect of factor XI and synthetic factor XI heavy chain domain A1-, A2-, A3-, and A4-derived peptides on the binding of radiolabelled factor XI to activated platelets in the presence of ZnCl₂ (25 μM), CaCl₂ (2 mM), and high molecular weight kininogen (42 nM). The binding of ¹²⁵I-factor XI was compared to control binding in the absence of competing XI or competing peptides. The percentage of factor XI binding was then plotted against the concentration of XI or the synthetic peptide. The experimental protocol is set forth in detail in Example 13(d) below.

Detailed Description of the Invention

Four tandem repeat sequences (designated A1, A2, A3 and A4) comprising four separate domains, are present in the factor XI heavy chain. We have found that the platelet binding site on factor XI is located in the carboxy-terminal seventy-five residues of domain A3. The binding site consists of the sequence of amino acids Ala 193 to Arg 266 in the A3 domain. The sequence consists of anti-parallel β-strands connected by β-turns, forming three stem-loop structures. We have found that these three stem-loop structures together form a continuous surface which is utilized for the binding of platelets. The deduction of the platelet binding site structure was accomplished by computer modeling to calculate a testable three-dimensional structure utilizing the primary amino acid sequence and disulfide linkages within the A3 domain. The calculated structure shows that the three stem-loop structure are defined by amino acid residues Pro 229 - Gln 233, Thr 241 - Leu 246 and Ser 248 - Ser 261, which correspond to SEQ ID NO:1, amino acids 49-53, 61-66, and 68-81, respectively.

The modeled A3 domain structure is used as a design template for synthesizing peptides according to the present invention that are expected to adopt a conformational repertoire overlapping that of the native protein. The sequences identified herein from the factor XI heavy chain

sequences identified herein from the factor XI heavy chain have not been previously identified as inhibitory of XI binding to platelets, and thus inhibitory of factor IX activation on the platelet surface. The peptides of the invention, which mimic the platelet binding site on factor XI and factor XIa, are potent inhibitors on the platelet surface of the enzymatic activity of factor XIa against its macromolecular substrate, factor IX. The peptides are potent anticoagulants, which are believed useful as antithrombotic agents.

Ideally, an antithrombotic agent should interfere with intrinsic coagulation reactions leading to the activation of factors XI and IX, while leaving extrinsic coagulation reactions intact, so that normal hemostatic plug formation can occur at sites of vascular injury. The peptides of the invention, by virtue of their specificity for the platelet binding site on factor XI/XIa, are believed to inhibit factor XIa-catalyzed factor IX activation on the surface of platelets, without affecting the extrinsic pathway of blood coagulation involving factors VII, X and V, and prothrombin. The inventive peptides' inhibition of platelet binding to factor XI and subsequent effect on activated partial thromboplastin time, without effect on prothrombin time, evidences their specificity for the intrinsic coagulation pathway. Thus, it is believed that the peptides inhibit or minimize intravascular thrombus formation without sacrificing normal hemostatic plug formation.

Traditional syntheses of the linear amino acid sequence of biologically interesting proteins may result in peptides that are either biologically inactive or, at best, marginally active. We have created a molecular model of the three-dimensional structure of factor XI heavy chain domain A3. The structure created in this manner is used as a template for designing conformationally-restricted synthetic analogs having the ability to inhibit the binding of factor XI and/or XIa to platelet surfaces and thus inhibit the factor XIa-induced activation of factor IX on the surface of platelets. Using both distance and geometric constraints imparted through measurements of the subdomains within the

- 9 -

calculated structure, constraints are artificially introduced, e.g., disulfide bonds, to limit the conformational freedom of a synthetic peptide that incorporates the relevant amino acids. Certain conformationally-restricted synthetic peptide analogs having the ability to inhibit the binding of factor XI or factor XIa to platelets correspond to factor XI heavy chain residues 225-236, 229-233, 241-246 and 248-261, according to the numbering of the amino acids of the mature polypeptide. The model disclosed herein may be utilized to prepare additional conformationally-restricted synthetic peptides having similar activity.

Appendix 1 included herein contains the set of Brookhaven coordinates and connect statements specifying our equilibrium conformation model of the major portion of factor XI heavy chain domain A3 comprising the 85 amino acids spanning positions Ala 181 to Cys 265, inclusive (SEQ ID NO:1, amino acids 1-85). The remaining amino acids of the A3 segment, Arg 266 and His 267 - Phe 272 (SEQ ID NO:16), of the factor XI heavy chain were truncated. The corresponding graphic molecular model satisfying these coordinates may be

two γ carbons of VAL 11 are designated "CG 1" and "CG 2" respectively.

The data file further comprises a connect statement which begins immediately after the coordinates for atom 771. The connect statement identifies the covalent bonding pattern of each of the 771 atoms. Thus, for example, the 68th entry of the connect statement (CONNECT 68) indicates that atom 68, which is the α carbon atom PRO 8 (corresponding to amino acid 188 of the mature factor XI heavy chain sequence), is bonded to atom 67 (the nitrogen of the same residue), atom 69 (the carbonyl carbon of the same amino acid residue), and atom 71 (the β carbon of the same amino acid residue). The complete data file of 771 coordinates, together with the connect statement for these entries, specifies the equilibrium conformation of factor XI heavy chain domain A3.

The peptides of the invention generally have an amino acid sequence similar to the native domain A3 sequence in the vicinity of the platelet binding site. However, a covalent modification is artificially introduced to restrict the analog to the conformation (or one close to it) displayed by the above model. Preferably, the synthetic peptides consist essentially of peptide having from at least five to about 80 amino acid residues, which peptide has a restricted conformation. Generally, the covalent modification is accomplished by determining a distance between two non-contiguous parts of the amino acid chain according to the model. Then a chemical moiety is introduced to fix that determined distance in the analog. For example, a 5-6A distance can be fixed using a disulfide bond. Cysteine residues can be introduced at the appropriate positions in the model and then the new cysteine-containing model is tested for its ability to mimic the structure observed in the model. Alternatively, the disulfide bond can be artificially introduced by generating a disulfide bond between native cysteine residues when this will produce a polypeptide with a restricted conformation corresponding to the above model.

In constraining the peptides it is sometimes necessary to compensate for the orientation of amino acid

side chains such that torsional stress does not misalign the peptide structure. Thus, in some instances, it is desirable to employ D-Cys analogs or appropriate combinations of D-L cysteines to mimic the correct stereochemistry. In general, these peptides are then synthesized according to the standard chemistry described below.

The use of native or artificially introduced cysteine residues to create the artificially introduced disulfide bridge is one way to conformationally restrict the peptides. Disulfide bonds, however, can be intrinsically unstable and it is sometimes difficult to obtain a homogeneous solution of intradisulfide-bonded species without concomitant mixed disulfides. If a biologically active conformationally restricted peptide having a cysteine-cysteine disulfide bond tends to unfold, it may be more effective to constrain the peptide in a folded conformation via a covalent bond which is more stable than a disulfide bridge. There are several strategies which can be utilized in the covalent closure of the peptides. Two of these strategies are described below.

The peptide can be internally cross-linked via the side chains of a lysine ϵ -amino group and the carboxylic acid function of a glutamic or aspartic acid side chain, thus creating an amide bond. The peptide is synthesized according to standard procedures on a low substitution (0.2 mmol/gm or less) paramethylbenzhydrylamine resin. The first residue added to the resin is an N- α -tBOC, ϵ -fMOC lysine. The rest of the peptide synthesis is continued normally using tBOC chemistry until the final residue is added. The last residue to be added is a Z-protected glutamic acid, where the carboxylic acid moiety is protected with a tert-butyl group. Treatment of the peptide resin with piperidine/DMF removes the fMOC group from the ϵ -amino group of the initial lysine without affecting any other protection groups. Subsequent treatment with trifluoroacetic acid removes the protection of the carboxylic acid group of the glutamic acid. Following neutralization, the peptide is covalently closed using a standard diimide-mediated coupling reaction. It should be

emphasized that this is only one of the ways in which the synthetic peptide can be covalently closed.

Other Fmoc/tBOC strategies include covalent closure of the peptide between two free amino groups utilizing
5 toluene-2,4-diisocyanate (TDI), a heterobifunctional cross-linker. The methyl group of the aromatic ring of TDI prevents the isocyanate group in the 2 position from reacting at a pH 7.5 or below, whereas the isocyanate group in the para position is highly reactive. A shift in pH to greater
10 than 9.0 will initiate a reaction with the isocyanate group in the 2 position, thus enabling highly specific and controlled conditions for covalent closure of the peptide.

By utilizing a variety of different strategies for restricting the conformation of peptides, distance geometries
15 and orientation of the folded peptide can be controlled. Any such strategies employing chemical reactions known in the art may be used.

Using these techniques, synthetic peptide analogs can be made and tested for their ability to inhibit factor
20 XI binding to platelets and factor XIa-induced activation of factor IX on the platelet surface. Particularly useful peptide analogs which were derived using the techniques described herein comprise amino acids 181-265, 191-266, 193-199, 226-235, 229-233, 235-266, 241-246, 248-253 and 248-261
25 of the factor XI heavy chain.

The 181-265, 191-266 and 235-266 peptides have an amino acid sequence identical to segments of the native factor XI sequence, i.e., SEQ ID NO:1 amino acids 1-85 and 8-86, and SEQ ID NO:2, respectively. Each of the three
30 peptides has at least one artificially introduced disulfide bond, i.e., between their cysteine residues corresponding to positions 242 and 265 in the factor XI mature polypeptide chain. The disulfide bond is artificially introduced in the peptide chain by a chemical reaction step after the synthetic
35 peptide is made and purified.

The 193-199, 226-235, 229-233, 241-246 and 248-261 are identical in sequence to the corresponding sequence of native factor XI, except for two modifications in each molecule. In the 193-199 peptide, Ala 193 and Ser 199 were

replaced by cysteine residues to generate SEQ ID NO:12. This modified 193-199 peptide is designated "Ala 193(C) - Ser 199(C)" to distinguish it from the native 193-199 peptide. In each of the 226-235, 229-233, 241-246 and 248-261 peptides, the first-numbered and last-numbered amino acids were replaced by cysteine residues to generate SEQ ID NOS:11, 9, and 8, and D-Cys-(SEQ ID NO:7)-Cys, respectively. As in the designation of the modified 193-199 peptide, the modified peptides corresponding to each of the 226-235, 229-233, 241-246 and 248-261 peptides, are listed with their native first-numbered and last-numbered amino acids followed by a "(C)" to indicate that the native amino acids have been replaced by cysteine residues. The "(C)" after the amino acid number distinguishes the modified peptides from the native sequence peptides to which they correspond.

In the 248-253 peptide, Ser 248 was replaced by a cysteine residue, a glycine residue was inserted between amino acid Lys 252 and Lys 253, and Lys 253 was replaced by a cysteine residue to generate SEQ ID NO:10. This modified 248-253 peptide is designated "Ser 248(C) -Lys 253(G - C)" to distinguish it from the native 248-253 peptide.

All eight peptides were restricted conformationally using cysteine-cysteine disulfide bonds, but other restricting means may be advantageously used. Each peptide inhibits the activation of factor IX by factor XIa, and, as a consequence, may be used to inhibit the procoagulant function of factor XIa. Methods of assaying factor XI binding to platelets are known in the art. One such method is described hereinafter in Example 10(d).

The present peptides are relatively short in length and therefore they are easily synthesized by chemical means. Such synthetic peptides have many advantages over the use of the entire A3 domain, or the entire factor XI heavy chain. Large portions of the heavy chain cannot conveniently be made by synthetic techniques and must be made by recombinant DNA techniques, which are expensive and time consuming. Additionally, larger proteins may be insoluble, or may be immunogenic when introduced into a patient. Shorter synthet-

ic peptides may be more soluble and less immunogenic than larger proteins.

As used herein, "peptide" refers to a linear series of no more than about eighty (80) amino acid residues connected to one another by peptide bonds between the alpha-amino groups and carboxy groups of adjacent amino acid residues. Additional covalent bonds between portions of the peptide are also present to restrain the conformation of the molecule, such as amide and disulfide bonds. The term "synthetic peptide" means a chemically derived chain of amino acid residues linked together by peptide bonds that is free of naturally occurring proteins and fragments thereof.

The term "homology" as describing the relationship between two amino acid sequences means the extent to which the sequences, viewed from the N-terminal to the C-terminal direction, have segments of their sequences which are identical and which occur in the same N-terminal to C-terminal order in the overall sequence. The synthetic peptides according to the invention have an amino acid sequence which is the same as that of the native amino acid sequence, but for inserted, deleted, or interchanged (one or more amino acids is substituted for the same number of other amino acids) portions.

The degree of amino acid sequence homology between the amino acid sequence of a synthetic peptide according to the invention and that of the native peptide is expressed as a percentage. This percentage is obtained by determining the number of amino acids in the sequence of the synthetic peptide which occur in segments that are identical to segments of the native amino acid sequence and which occur in the same N-terminal to C-terminal order as the native segments, divided by the total number of amino acids in the native sequence.

A "substantial amino acid sequence homology" is any amino acid sequence homology greater than 30 percent. Preferably the homology is greater than 80 percent, most preferably greater than 90 percent.

Peptides of the present invention include any analog, fragment or chemical derivative of the peptides capable of inhibiting the binding of factor XI and/or XIa binding to

platelets. The term "analog" includes any peptide having substantial amino acid sequence homology to the peptides of the invention in which one or more amino acids have been substituted with other amino acids, and the substituted amino acids allow or require the peptide to assume the equilibrium conformation of the domain of the parent protein. Often, cysteine, lysine and glutamic acid will be used for their side chains which can form covalent linkages to restrict the conformation of a peptide. In addition, conservative amino acid changes may be made which do not alter the biological function of the peptide. For instance, one polar amino acid, such as glycine, may be substituted for another polar amino acid; or one acidic amino acid, such as aspartic acid may be substituted for another acidic amino acid, such as glutamic acid; or a basic amino acid, such as lysine, arginine or histidine may be substituted for another basic amino acid; or a non-polar amino acid, such as alanine, leucine or isoleucine may be substituted for another non-polar amino acid.

The term "analog" shall also include any peptide which has one or more amino acids deleted from or added to an amino acid sequence identical to that of native fragment of the amino acid sequence of factor XI heavy chain domain A3, but which still retains a substantial amino acid sequence homology to the platelet binding site on factor XI or factor XIa, as well as the ability to inhibit the binding of platelets to factor XI or factor XIa.

The term "fragment" shall refer to any shorter version of the peptides identified herein having at least five amino acid residues, wherein the fragment is a synthetic peptide which is capable of inhibiting the binding of platelets to factor XI or factor XIa.

The three-letter symbols used to represent the amino acid residues in the peptides of the present invention are those symbols commonly used in the art. The amino acid residues are preferred to be in the "L" isomeric form. However, residues in the "D" isomeric form may be substituted for any L-amino acid, as long as the desired functional property of inhibition of factor XIa-induced factor IX activation is retained by the peptide. The three-letter symbols used

herein refer to the following amino acids: Ser is serine; Ile is isoleucine; Gln is glutamine; Phe is phenylalanine; His is histidine; Trp is tryptophan; Lys is lysine; Asn is asparagine; Leu is leucine; Gly is glycine; Thr is threonine; Asp is aspartic acid; Arg is arginine; and Ala is alanine.

The peptides of the present invention may be prepared by any of the following known techniques. Conveniently, the peptides may be prepared using the solid-phase synthetic technique initially described by Merrifield, in J. Am. Chem. Soc. 15, 2149-2154 (1963). Other peptide synthesis techniques may be found, for example, in M. Bodanszky et al., Peptide Synthesis, John Wiley & Sons, 2d Ed. (1976); Kent and Clark-Lewis in Synthetic Peptides in Biology and Medicine, eds. Alitalo, K., Partanen, P. and Vakeri, A., (Elsevier Science Publishers, Amsterdam, 1985) p. 295-58; as well as other reference works known to those skilled in the art. A summary of peptide synthesis techniques may be found in J. Stuart and J.D. Young, Solid Phase Peptide Synthesis, Pierce Chemical Company, Rockford, IL (1984). The synthesis of peptides by solution methods may also be used, as described in The Proteins, vol II, 3d Ed., Neurath, H. et al., Eds., p. 105-237, Academic Press, New York, NY (1976). Appropriate protective groups for use in such syntheses will be found in the above texts as well as in J. F. W. McOmie, Protective Groups in Organic Chemistry, Plenum Press, New York, NY (1973). Of course, the present peptides may also be prepared by recombinant DNA techniques. But, such methods are not preferred because of the need for purification and subsequent chemical modifications to conformationally restrain the peptides.

In general, these synthetic methods involve the sequential addition of one or more amino acid residues or suitably protected amino acid residues to a growing peptide chain. Normally, either the amino or carboxyl group of the first amino acid residue is protected by a suitable, selectively-removable protecting group. A different, selectively-removable protecting group is utilized for amino acids containing a reactive side group, such as lysine.

Using a solid phase synthesis as an example, the protected or derivatized amino acid is attached to an inert solid support through its unprotected carboxyl or amino group. The protecting group of the amino or carboxyl group is then selectively removed and the next amino acid in the sequence having the complementary (amino or carboxyl) group suitably protected is admixed and reacted under conditions suitable for forming the amide linkage with the residue already attached to the solid support. The protecting group of the amino or carboxyl group is then removed from this newly added amino acid residue, and the next amino acid (suitably protected) is then added, and so forth. After all the desired amino acids have been linked in the proper sequence, any remaining terminal and side group protecting groups (and solid support) are removed sequentially or concurrently, to provide the final peptide. The peptides of the invention are devoid of benzylate or methylbenzylated amino acids. Such protecting group moieties may be used in the course of synthesis, but they are removed before the peptides are used. Additional reactions may be necessary, as described elsewhere, to form intramolecular linkages to restrain conformation.

The A3 domain-derived peptides of the present invention generally contain at least five (5) amino acid residues and up to eighty (80) amino acid residues, preferably from about five (5) to about forty-five (45) amino acid residues, and as small as about five (5) to about twenty (20) amino acids. These peptides may be linked to an additional sequence of amino acids either or both at the N-terminus and at the C-terminus, wherein the additional sequences are from 1-100 amino acids in length. Such additional amino acid sequences, or linker sequences, can be conveniently affixed to a detectable label or solid matrix, or carrier. Typical amino acid residues used for linking are tyrosine, cysteine, lysine, glutamic acid and aspartic acid, or the like.

As described above, the A3 domain-derived peptides according to the invention directly inhibit the binding of platelets to factor XI or factor XIa by competing with factor XI for binding sites on the platelet surface. Furthermore,

high molecular weight binding to factor XI has been observed to insure the efficiency of factor XI binding to platelets, Sinha, et al. J. Clin. Invest. 73 1550-1556, at 1552, col. 2, ¶2 (1984). Factor XI heavy chain A1 domain-derived peptides, are known to inhibit the binding of factor XI or factor XIa to high molecular weight kininogen, thereby indirectly inhibiting the binding of factor XI/XIa to the platelet surface. A3 domain-derived peptides of the invention may be combined with A1 domain-derived peptides to provide a dual effect.

The dual effect is attained when platelets are treated with A3 domain-derived peptides and high molecular weight kininogen is treated with A1 domain-derived peptides prior to adding factor XI/XIa to the platelets and kininogen. The A3 domain peptides directly inhibit factor XI/XIa binding to platelets by competing with intact factor XI/XIa. The A1 domain-derived peptides indirectly inhibit factor XI/XIa binding to platelets by inhibiting high molecular weight kininogen binding to factor XI/XIa.

A1 Domain-Derived Peptides

Baglia et al., J. Biolog. Chem. 267, 4247-4252 (1992); and Baglia et al., J. Biolog. Chem. 265, 4149-4154 (1990) have characterized the high molecular weight kininogen binding site on the domain A1 of the factor XI heavy chain. A computer structural model useful for producing constrained peptides capable of inhibiting the binding of factor XI and high molecular weight kininogen and examples of peptides which compete with factor XI for binding to kininogen were described. Artificially constrained synthetic peptides corresponding to amino acids 44 (Thr) to 86 (Ser) of the intact factor XI heavy chain and constrained active analogs, which are capable of inhibiting the binding of factor XI and high molecular weight kininogen by competing with factor XI for binding to kininogen, were also characterized. Examples of such peptides which inhibit the binding of factor XI and high molecular weight kininogen have amino acid sequences as set forth in SEQ ID NOS: 13, and 17-22.

The modeled A1-domain structure is used as a design template for synthesizing peptides that are expected

to adopt a conformational repertoire overlapping that of the native protein in the same manner as described for the modeled A3-domain structure. The model for the A1-domain structure disclosed herein may be utilized to prepare additional conformationally-restricted synthetic peptides having similar activity to the A1-domain derived synthetic peptides described above. Such synthetic A1-domain derived conformationally restricted peptides may be prepared, modified and constrained in essentially the same manner as described above for the A3 domain-derived peptides according to the invention.

Appendix 2 included herein contains the set of Brookhaven coordinates and connect statements specifying the equilibrium conformation model of Baglia *et al.*, J. Biolog. Chem. 267, 4247-4252 (1992) (incorporated herein by reference) which characterizes the structure of the high molecular weight kininogen binding site corresponding to amino acids 44 (Thr) to 85 (Ser) of the intact factor XI heavy chain. The major portion of factor XI heavy chain domain A1 comprising the 85 amino acids spanning positions Glu 1 to Cys 85, inclusive (SEQ ID NO:23) is utilized. The corresponding graphic molecular model satisfying these coordinates may be generated by inputting the coordinates and connect statement into any of the many commercially available molecular modeling programs which are capable of reading files in the Brookhaven format.

The A1 domain-derived peptide is preferably a synthetic peptide comprising an amino acid sequence from at least five to about fifty amino acids in length, which corresponds to a portion of the sequence of the binding site for high molecular weight kininogen on the heavy chain of XI. The A1 domain-derived peptide has an artificially restricted conformation and the ability to inhibit the binding of factor XI to high molecular weight kininogen. Particularly preferred A1 domain-derived peptides comprise at least one amino acid sequence selected from the group consisting of SEQ ID NO:13 and SEQ ID NOS: 17-22.

Preferably the restricted conformation of the A1 domain-derived peptide is determined from the equilibrium

conformation model comprising the set of coordinates and connect statements of Appendix 2. The restricted conformation may be provided in the same manner as for the A3 domain-derived peptides.

5

Pharmaceutical Salts of Peptides

The A3 domain-derived peptide of the present invention and the A1 domain-derived peptide may be used in the form of a pharmaceutically acceptable salt. Suitable acids which are capable of forming salts with the peptides include inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, phosphoric acid and the like; and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, anthranilic acid, cinnamic acid, naphthalene sulfonic acid, sulfanilic acid or the like.

Suitable bases capable of forming salts with the peptides include inorganic bases such as sodium hydroxide, ammonium hydroxide, potassium hydroxide and the like; and organic bases such as mono-, di- and tri-alkyl and aryl amines (e.g., triethylamine, diisopropyl amine, methyl amine, dimethyl amine and the like) and optionally substituted ethanolamines (e.g., ethanolamine, diethanolamine and the like).

Pharmaceutical Compositions

For use in a method of treatment, such as treatment for inhibiting the binding of platelets to factor XI or XIa and/or inhibiting the coagulant activity of factor XIa on the platelet surface, one or more of the synthetic A3 domain derived peptides of the present invention may be present in a pharmaceutical composition in admixture with a pharmaceutically acceptable carrier.

Preferred pharmaceutical compositions for inhibiting the binding of platelets to factor XI or factor XIa in a mammal also include a second peptide which inhibits the binding of factor XI or factor XIa to high-molecular weight kininogen to inhibit the binding of factor XI or factor XIa

to the platelet surface. The second peptide is an artificially constrained A1 domain-derived synthetic peptide as described above.

The pharmaceutical composition may be compounded according to conventional pharmaceutical formulation techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., sublingual, rectal, nasal, oral or parenteral. Compositions for oral dosage form may include any of the usual pharmaceutical media, such as, for example, water, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations (e.g., suspensions, elixirs and solutions) or carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations (e.g., powders, capsules and tablets). Controlled release forms may also be used. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar coated or enteric coated by standard techniques.

For compositions to be administered parenterally, the carrier will usually comprise sterile water, although other ingredients to aid solubility or for preservation purposes may be included. Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed. The parenteral routes of administration may be intravenous injection, intramuscular injection or subcutaneous injection.

For intravenous administration, the peptides may be dissolved in an appropriate intravenous delivery vehicle containing physiologically compatible substances such as sodium chloride, glycine and the like, having a buffered pH compatible with physiologic conditions. Such intravenous delivery vehicles are known to those skilled in the art.

It is contemplated that the A3 domain-derived peptides of the present invention, both alone or in combination with the A1 domain-derived peptides, have utility as

anticoagulant and/or antithrombotic agents. It is contemplated that the A3 domain-derived peptides, both alone or in combination with the A1 domain-derived peptides, may be administered to patients either at risk for developing arterial or venous thrombosis, or to patients with established thromboembolism to prevent extension of the thrombi. For example, it is contemplated that the A3 domain-derived peptides and optionally the A1 domain-derived peptides may find utility in the prevention and treatment of deep venous thrombosis and pulmonary embolism, treatment and prevention of cerebral vascular thromboembolism, the treatment and prevention of systemic arterial thrombosis and embolism, and the treatment and possibly the prophylaxis of established disseminated intravascular coagulation. Patients suffering from transient ischemic attacks are, in particular, at increased risk of brain damage through thrombus formation.

In particular, it is contemplated that the synthetic peptides will find utility in the prevention of rethrombosis following lytic therapy. While lytic agents such as tissue plasminogen activator, urokinase and streptokinase have been utilized to dissolve vascular thrombi, their use is associated with a significant rate of rethrombosis, about 20-30%. This is because lytic therapy results in the exposure of a thrombogenic site, at the location of the prior thrombus. While lytic agents are effective in dissolving vascular thrombi, they offer no protection from clot reformation. The A3 domain-derived peptides of the present invention, alone or in combination with the A1 domain-derived peptides are expected to possess substantial rethrombosis inhibiting activity, by virtue of their inhibition of the binding of platelets to factor XI or factor XIa and thus inhibition of factor XIa-induced activation of factor IX on the platelet surface, are expected to possess substantial rethrombosis inhibiting activity. The peptides may thus be administered as an adjuvant to lytic therapy to prevent reformation of dissolved vascular thrombi.

The A3 domain-derived type and A1 domain-derived peptides, which respectively directly and indirectly inhibit the binding of factor XI/XIa to a platelet surface, may be

administered by any convenient means which will result in the delivery of each peptide type to the bloodstream in an amount effective to inhibit the binding of factor XI and/or factor XIa to platelets. Intravenous administration is presently contemplated as the preferred administration route. The amount administered will depend on the activity of the particular compound administered, which may be readily determined by those of ordinary skill in the art. The amount may also vary depending on the nature and extent of the lesion which is to be protected from rethrombosis; the size and weight of the patient; the route of administration, the age, sex and health of the patient; and other factors. Generally, the A3 domain-derived and A1 domain-derived peptides may each be administered in an amount sufficient to individually or collectively provide a plasma concentration in the range of from about 10^{-9} to about 10^{-5} M, more preferably in the range of from about 1×10^{-8} to about 5×10^{-6} M. Plasma concentrations higher or lower than these may be utilized, depending upon the activity of the particular compound being administered, and the nature of the treatment.

It may be appreciated that a single bolus injection of 1 mg of each of the two types of peptides per kilogram of treated subject body weight would achieve a maximum in vivo plasma concentration of 100 nM for each peptide type, assuming 100% recovery of drug. It is therefore contemplated that bolus administration will comprise a dosage of from about 0.1 mg to about 1 gram of each peptide type, per kilogram subject body weight. The bolus administration is most advantageously followed by a continuous infusion of each type of peptide, or a mixture of the two types of peptides, as needed. The amount of each peptide type continuously infused depends on the approximate half-life of that peptide in the circulation. Those skilled in the art would, for any factor XI- or factor XIa- platelet-binding-inhibiting peptide and for any peptide inhibiting heavyweight kininogen binding to factor XI or factor XIa, be able readily to determine the half-life from routine experimentation.

Therefore, a preferred method for inhibiting thrombosis comprises administering to a mammal in need of such treatment an effective amount of

5 i) an A3 domain-derived synthetic peptide according to the invention corresponding to a portion of the sequence of the binding site for activated platelets on the factor XI heavy chain, which has an artificially restricted conformation and the ability to compete with factor XI in the binding of the activated platelets, or a pharmaceutically acceptable salt of said A3 domain-derived peptide; and

10 ii) an A1 domain-derived synthetic peptide corresponding to a portion of the sequence of the binding site for high molecular weight kininogen on the heavy chain of XI, which A1 domain-derived peptide has an artificially restricted conformation and the ability to inhibit the binding of factor XI to high molecular weight kininogen, or a pharmaceutically acceptable salt of said A1 domain-derived peptide.

20 The A3 domain-derived peptides of the invention, either alone, or in combination with an A1 domain-derived peptide, inhibit the activated partial thromboplastin time without affecting the prothrombin time. According to one exemplary treatment protocol, an amount of each of the A3 domain-derived peptide and A1 domain-derived peptide, shown effective by the in vitro assay described elsewhere herein, is administered to a patient by bolus administration and/or continuous infusion. The potency of each peptide, or the combination, and its clearance from the circulation is then monitored by drawing blood samples at timed intervals and assaying the patient's partial thromboplastin time. At the end of the evaluation period, the dosage of each peptide is adjusted to provide the desired in vivo effect.

30 The following non-limiting examples serve to illustrate the practice of the invention.

35

Example 1

Computer Model

A structural model of the A3 domain (residues Ala 181-Arg 266) was constructed using the computational chemis-

try package supplied by Molecular Simulations, Inc., Pasadena CA and a Silicon Graphics 4D 280 Parallel Processing Supercomputer. A description of the modeling package and methods has been previously published (Jameson, Nature 349, 465-466 (1989)). The A3 domain was prematurely truncated at Cys 265 because residues Arg 266 and His 267 - Phe 272 (SEQ ID NO:16) comprise a short connecting peptide not expected to contribute to either the conformation or the function of the A3 domain. Information concerning cysteine disulfide constraints was used to initiate model building, after which extended energy minimization calculations were carried out. Ten picosecond high energy (900°K) dynamic runs (energy-dependent simulations of molecular motion) were used to dislodge inappropriate amino acid contacts. The structure was allowed to cool to 300°K over a 100 picosecond dynamics calculation, followed by minimization of the resulting structure. A trajectory file, recorded over the entire dynamics run, indicated that after ~55 picoseconds of dynamics, the calculated backbone structure had stabilized, i.e., reached a low energy well. Since a disulfide-bonded cysteine has an ideal bond length from α -carbon to α -carbon of ~5-6Å, we searched the region between the β -stranded pairs (the stem portion of the stem-loop) for ideal disulfide distances as well as for locations where a disulfide bond would not be expected to induce torsional stress. The calculated structure shows 3 stem-loop structures defined by amino acid residues Pro 229 - Gln 233, Thr 241 - Leu 246, and Ser 248 - Ser 261.

30

Examples 2-3

Ala 181-Arg 266 and Asn 235-Arg 266 Peptides

The model structure of Appendix 1 was used as a design template in the construction of conformationally restricted peptides corresponding to factor XI heavy chain residues 181-266 (SEQ ID NO:1) and 235-266 (SEQ ID NO:2). An intrachain disulfide bond between the cysteine residues at positions 242 and 265 was allowed to form in the computer-assisted model. The predicted folding pattern of the putative structure was tested for its ability to mimic the structure

35

observed in our model of domain of A3. Finding satisfactory agreement, the peptides were synthesized according to conventional solid phase procedures on an Applied Biosystems 430A peptide synthesizer by a modification of the procedure described by Kent and Clark-Lewis in Synthetic Peptides in Biology and Medicine, eds. Alitalo, K., Partanen P., and Vakeri, A. (Elsevier Science Publishers, Amsterdam (pp. 29-58 (1985))), in which dimethyl formamide replaced methylene chloride in the routine wash cycles. The synthesis was carried out using a paramethylbenzhydrylamine resin (United States Biochemical Corp., Cleveland, OH). The solvents and protected amino acids were synthesis grade biotechnology products purchased from Fischer Scientific Co., Pittsburgh, PA. The resulting peptide was refolded by dissolving it in deionized water as a 0.1 mg/ml solution in a flask containing a stir bar. The pH was adjusted to 8.5 with NH_4OH and the solution was allowed to stir at 5°C for at least three days. The resulting solution was lyophilized.

The folded peptides were examined by both reverse phase and gel filtration high performance liquid chromatography (HPLC). The HPLC system was the Waters 600 Gradient Module, Model 740 Data Module, Model 46K Universal Injector and Lambda-Max Model 481 Detector. Reverse phase chromatography was performed using a Waters C8 μ Bondapak Column equilibrated with 0.1% (V/V) trifluoroacetic acid. The column was eluted with a linear gradient of aqueous acetonitrile containing 0.1% trifluoroacetic acid with a detector set at a wavelength of 220 nm. Gel filtration of the peptides was also carried out using a Waters Protein-Pak 60 column which was run isocratically with 0.1% (V/V) trifluoroacetic in 20% acetonitrile. Each of the two folded peptides demonstrated a single homogenous peak with a retention time identical to the corresponding unfolded peptide. This indicates the presence of a single homogeneous mixture for each refolded peptide, and not a mixed population of diverse polymers.

Example 4

Ser 248(C)-Ser 261(C) Peptide.

Following the procedures of Example 1-3, a synthetic peptide corresponding to factor XI heavy chain residues 248-261 was modeled and prepared, except that the amino acid residues Ser 248 and Ser 261 of the native peptide were replaced with cysteine residues. The resulting modified peptide, Ser 248(C)-Ser 261(C), had the amino acid sequence of D-Cys-(SEQ ID NO:7)-Cys. The peptide was "refolded" to assume its correct conformation, as described in Examples 2-3.

Alternatively, the peptide was reduced with dithiothreitol and alkylated with iodoacetamide as previously described by Sinha *et al.*, *J. Biol. Chem.* 260, 10714-10719 (1985). The chromatography results were the same after reduction and alkylation of the peptide, that is, a single peak with retention times identical to the original peptide was observed upon both reverse phase and gel filtration HPLC. The reduced/alkylated and corresponding refolded peptides were examined for free SH groups using the Ellman reagent, 5, 5'-dithiobis[2-nitro-benzoic acid]. It was determined that there was less than 0.02 mole of free SH per mole of peptide, which further verifies that the refolded peptide was a homogenous preparation consisting of the intramolecular disulfide-bonded peptide.

25

Example 5

Thr 241(C)-Leu 246(C) Peptide

Following the procedure of Examples 1-3, a synthetic peptide corresponding to factor XI heavy chain residues 241-246 was modeled and prepared, except that Thr 241 and Leu 246 were both replaced by Cys residues. The modified peptide, Thr 241(C)-Leu 246(C), thus had the amino acid sequence of SEQ ID NO:8.

The refolded peptide and the corresponding reduced/alkylated preparation were again found to have identical retention times by gel filtration and reverse phase HPLC. Moreover, the refolded peptide, as well as the reduced/alkylated peptide, were devoid of free thiols, thus confirming that all free SH groups were either oxidized to

disulfides during the refolding procedure, or were reduced and alkylated during alkylation treatment.

5

Example 6

Pro 229(C)-Gln 233(C) Peptide

Following the procedure of Examples 1-3, a synthetic peptide corresponding to factor XI heavy chain residues 229-233 was modeled and prepared, except that Pro 229 and Gln 233 were both replaced by Cys residues. The modified peptide, Pro 229(C)-Gln 233(C), thus had the amino acid sequence of SEQ ID NO:9.

The refolded peptide and the corresponding reduced/alkylated preparation were again found to have identical retention times by gel filtration and reverse phase HPLC. Moreover, the refolded peptide, as well as the reduced/alkylated peptide, were devoid of free thiols, thus confirming that all free SH groups were either oxidized to disulfides during the refolding procedure, or were reduced and alkylated during alkylation treatment.

Example 7

Gln 226(C)-Asn 235(C) Peptide

Following the procedure of Examples 1-3, a synthetic peptide corresponding to factor XI heavy chain residues 226-235 was modeled and prepared, except that Gln 226 and Asn 235 were both replaced by Cys residues. The modified peptide, Gln 226(C)-Asn 235(C), thus had the amino acid sequence of SEQ ID NO:11.

The refolded peptide and the corresponding reduced/alkylated preparation were again found to have identical retention times by gel filtration and reverse phase HPLC. Moreover, the refolded peptide, as well as the reduced/alkylated peptide, were devoid of free thiols, thus confirming that all free SH groups were either oxidized to disulfides during the refolding procedure, or were reduced and alkylated during alkylation treatment.

Example 8Ala 193(C)-Ser 199(C) Peptide

Following the procedure of Examples 1-3, a synthetic peptide corresponding to factor XI heavy chain residues 193-199 was modeled and prepared, except that Ala 193 and Ser 199 were both replaced by Cys residues. The modified peptide, Ala 193(C)-Ser 199(C), thus had the amino acid sequence of SEQ ID NO:12.

The refolded peptide and the corresponding reduced/alkylated preparation were again found to have identical retention times by gel filtration and reverse phase HPLC. Moreover, the refolded peptide, as well as the reduced/alkylated peptide, were devoid of free thiols, thus confirming that all free SH groups were either oxidized to disulfides during the refolding procedure, or were reduced and alkylated during alkylation treatment.

Example 9Ser 248(C)-Lys 253(G-C) Peptide

Following the procedure of Examples 1-3, a synthetic peptide corresponding to factor XI heavy chain residues 248-253 was modeled and prepared, except that Ser 248 was replaced with a Cys residue, a glycine residue was inserted between Lys 252 and Lys 253, and Lys 253 was replaced by a Cys residue. The modified peptide, Ser 249(C)-Lys 253(G-C), thus had the amino acid sequence of SEQ ID NO:10.

The refolded peptide and the corresponding reduced/alkylated preparation were again found to have identical retention times by gel filtration and reverse phase HPLC. Moreover, the refolded peptide, as well as the reduced/alkylated peptide, were devoid of free thiols, thus confirming that all free SH groups were either oxidized to disulfides during the refolding procedure, or were reduced and alkylated during alkylation treatment.

- 30 -

Example 10Val 191 - Arg 266 Peptide

Following the procedure of Examples 1-3, a synthetic peptide corresponding to factor XI heavy chain residues 191-266 was modeled and prepared. The peptide, Val 191 - Arg 266, thus had the amino acid sequence of SEQ ID NO:1, amino acids 11-86.

The refolded peptide and the corresponding reduced/alkylated preparation were again found to have identical retention times by gel filtration and reverse phase HPLC. Moreover, the refolded peptide, as well as the reduced/alkylated peptide, were devoid of free thiols, thus confirming that all free SH groups were either oxidized to disulfides during the refolding procedure, or were reduced and alkylated during alkylation treatment.

Example 11Synthesis of Heavy-Chain A1-domain Derived Peptides

Peptides corresponding to the A1-domain high molecular weight kininogen binding site in the factor XI heavy chain were synthesized and conformationally constrained in the same general manner as set forth in Examples 1-3. However, the model structure as provided by Baglia *et al.*, *J. Biol. Chem.* 267, 4247-4252 (1992), corresponding to the A1 domain was used as a design template instead of the A3 domain. The A1-domain derived peptides were conformationally restricted peptides corresponding to factor XI heavy chain high molecular weight kininogen binding site. The peptides produced have an amino acid sequence according to SEQ ID NOS:13 and 17-22.

Example 12Heavy-Chain A2-domain and A4-domain Derived Peptides

Comparative peptides corresponding to the A2-domain segment (SEQ ID NO:14) and to the A4-domain segment (SEQ ID NO:15) in the factor XI heavy chain were synthesized in the same general manner as set forth in Examples 2-3, except that no three-dimensional modeling was attempted. The peptides were conformationally constrained by introducing

cysteine-cysteine disulfide bonds between the native cysteines.

Example 13

5 Effect of Heavy-Chain Derived Peptides on the Binding of Factor XI to Platelets

A. Purification of Human Coagulation Proteins.

Factor XI (specific activity 250 U/mg of protein)
10 was purified from human plasma by immunoaffinity chromatography using a monoclonal antibody to factor XI (Sinha et al., J. Biol. Chem. 260, 10714-10719 (1985)).
High molecular weight kininogen (specific activity 15 U/mg) was purified by the method of Kerbiriou et al. (J. Biol. Chem. 254, 12020-12027 (1979)). Factor XI and high molecular
15 weight kininogen were assayed by minor modifications (Scott et al., Blood 63, 42-50 (1984)) of the kaolin-activated partial thromboplastin time (Proctor et al., Am. J. Clin. Pathol. 36, 212-219 (1961)). All purified proteins appeared
20 homogeneous by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.

B. Radiolabeling

Purified XI was labeled with ^{125}I by a minor modification (Sinha et al., J. Biol. Chem. 260, 10714-10719 (1985))
25 of the iodogen method to a specific activity of 5×10^6 cpm/mg. The radiolabeled protein retained >90% of its biological activity compared with unlabeled factor XI.

30 C. Assay of Factor XI Binding to Platelets

All incubations were performed at 37°C without stirring the reaction mixture. Platelets were prewarmed and incubated at a concentration of $(2-3) \times 10^8/\text{mL}$ in calcium-free HEPES-Tyrodes buffer, pH 7.3, in a 1.5 mL Eppendorf plastic
35 centrifuge tube with a mixture of radiolabeled and unlabeled factor XI, CaCl_2 (2 mM), ZnCl_2 (25 μM), thrombin (0.1 U/ml) and high molecular weight kininogen (42 nM) or other proteins. At various times after the addition of the platelet stimulus, aliquots were removed and centrifuged through a

mixture of silicone oils as described (Greengard et al., Biochem., 25, 3884-3890 (1986)). Total binding was not corrected for any nonsaturable component. More than 86% of the platelets were sedimented under these conditions.

5

D. Effect of Peptides on Factor XI-Platelet Binding.

Platelets were incubated with ZnCl_2 (25 μM), CaCl_2 (2 mM), thrombin (0.1 U/ml) and high molecular weight kininogen (42 nM), and ^{125}I -factor XI (0.025 $\mu\text{g/mL}$) and then mixed with various concentrations of A1-, A2-, A3- or A4- derived synthetic peptides, factor XI or buffer. After 20 minutes, samples were centrifuged. Binding of ^{125}I -factor XI was compared to control binding in the absence of competing proteins.

The I_{50} method of Cha, Biochem. Pharmacol. 24, 2177-2185 (1975) was used to determine the inhibitor constants as previously described (Sinha et al., Biochem. 26, 3768-3775 (1987)). In the case of classical competitive inhibition, IC_{50} (total inhibitor concentration at which the enzyme reaction velocity is 50% of the uninhibited reaction) is related to the substrate concentration as follows,

$$I_{50} = 1/2 Et + K_i + K_i S / K_m$$

where Et equals the total enzyme concentration and S equals the substrate concentration. K_i was thus determined from the plot of I_{50} vs S. The results are set forth in Table 1:

25

TABLE 1

| 5 | Competing Factor XI or Heavy Chain Peptide | K_i of Peptide Inhibition of Factor XI Binding to Platelets |
|----|---|--|
| 10 | 1. Factor XI 2. Asn 235-Arg 266 (A3 Domain) (SEQ ID NO:2) 3. Phe 56-Ser 86 (A1 Domain) (SEQ ID NO:13) | 5.0×10^{-8} 7.0×10^{-8} 6.0×10^{-6} |
| 15 | 4. Ala 134-Ala 176 (A2 domain) (SEQ ID NO:14) 5. Ala 317-Gly 350 (A4 domain) (SEQ ID NO:15) | NE* NE* |
| 20 | 6. Ser 248(C)-Ser 261(C) (A3 Domain) (D-Cys-(SEQ ID NO:7)-Cys) 7. Pro 229(C)-Gln 233(C) (A3 Domain) (SEQ ID NO:9) 8. Thr 241(C)-Leu 246(C) (A3 Domain) (SEQ ID NO:8) | 3.0×10^{-4} 1.0×10^{-3} 3.0×10^{-3} |
| 25 | | |

* NE = No effect at concentrations up to 10^{-2} M

30

The K_i of XI is included in Table 1 for comparison. The factor XI A3 peptide Asn 235 - Arg 266 of SEQ ID NO:2 is a potent inhibitor of factor XI binding to platelets in the presence of high molecular weight kininogen, CaCl_2 , and ZnCl_2 . The K_i is about 10 nM which is almost identical to the K_i for factor XI binding to platelets (See Table 1). In addition, the three peptides designed from the computer model of the A3 domain all have inhibitory activity in the binding assay.

By comparison peptides from the A2 domain, e.g., Ala 134-Ala 176 (SEQ ID NO:14) and from the A4 domain, e.g., Ala 317-Gly 350 (SEQ ID NO:15), have no effect upon the binding of factor XI to platelets. A peptide from the A1 domain, i.e., Phe 56-Ser 86 (SEQ ID NO:13), is an indirect but potent inhibitor of factor XI binding to platelets. The A1 domain peptide inhibits the binding of factor XI to high molecular weight kininogen, which is essential to promote

45

factor XI binding to a platelet receptor. Thus, the inhibition of factor XI binding to platelets by the A1 peptides is an indirect inhibition since the A1 peptides do not directly compete with factor XI for a binding site on the platelet surface. Conversely, the A3 peptides directly compete with factor XI for the binding site on the platelet surface.

Thus, the major binding site for platelets is located on factor XI A3 domain within residues Asn 235-Arg 266.

E. Synergism Between Ser 248(C)-Ser 261(C) Peptide and Folded Peptides from First and Second Stem Loops

The above factor XI binding of platelets assay was repeated with a mixture comprising equimolar amounts of the three peptides: Ser 248(C)-Ser 261(C), (D-Cys-(SEQ ID NO:7)-Cys); Pro 229(C)-Gln 233(C), (SEQ ID NO:9); and Thr 241(C)-Leu 246(C), (SEQ ID NO:8). These peptides added together showed mild synergism.

Example 14

Effect of A3-Derived Peptides on Coagulant Activity

Factor XI heavy chain peptides were assayed for inhibitory effects on blood coagulation. The activated partial thromboplastin time was measured in the presence of activated platelets or phospholipids. Since phospholipids can substitute for platelets in most coagulation reactions, parallel assays were run with the peptides to determine whether their inhibitory effects were specific for their interaction of platelets.

Factor XI activity was assayed the method of Scott et al., Blood 63, 42-50 (1984), with minor modifications. The assay determines the kaolin-activated partial thromboplastin time (Proctor et al., Am. J. Clin. Pathol. 36, 212-219 (1961)) using factor XI congenitally deficient substrate plasma. Coagulation mixtures containing kaolin, phospholipids or thrombin-activated platelets and factor XI deficient plasma were incubated at 37°C for five minutes in the presence of factor and various concentrations of the synthet-

- 35 -

ic peptides. The assay results were quantitated on double logarithmic plots of clotting times vs. concentrations of pooled normal plasma.

5 The A1 domain contains a binding site for high molecular weight kininogen, the A2 domain contains a substrate binding site for factor IX, and the A4 domain contains a binding site for factor XIIa. The peptides representing these respective binding sites showed inhibitory effects on intrinsic coagulation in the presence of both phospholipids and platelets, as manifested by the activated partial throm-
10 boplastin times.

By contrast, an A3 domain derived peptide according to the invention, e.g., Asn 235-Arg 266 (SEQ ID NO:2), was shown to be significantly inhibitory (K_i of about 2×10^{-6}
15 M) only in the presence of activated platelets. A 100-fold higher concentration of Asn 235-Arg 266 (SEQ ID NO:2) was required to demonstrate a similar inhibitory effect in the presence of phospholipids.

The parallel results indicate the specificity of
20 the A3-derived peptides according to the invention for binding to platelets, and not to phospholipids.

Example 15

Effect of Mixtures of A1- and A3-Derived Peptides on 25 Coagulant Activity

The factor XI heavy chain A1- and A3- derived artificially constrained peptides Phe 56 - Ser 86 (SEQ ID NO:13) and Asn 235 - Arg 266 (SEQ ID NO:2) are assayed for
30 cumulative and synergistic effects by repeating the factor XI binding of platelets assay according to Example 13(d) with a mixture comprising equimolar amounts of the two peptides. Thus, the mixture is assayed for possible inhibitory effects on blood coagulation. The activated partial thromboplastin
35 time is assessed in the presence of activated platelets or phospholipids. The inhibitory effect on intrinsic coagulation is greater in the presence of platelets than in the presence of phospholipids. This assay indicates the cumulative and synergistic anticoagulant effects of mixtures of

- 36 -

constrained A1-domain and A3-domain peptides, which peptides respectively correspond to the high molecular weight kininogen and platelet binding sites on factor XI.

5 All references with respect to synthetic, preparative and analytic procedures are incorporated herein by reference.

The present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof and, accordingly, reference should be made
10 to the appended claims, rather than to the foregoing specification, as indicating the scope of the invention.

-37-

APPENDIX 1

Factor XI Heavy Chain Domain A3

5

10

15

20

25

30

35

40

45

50

| | | | | | | | | | |
|------|----|------|-----|-----|--------|--------|---------|------|------|
| ATOM | 1 | N | ALA | 181 | 1.681 | 6.178 | -12.945 | 1.00 | 0.00 |
| ATOM | 2 | CA | ALA | 181 | 1.610 | 4.951 | -12.171 | 1.00 | 0.00 |
| ATOM | 3 | C | ALA | 181 | 1.733 | 5.177 | -10.659 | 1.00 | 0.00 |
| ATOM | 4 | O | ALA | 181 | 1.441 | 4.262 | -9.891 | 1.00 | 0.00 |
| ATOM | 5 | CB | ALA | 181 | 0.324 | 4.205 | -12.524 | 1.00 | 0.00 |
| ATOM | 6 | H | ALA | 181 | 1.161 | 6.237 | -13.808 | 1.00 | 0.00 |
| ATOM | 7 | N | CYS | 182 | 2.160 | 6.380 | -10.239 | 1.00 | 0.00 |
| ATOM | 8 | CA | CYS | 182 | 2.284 | 6.814 | -8.849 | 1.00 | 0.00 |
| ATOM | 9 | C | CYS | 182 | 1.128 | 6.376 | -7.948 | 1.00 | 0.00 |
| ATOM | 10 | O | CYS | 182 | 1.357 | 5.728 | -6.929 | 1.00 | 0.00 |
| ATOM | 11 | CB | CYS | 182 | 3.649 | 6.433 | -8.269 | 1.00 | 0.00 |
| ATOM | 12 | SG | CYS | 182 | 4.253 | 7.558 | -6.976 | 1.00 | 0.00 |
| ATOM | 13 | LPG1 | CYS | 182 | 4.465 | 6.054 | -7.396 | 1.00 | 0.00 |
| ATOM | 14 | LPG2 | CYS | 182 | 3.924 | 7.273 | -6.461 | 1.00 | 0.00 |
| ATOM | 15 | H | CYS | 182 | 2.386 | 7.073 | -10.938 | 1.00 | 0.00 |
| ATOM | 16 | N | ILE | 183 | -0.120 | 6.711 | -8.296 | 1.00 | 0.00 |
| ATOM | 17 | CA | ILE | 183 | -0.499 | 7.503 | -9.456 | 1.00 | 0.00 |
| ATOM | 18 | C | ILE | 183 | -0.466 | 9.031 | -9.260 | 1.00 | 0.00 |
| ATOM | 19 | O | ILE | 183 | -0.291 | 9.742 | -10.248 | 1.00 | 0.00 |
| ATOM | 20 | CB | ILE | 183 | -1.854 | 7.030 | -9.992 | 1.00 | 0.00 |
| ATOM | 21 | CG1 | ILE | 183 | -1.889 | 5.506 | -10.109 | 1.00 | 0.00 |
| ATOM | 22 | CG2 | ILE | 183 | -2.116 | 7.635 | -11.371 | 1.00 | 0.00 |
| ATOM | 23 | CD1 | ILE | 183 | -3.259 | 5.046 | -10.603 | 1.00 | 0.00 |
| ATOM | 24 | H | ILE | 183 | -0.873 | 6.392 | -7.704 | 1.00 | 0.00 |
| ATOM | 25 | N | ARG | 184 | -0.644 | 9.585 | -8.050 | 1.00 | 0.00 |
| ATOM | 26 | CA | ARG | 184 | -0.723 | 8.870 | -6.792 | 1.00 | 0.00 |
| ATOM | 27 | C | ARG | 184 | -2.132 | 8.417 | -6.434 | 1.00 | 0.00 |
| ATOM | 28 | O | ARG | 184 | -3.117 | 9.048 | -6.817 | 1.00 | 0.00 |
| ATOM | 29 | CB | ARG | 184 | -0.051 | 9.651 | -5.669 | 1.00 | 0.00 |
| ATOM | 30 | CG | ARG | 184 | 0.175 | 8.685 | -4.512 | 1.00 | 0.00 |
| ATOM | 31 | CD | ARG | 184 | 0.890 | 9.372 | -3.360 | 1.00 | 0.00 |
| ATOM | 32 | NE | ARG | 184 | 0.808 | 8.554 | -2.152 | 1.00 | 0.00 |
| ATOM | 33 | CZ | ARG | 184 | 1.865 | 8.157 | -1.421 | 1.00 | 0.00 |
| ATOM | 34 | NH1 | ARG | 184 | 3.114 | 8.438 | -1.824 | 1.00 | 0.00 |
| ATOM | 35 | NH2 | ARG | 184 | 1.662 | 7.503 | -0.276 | 1.00 | 0.00 |
| ATOM | 36 | H | ARG | 184 | -0.663 | 10.593 | -7.991 | 1.00 | 0.00 |
| ATOM | 37 | N | ASP | 185 | -2.180 | 7.311 | -5.683 | 1.00 | 0.00 |
| ATOM | 38 | CA | ASP | 185 | -3.376 | 6.698 | -5.148 | 1.00 | 0.00 |
| ATOM | 39 | C | ASP | 185 | -3.593 | 7.193 | -3.716 | 1.00 | 0.00 |
| ATOM | 40 | O | ASP | 185 | -3.568 | 8.394 | -3.470 | 1.00 | 0.00 |
| ATOM | 41 | CB | ASP | 185 | -4.532 | 6.737 | -6.171 | 1.00 | 0.00 |
| ATOM | 42 | CG | ASP | 185 | -5.894 | 7.245 | -5.702 | 1.00 | 0.00 |
| ATOM | 43 | OD1 | ASP | 185 | -6.609 | 7.828 | -6.544 | 1.00 | 0.00 |
| ATOM | 44 | OD2 | ASP | 185 | -6.216 | 7.010 | -4.528 | 1.00 | 0.00 |
| ATOM | 45 | H | ASP | 185 | -1.305 | 6.927 | -5.356 | 1.00 | 0.00 |
| ATOM | 46 | N | ILE | 186 | -3.750 | 6.259 | -2.774 | 1.00 | 0.00 |
| ATOM | 47 | CA | ILE | 186 | -3.961 | 6.543 | -1.357 | 1.00 | 0.00 |
| ATOM | 48 | C | ILE | 186 | -5.403 | 6.966 | -1.019 | 1.00 | 0.00 |
| ATOM | 49 | O | ILE | 186 | -5.608 | 7.652 | -0.020 | 1.00 | 0.00 |
| ATOM | 50 | CB | ILE | 186 | -3.497 | 5.359 | -0.500 | 1.00 | 0.00 |
| ATOM | 51 | CG1 | ILE | 186 | -3.000 | 5.850 | 0.858 | 1.00 | 0.00 |
| ATOM | 52 | CG2 | ILE | 186 | -2.352 | 4.587 | -1.157 | 1.00 | 0.00 |
| ATOM | 53 | CD1 | ILE | 186 | -4.042 | 5.560 | 1.931 | 1.00 | 0.00 |
| ATOM | 54 | H | ILE | 186 | -3.628 | 5.291 | -3.036 | 1.00 | 0.00 |
| ATOM | 55 | N | PHE | 187 | -6.386 | 6.570 | -1.846 | 1.00 | 0.00 |
| ATOM | 56 | CA | PHE | 187 | -7.802 | 6.935 | -1.730 | 1.00 | 0.00 |
| ATOM | 57 | C | PHE | 187 | -8.686 | 6.355 | -2.852 | 1.00 | 0.00 |
| ATOM | 58 | O | PHE | 187 | -8.790 | 6.910 | -3.942 | 1.00 | 0.00 |
| ATOM | 59 | CB | PHE | 187 | -8.011 | 8.442 | -1.534 | 1.00 | 0.00 |
| ATOM | 60 | CG | PHE | 187 | -7.459 | 9.354 | -2.607 | 1.00 | 0.00 |

-38-

| | | | | | | | | | | |
|----|------|-----|-----|-----|-----|---------|---------|--------|------|------|
| | ATOM | 61 | CD1 | PHE | 187 | -8.323 | 9.989 | -3.515 | 1.00 | 0.00 |
| | ATOM | 62 | CD2 | PHE | 187 | -6.085 | 9.653 | -2.636 | 1.00 | 0.00 |
| | ATOM | 63 | CE1 | PHE | 187 | -7.797 | 10.800 | -4.537 | 1.00 | 0.00 |
| | ATOM | 64 | CE2 | PHE | 187 | -5.560 | 10.456 | -3.659 | 1.00 | 0.00 |
| 5 | ATOM | 65 | CZ | PHE | 187 | -6.409 | 10.986 | -4.645 | 1.00 | 0.00 |
| | ATOM | 66 | H | PHE | 187 | -6.121 | 6.029 | -2.655 | 1.00 | 0.00 |
| | ATOM | 67 | N | PRO | 188 | -9.356 | 5.235 | -2.578 | 1.00 | 0.00 |
| | ATOM | 68 | CA | PRO | 188 | -10.149 | 4.464 | -3.517 | 1.00 | 0.00 |
| | ATOM | 69 | C | PRO | 188 | -9.227 | 3.483 | -4.218 | 1.00 | 0.00 |
| | ATOM | 70 | O | PRO | 188 | -8.158 | 3.177 | -3.705 | 1.00 | 0.00 |
| | ATOM | 71 | CB | PRO | 188 | -11.019 | 3.577 | -2.632 | 1.00 | 0.00 |
| 10 | ATOM | 72 | CG | PRO | 188 | -10.088 | 3.265 | -1.464 | 1.00 | 0.00 |
| | ATOM | 73 | CD | PRO | 188 | -9.285 | 4.559 | -1.318 | 1.00 | 0.00 |
| | ATOM | 74 | N | ASN | 189 | -9.685 | 2.914 | -5.332 | 1.00 | 0.00 |
| | ATOM | 75 | CA | ASN | 189 | -9.375 | 1.533 | -5.665 | 1.00 | 0.00 |
| | ATOM | 76 | C | ASN | 189 | -10.269 | 0.445 | -5.032 | 1.00 | 0.00 |
| | ATOM | 77 | O | ASN | 189 | -11.276 | 0.087 | -5.638 | 1.00 | 0.00 |
| | ATOM | 78 | CB | ASN | 189 | -7.901 | 1.246 | -6.021 | 1.00 | 0.00 |
| | ATOM | 79 | CG | ASN | 189 | -7.009 | 0.627 | -4.939 | 1.00 | 0.00 |
| 15 | ATOM | 80 | OD1 | ASN | 189 | -7.006 | -0.585 | -4.750 | 1.00 | 0.00 |
| | ATOM | 81 | ND2 | ASN | 189 | -6.181 | 1.439 | -4.278 | 1.00 | 0.00 |
| | ATOM | 82 | H | ASN | 189 | -10.371 | 3.399 | -5.893 | 1.00 | 0.00 |
| | ATOM | 83 | N | THR | 190 | -9.867 | -0.095 | -3.866 | 1.00 | 0.00 |
| | ATOM | 84 | CA | THR | 190 | -10.287 | -1.371 | -3.261 | 1.00 | 0.00 |
| | ATOM | 85 | C | THR | 190 | -11.449 | -2.119 | -3.915 | 1.00 | 0.00 |
| | ATOM | 86 | O | THR | 190 | -12.603 | -1.783 | -3.655 | 1.00 | 0.00 |
| 20 | ATOM | 87 | CB | THR | 190 | -10.481 | -1.228 | -1.747 | 1.00 | 0.00 |
| | ATOM | 88 | OG1 | THR | 190 | -11.148 | -0.023 | -1.436 | 1.00 | 0.00 |
| | ATOM | 89 | CG2 | THR | 190 | -9.126 | -1.273 | -1.047 | 1.00 | 0.00 |
| | ATOM | 90 | HG1 | THR | 190 | -10.871 | 0.265 | -0.564 | 1.00 | 0.00 |
| | ATOM | 91 | H | THR | 190 | -9.112 | 0.371 | -3.388 | 1.00 | 0.00 |
| | ATOM | 92 | N | VAL | 191 | -11.204 | -3.148 | -4.746 | 1.00 | 0.00 |
| | ATOM | 93 | CA | VAL | 191 | -9.928 | -3.696 | -5.196 | 1.00 | 0.00 |
| 25 | ATOM | 94 | C | VAL | 191 | -9.490 | -4.942 | -4.442 | 1.00 | 0.00 |
| | ATOM | 95 | O | VAL | 191 | -9.412 | -6.016 | -5.032 | 1.00 | 0.00 |
| | ATOM | 96 | CB | VAL | 191 | -8.813 | -2.676 | -5.416 | 1.00 | 0.00 |
| | ATOM | 97 | CG1 | VAL | 191 | -7.533 | -3.395 | -5.831 | 1.00 | 0.00 |
| | ATOM | 98 | CG2 | VAL | 191 | -9.190 | -1.778 | -6.585 | 1.00 | 0.00 |
| | ATOM | 99 | H | VAL | 191 | -12.015 | -3.621 | -5.114 | 1.00 | 0.00 |
| | ATOM | 100 | N | PHE | 192 | -9.171 | -4.804 | -3.155 | 1.00 | 0.00 |
| 30 | ATOM | 101 | CA | PHE | 192 | -8.740 | -5.946 | -2.376 | 1.00 | 0.00 |
| | ATOM | 102 | C | PHE | 192 | -9.781 | -6.336 | -1.338 | 1.00 | 0.00 |
| | ATOM | 103 | O | PHE | 192 | -10.434 | -5.484 | -0.739 | 1.00 | 0.00 |
| | ATOM | 104 | CB | PHE | 192 | -7.353 | -5.716 | -1.783 | 1.00 | 0.00 |
| | ATOM | 105 | CG | PHE | 192 | -6.274 | -5.522 | -2.823 | 1.00 | 0.00 |
| | ATOM | 106 | CD1 | PHE | 192 | -5.711 | -4.248 | -3.010 | 1.00 | 0.00 |
| | ATOM | 107 | CD2 | PHE | 192 | -5.936 | -6.574 | -3.693 | 1.00 | 0.00 |
| 35 | ATOM | 108 | CE1 | PHE | 192 | -4.787 | -4.032 | -4.048 | 1.00 | 0.00 |
| | ATOM | 109 | CE2 | PHE | 192 | -5.015 | -6.358 | -4.734 | 1.00 | 0.00 |
| | ATOM | 110 | CZ | PHE | 192 | -4.443 | -5.086 | -4.912 | 1.00 | 0.00 |
| | ATOM | 111 | H | PHE | 192 | -9.214 | -3.900 | -2.709 | 1.00 | 0.00 |
| | ATOM | 112 | N | ALA | 193 | -9.947 | -7.644 | -1.144 | 1.00 | 0.00 |
| | ATOM | 113 | CA | ALA | 193 | -9.199 | -8.618 | -1.910 | 1.00 | 0.00 |
| | ATOM | 114 | C | ALA | 193 | -10.134 | -9.300 | -2.896 | 1.00 | 0.00 |
| | ATOM | 115 | O | ALA | 193 | -10.801 | -10.254 | -2.500 | 1.00 | 0.00 |
| 40 | ATOM | 116 | CB | ALA | 193 | -8.568 | -9.633 | -0.959 | 1.00 | 0.00 |
| | ATOM | 117 | H | ALA | 193 | -10.636 | -7.979 | -0.485 | 1.00 | 0.00 |
| | ATOM | 118 | N | ASP | 194 | -10.163 | -8.811 | -4.150 | 1.00 | 0.00 |
| | ATOM | 119 | CA | ASP | 194 | -10.859 | -9.410 | -5.293 | 1.00 | 0.00 |
| | ATOM | 120 | C | ASP | 194 | -11.956 | -8.497 | -5.846 | 1.00 | 0.00 |
| | ATOM | 121 | O | ASP | 194 | -13.108 | -8.915 | -5.926 | 1.00 | 0.00 |
| | ATOM | 122 | CB | ASP | 194 | -11.338 | -10.635 | -4.959 | 1.00 | 0.00 |
| 45 | ATOM | 123 | CG | ASP | 194 | -12.128 | -11.621 | -6.002 | 1.00 | 0.00 |
| | ATOM | 124 | OD1 | ASP | 194 | -12.127 | -11.216 | -7.186 | 1.00 | 0.00 |
| | ATOM | 125 | OD2 | ASP | 194 | -12.723 | -12.634 | -5.578 | 1.00 | 0.00 |
| | ATOM | 126 | H | ASP | 194 | -9.618 | -7.981 | -4.343 | 1.00 | 0.00 |
| | ATOM | 127 | N | SER | 195 | -11.603 | -7.272 | -6.265 | 1.00 | 0.00 |
| | ATOM | 128 | CA | SER | 195 | -12.504 | -6.379 | -6.978 | 1.00 | 0.00 |
| | ATOM | 129 | C | SER | 195 | -13.561 | -5.770 | -6.054 | 1.00 | 0.00 |
| | ATOM | 130 | O | SER | 195 | -13.527 | -4.575 | -5.771 | 1.00 | 0.00 |
| 50 | ATOM | 131 | CB | SER | 195 | -13.122 | -7.119 | -6.170 | 1.00 | 0.00 |
| | ATOM | 132 | OG | SER | 195 | -13.982 | -6.283 | -8.908 | 1.00 | 0.00 |
| | ATOM | 133 | H | SER | 195 | -10.652 | -6.952 | -6.138 | 1.00 | 0.00 |

-39-

| | | | | | | | | | | |
|----|------|-----|------|-----|-----|---------|--------|--------|------|------|
| | ATOM | 134 | N | ASN | 196 | -14.522 | -6.590 | -5.628 | 1.00 | 0.00 |
| | ATOM | 135 | CA | ASN | 196 | -15.708 | -6.133 | -6.941 | 1.00 | 0.00 |
| | ATOM | 136 | C | ASN | 196 | -15.618 | -6.386 | -3.443 | 1.00 | 0.00 |
| | ATOM | 137 | O | ASN | 196 | -15.437 | -7.523 | -3.011 | 1.00 | 0.00 |
| 5 | ATOM | 138 | CB | ASN | 196 | -16.934 | -6.814 | -5.544 | 1.00 | 0.00 |
| | ATOM | 139 | CG | ASN | 196 | -17.418 | -6.089 | -6.793 | 1.00 | 0.00 |
| | ATOM | 140 | OD1 | ASN | 196 | -18.419 | -5.377 | -6.746 | 1.00 | 0.00 |
| | ATOM | 141 | ND2 | ASN | 196 | -16.718 | -6.274 | -7.913 | 1.00 | 0.00 |
| | ATOM | 142 | H | ASN | 196 | -14.470 | -7.570 | -5.869 | 1.00 | 0.00 |
| | ATOM | 143 | N | ILE | 197 | -15.761 | -5.327 | -2.641 | 1.00 | 0.00 |
| | ATOM | 144 | CA | ILE | 197 | -15.845 | -3.952 | -3.110 | 1.00 | 0.00 |
| | ATOM | 145 | C | ILE | 197 | -15.862 | -3.007 | -1.920 | 1.00 | 0.00 |
| 10 | ATOM | 146 | O | ILE | 197 | -16.788 | -3.026 | -1.115 | 1.00 | 0.00 |
| | ATOM | 147 | CB | ILE | 197 | -17.038 | -3.724 | -4.045 | 1.00 | 0.00 |
| | ATOM | 148 | CG1 | ILE | 197 | -17.129 | -2.251 | -4.446 | 1.00 | 0.00 |
| | ATOM | 149 | CG2 | ILE | 197 | -18.352 | -4.166 | -3.405 | 1.00 | 0.00 |
| | ATOM | 150 | CD1 | ILE | 197 | -15.829 | -1.795 | -5.104 | 1.00 | 0.00 |
| | ATOM | 151 | H | ILE | 197 | -15.755 | -5.476 | -1.642 | 1.00 | 0.00 |
| | ATOM | 152 | N | ASP | 198 | -14.814 | -2.194 | -1.800 | 1.00 | 0.00 |
| 15 | ATOM | 153 | CA | ASP | 198 | -14.632 | -1.337 | -0.645 | 1.00 | 0.00 |
| | ATOM | 154 | C | ASP | 198 | -14.762 | 0.108 | -1.115 | 1.00 | 0.00 |
| | ATOM | 155 | O | ASP | 198 | -14.383 | 0.423 | -2.242 | 1.00 | 0.00 |
| | ATOM | 156 | CB | ASP | 198 | -13.264 | -1.570 | 0.014 | 1.00 | 0.00 |
| | ATOM | 157 | CG | ASP | 198 | -12.774 | -3.021 | 0.138 | 1.00 | 0.00 |
| | ATOM | 158 | OD1 | ASP | 198 | -13.450 | -3.939 | -0.370 | 1.00 | 0.00 |
| | ATOM | 159 | OD2 | ASP | 198 | -11.696 | -3.183 | 0.743 | 1.00 | 0.00 |
| 20 | ATOM | 160 | H | ASP | 198 | -14.064 | -2.241 | -2.475 | 1.00 | 0.00 |
| | ATOM | 161 | N | SER | 199 | -15.309 | 1.006 | -0.291 | 1.00 | 0.00 |
| | ATOM | 162 | CA | SER | 199 | -15.771 | 0.784 | 1.071 | 1.00 | 0.00 |
| | ATOM | 163 | C | SER | 199 | -17.046 | -0.069 | 1.155 | 1.00 | 0.00 |
| | ATOM | 164 | O | SER | 199 | -17.331 | -0.630 | 2.211 | 1.00 | 0.00 |
| | ATOM | 165 | CB | SER | 199 | -15.988 | 2.177 | 1.674 | 1.00 | 0.00 |
| | ATOM | 166 | CG | SER | 199 | -16.662 | 2.154 | 2.911 | 1.00 | 0.00 |
| 25 | ATOM | 167 | H | SER | 199 | -15.400 | 1.949 | -0.639 | 1.00 | 0.00 |
| | ATOM | 168 | N | VAL | 200 | -17.823 | -0.129 | 0.064 | 1.00 | 0.00 |
| | ATOM | 169 | CA | VAL | 200 | -19.237 | -0.477 | 0.055 | 1.00 | 0.00 |
| | ATOM | 170 | C | VAL | 200 | -19.695 | -1.741 | 0.790 | 1.00 | 0.00 |
| | ATOM | 171 | O | VAL | 200 | -20.743 | -1.696 | 1.431 | 1.00 | 0.00 |
| | ATOM | 172 | CB | VAL | 200 | -19.837 | -0.297 | -1.339 | 1.00 | 0.00 |
| | ATOM | 173 | CG1 | VAL | 200 | -19.734 | -1.571 | -2.174 | 1.00 | 0.00 |
| | ATOM | 174 | CG2 | VAL | 200 | -21.291 | 0.151 | -1.227 | 1.00 | 0.00 |
| 30 | ATOM | 175 | H | VAL | 200 | -17.481 | 0.309 | -0.779 | 1.00 | 0.00 |
| | ATOM | 176 | N | MET | 201 | -18.958 | -2.856 | 0.706 | 1.00 | 0.00 |
| | ATOM | 177 | CA | MET | 201 | -19.349 | -4.080 | 1.389 | 1.00 | 0.00 |
| | ATOM | 178 | C | MET | 201 | -19.136 | -3.944 | 2.894 | 1.00 | 0.00 |
| | ATOM | 179 | O | MET | 201 | -18.011 | -4.057 | 3.380 | 1.00 | 0.00 |
| | ATOM | 180 | CB | MET | 201 | -18.648 | -5.297 | 0.788 | 1.00 | 0.00 |
| | ATOM | 181 | CG | MET | 201 | -19.445 | -6.556 | 1.125 | 1.00 | 0.00 |
| 35 | ATOM | 182 | SD | MET | 201 | -18.595 | -7.703 | 2.238 | 1.00 | 0.00 |
| | ATOM | 183 | CE | MET | 201 | -19.884 | -8.961 | 2.420 | 1.00 | 0.00 |
| | ATOM | 184 | LPD1 | MET | 201 | -18.235 | -8.024 | 1.760 | 1.00 | 0.00 |
| | ATOM | 185 | LPD2 | MET | 201 | -18.727 | -7.367 | 2.813 | 1.00 | 0.00 |
| | ATOM | 186 | H | MET | 201 | -18.108 | -2.863 | 0.159 | 1.00 | 0.00 |
| | ATOM | 187 | N | ALA | 202 | -20.238 | -3.653 | 3.600 | 1.00 | 0.00 |
| | ATOM | 188 | CA | ALA | 202 | -20.261 | -3.210 | 4.986 | 1.00 | 0.00 |
| | ATOM | 189 | C | ALA | 202 | -19.309 | -2.033 | 5.178 | 1.00 | 0.00 |
| 40 | ATOM | 190 | O | ALA | 202 | -18.212 | -2.219 | 5.698 | 1.00 | 0.00 |
| | ATOM | 191 | CB | ALA | 202 | -19.991 | -4.373 | 5.940 | 1.00 | 0.00 |
| | ATOM | 192 | H | ALA | 202 | -21.111 | -3.597 | 3.096 | 1.00 | 0.00 |
| | ATOM | 193 | N | PRO | 203 | -19.729 | -0.847 | 4.708 | 1.00 | 0.00 |
| | ATOM | 194 | CA | PRO | 203 | -18.926 | 0.342 | 4.483 | 1.00 | 0.00 |
| | ATOM | 195 | C | PRO | 203 | -17.819 | 0.600 | 5.497 | 1.00 | 0.00 |
| | ATOM | 196 | O | PRO | 203 | -18.061 | 1.141 | 6.573 | 1.00 | 0.00 |
| 45 | ATOM | 197 | CB | PRO | 203 | -19.896 | 1.509 | 4.335 | 1.00 | 0.00 |
| | ATOM | 198 | CG | PRO | 203 | -21.239 | 0.864 | 3.986 | 1.00 | 0.00 |
| | ATOM | 199 | CD | PRO | 203 | -21.084 | -0.635 | 4.245 | 1.00 | 0.00 |
| | ATOM | 200 | N | ASP | 204 | -16.596 | 0.214 | 5.124 | 1.00 | 0.00 |
| | ATOM | 201 | CA | ASP | 204 | -15.427 | 0.422 | 5.951 | 1.00 | 0.00 |
| | ATOM | 202 | C | ASP | 204 | -14.546 | 1.506 | 5.349 | 1.00 | 0.00 |
| | ATOM | 203 | O | ASP | 204 | -13.969 | 1.323 | 4.277 | 1.00 | 0.00 |
| 50 | ATOM | 204 | CB | ASP | 204 | -14.653 | -0.887 | 6.118 | 1.00 | 0.00 |
| | ATOM | 205 | CG | ASP | 204 | -15.284 | -1.841 | 7.132 | 1.00 | 0.00 |
| | ATOM | 206 | OD1 | ASP | 204 | -16.337 | -1.478 | 7.700 | 1.00 | 0.00 |

-40-

| | | | | | | | | | | |
|----|------|-----|------|-----|-----|---------|--------|--------|------|------|
| | ATOM | 207 | OD2 | ASP | 204 | -14.690 | -2.922 | 7.321 | 1.00 | 0.00 |
| | ATOM | 208 | H | ASP | 204 | -16.464 | -0.214 | 4.218 | 1.00 | 0.00 |
| | ATOM | 209 | N | ALA | 205 | -14.419 | 2.620 | 6.076 | 1.00 | 0.00 |
| | ATOM | 210 | CA | ALA | 205 | -13.401 | 3.615 | 5.807 | 1.00 | 0.00 |
| 5 | ATOM | 211 | C | ALA | 205 | -12.030 | 3.011 | 6.068 | 1.00 | 0.00 |
| | ATOM | 212 | O | ALA | 205 | -11.858 | 2.242 | 7.011 | 1.00 | 0.00 |
| | ATOM | 213 | CB | ALA | 205 | -13.637 | 4.865 | 6.650 | 1.00 | 0.00 |
| | ATOM | 214 | H | ALA | 205 | -14.941 | 2.711 | 6.934 | 1.00 | 0.00 |
| | ATOM | 215 | N | PHE | 206 | -11.050 | 3.316 | 5.220 | 1.00 | 0.00 |
| | ATOM | 216 | CA | PHE | 206 | -11.085 | 4.394 | 4.245 | 1.00 | 0.00 |
| | ATOM | 217 | C | PHE | 206 | -9.741 | 4.428 | 3.540 | 1.00 | 0.00 |
| 10 | ATOM | 218 | O | PHE | 206 | -8.905 | 3.560 | 3.789 | 1.00 | 0.00 |
| | ATOM | 219 | CB | PHE | 206 | -12.229 | 4.239 | 3.241 | 1.00 | 0.00 |
| | ATOM | 220 | CG | PHE | 206 | -13.158 | 5.434 | 3.197 | 1.00 | 0.00 |
| | ATOM | 221 | CD1 | PHE | 206 | -12.674 | 6.698 | 2.813 | 1.00 | 0.00 |
| | ATOM | 222 | CD2 | PHE | 206 | -14.491 | 5.297 | 3.622 | 1.00 | 0.00 |
| | ATOM | 223 | CE1 | PHE | 206 | -13.523 | 7.818 | 2.850 | 1.00 | 0.00 |
| | ATOM | 224 | CE2 | PHE | 206 | -15.322 | 6.425 | 3.715 | 1.00 | 0.00 |
| | ATOM | 225 | CZ | PHE | 206 | -14.842 | 7.685 | 3.318 | 1.00 | 0.00 |
| 15 | ATOM | 226 | H | PHE | 206 | -10.166 | 2.839 | 5.332 | 1.00 | 0.00 |
| | ATOM | 227 | N | VAL | 207 | -9.550 | 5.401 | 2.638 | 1.00 | 0.00 |
| | ATOM | 228 | CA | VAL | 207 | -8.374 | 5.477 | 1.781 | 1.00 | 0.00 |
| | ATOM | 229 | C | VAL | 207 | -8.103 | 4.109 | 1.155 | 1.00 | 0.00 |
| | ATOM | 230 | O | VAL | 207 | -9.021 | 3.301 | 1.023 | 1.00 | 0.00 |
| | ATOM | 231 | CB | VAL | 207 | -7.158 | 6.088 | 2.489 | 1.00 | 0.00 |
| 20 | ATOM | 232 | CG1 | VAL | 207 | -7.405 | 7.513 | 2.979 | 1.00 | 0.00 |
| | ATOM | 233 | CG2 | VAL | 207 | -6.665 | 5.225 | 3.639 | 1.00 | 0.00 |
| | ATOM | 234 | H | VAL | 207 | -10.322 | 6.012 | 2.413 | 1.00 | 0.00 |
| | ATOM | 235 | N | CYS | 208 | -6.864 | 3.814 | 0.770 | 1.00 | 0.00 |
| | ATOM | 236 | CA | CYS | 208 | -6.649 | 2.584 | 0.026 | 1.00 | 0.00 |
| | ATOM | 237 | C | CYS | 208 | -6.559 | 1.350 | 0.927 | 1.00 | 0.00 |
| | ATOM | 238 | O | CYS | 208 | -6.523 | 0.225 | 0.433 | 1.00 | 0.00 |
| | ATOM | 239 | CB | CYS | 208 | -5.532 | 2.742 | -1.006 | 1.00 | 0.00 |
| 25 | ATOM | 240 | SG | CYS | 208 | -3.967 | 1.906 | -0.650 | 1.00 | 0.00 |
| | ATOM | 241 | LPG1 | CYS | 208 | -4.129 | 1.674 | -0.056 | 1.00 | 0.00 |
| | ATOM | 242 | LPG2 | CYS | 208 | -4.129 | 1.674 | -0.056 | 1.00 | 0.00 |
| | ATOM | 243 | H | CYS | 208 | -6.078 | 4.353 | 1.102 | 1.00 | 0.00 |
| | ATOM | 244 | N | GLY | 209 | -6.538 | 1.573 | 2.246 | 1.00 | 0.00 |
| | ATOM | 245 | CA | GLY | 209 | -6.384 | 0.555 | 3.258 | 1.00 | 0.00 |
| | ATOM | 246 | C | GLY | 209 | -5.937 | 1.246 | 4.541 | 1.00 | 0.00 |
| 30 | ATOM | 247 | O | GLY | 209 | -4.826 | 1.007 | 5.001 | 1.00 | 0.00 |
| | ATOM | 248 | H | GLY | 209 | -6.623 | 2.521 | 2.582 | 1.00 | 0.00 |
| | ATOM | 249 | N | ARG | 210 | -6.815 | 2.102 | 5.085 | 1.00 | 0.00 |
| | ATOM | 250 | CA | ARG | 210 | -6.668 | 2.886 | 6.312 | 1.00 | 0.00 |
| | ATOM | 251 | C | ARG | 210 | -6.094 | 2.114 | 7.492 | 1.00 | 0.00 |
| | ATOM | 252 | O | ARG | 210 | -4.879 | 1.982 | 7.622 | 1.00 | 0.00 |
| | ATOM | 253 | CB | ARG | 210 | -5.956 | 4.221 | 6.092 | 1.00 | 0.00 |
| 35 | ATOM | 254 | CG | ARG | 210 | -6.442 | 5.261 | 7.107 | 1.00 | 0.00 |
| | ATOM | 255 | CD | ARG | 210 | -6.055 | 6.676 | 6.667 | 1.00 | 0.00 |
| | ATOM | 256 | NE | ARG | 210 | -6.500 | 7.693 | 7.629 | 1.00 | 0.00 |
| | ATOM | 257 | CZ | ARG | 210 | -5.956 | 8.919 | 7.755 | 1.00 | 0.00 |
| | ATOM | 258 | NH1 | ARG | 210 | -5.029 | 9.347 | 6.891 | 1.00 | 0.00 |
| | ATOM | 259 | NH2 | ARG | 210 | -6.324 | 9.713 | 8.773 | 1.00 | 0.00 |
| | ATOM | 260 | H | ARG | 210 | -7.695 | 2.209 | 4.599 | 1.00 | 0.00 |
| 40 | ATOM | 261 | N | ILE | 211 | -6.966 | 1.624 | 8.376 | 1.00 | 0.00 |
| | ATOM | 262 | CA | ILE | 211 | -8.405 | 1.782 | 8.256 | 1.00 | 0.00 |
| | ATOM | 263 | C | ILE | 211 | -8.976 | 0.651 | 7.404 | 1.00 | 0.00 |
| | ATOM | 264 | O | ILE | 211 | -9.263 | 0.858 | 6.226 | 1.00 | 0.00 |
| | ATOM | 265 | CB | ILE | 211 | -9.017 | 1.850 | 9.658 | 1.00 | 0.00 |
| | ATOM | 266 | CG1 | ILE | 211 | -10.542 | 1.855 | 9.601 | 1.00 | 0.00 |
| | ATOM | 267 | CG2 | ILE | 211 | -8.529 | 3.115 | 10.362 | 1.00 | 0.00 |
| | ATOM | 268 | CD1 | ILE | 211 | -11.120 | 1.893 | 11.013 | 1.00 | 0.00 |
| | ATOM | 269 | H | ILE | 211 | -6.612 | 1.115 | 9.172 | 1.00 | 0.00 |
| 45 | ATOM | 270 | N | CYS | 212 | -9.086 | -0.548 | 7.996 | 1.00 | 0.00 |
| | ATOM | 271 | CA | CYS | 212 | -9.376 | -1.812 | 7.326 | 1.00 | 0.00 |
| | ATOM | 272 | C | CYS | 212 | -10.804 | -1.939 | 6.782 | 1.00 | 0.00 |
| | ATOM | 273 | O | CYS | 212 | -11.363 | -0.976 | 6.262 | 1.00 | 0.00 |
| | ATOM | 274 | CB | CYS | 212 | -8.287 | -2.251 | 6.336 | 1.00 | 0.00 |
| | ATOM | 275 | SC | CYS | 212 | -6.673 | -1.417 | 6.355 | 1.00 | 0.00 |
| | ATOM | 276 | LPG1 | CYS | 212 | -6.913 | -0.775 | 6.391 | 1.00 | 0.00 |
| 50 | ATOM | 277 | LPG2 | CYS | 212 | -6.913 | -0.775 | 6.391 | 1.00 | 0.00 |
| | ATOM | 278 | H | CYS | 212 | -8.844 | -0.607 | 8.974 | 1.00 | 0.00 |
| | ATOM | 279 | N | THR | 213 | -11.431 | -3.119 | 6.899 | 1.00 | 0.00 |

-41-

| | | | | | | | | | | |
|----|------|-----|------|-----|-----|---------|---------|--------|------|------|
| | ATOM | 280 | CA | THR | 213 | -10.891 | -4.347 | 7.466 | 1.00 | 0.00 |
| | ATOM | 281 | C | THR | 213 | -12.044 | -5.339 | 7.666 | 1.00 | 0.00 |
| | ATOM | 282 | O | THR | 213 | -12.626 | -5.392 | 8.747 | 1.00 | 0.00 |
| | ATOM | 283 | CB | THR | 213 | -10.107 | -4.066 | 8.760 | 1.00 | 0.00 |
| 5 | ATOM | 284 | OG1 | THR | 213 | -9.544 | -5.238 | 9.308 | 1.00 | 0.00 |
| | ATOM | 285 | CG2 | THR | 213 | -10.924 | -3.322 | 9.816 | 1.00 | 0.00 |
| | ATOM | 286 | HG1 | THR | 213 | -9.132 | -5.011 | 10.146 | 1.00 | 0.00 |
| | ATOM | 287 | H | THR | 213 | -12.376 | -3.175 | 6.548 | 1.00 | 0.00 |
| | ATOM | 288 | N | HIS | 214 | -12.411 | -6.130 | 6.645 | 1.00 | 0.00 |
| | ATOM | 289 | CA | HIS | 214 | -11.783 | -6.232 | 5.332 | 1.00 | 0.00 |
| | ATOM | 290 | C | HIS | 214 | -10.343 | -6.746 | 5.358 | 1.00 | 0.00 |
| | ATOM | 291 | O | HIS | 214 | -9.759 | -6.923 | 6.427 | 1.00 | 0.00 |
| 10 | ATOM | 292 | CB | HIS | 214 | -12.031 | -5.004 | 4.457 | 1.00 | 0.00 |
| | ATOM | 293 | CG | HIS | 214 | -12.807 | -5.327 | 3.202 | 1.00 | 0.00 |
| | ATOM | 294 | ND1 | HIS | 214 | -12.298 | -5.983 | 2.106 | 1.00 | 0.00 |
| | ATOM | 295 | CD2 | HIS | 214 | -14.160 | -5.183 | 3.051 | 1.00 | 0.00 |
| | ATOM | 296 | CE1 | HIS | 214 | -13.341 | -6.228 | 1.285 | 1.00 | 0.00 |
| | ATOM | 297 | NE2 | HIS | 214 | -14.476 | -5.746 | 1.809 | 1.00 | 0.00 |
| | ATOM | 298 | H | HIS | 214 | -13.191 | -6.751 | 6.805 | 1.00 | 0.00 |
| | ATOM | 299 | N | HIS | 215 | -9.779 | -7.034 | 4.179 | 1.00 | 0.00 |
| 15 | ATOM | 300 | CA | HIS | 215 | -8.493 | -7.705 | 4.102 | 1.00 | 0.00 |
| | ATOM | 301 | C | HIS | 215 | -7.322 | -6.855 | 4.584 | 1.00 | 0.00 |
| | ATOM | 302 | O | HIS | 215 | -7.318 | -5.639 | 4.397 | 1.00 | 0.00 |
| | ATOM | 303 | CB | HIS | 215 | -8.281 | -8.388 | 2.754 | 1.00 | 0.00 |
| | ATOM | 304 | CG | HIS | 215 | -8.442 | -9.882 | 2.858 | 1.00 | 0.00 |
| | ATOM | 305 | ND1 | HIS | 215 | -7.927 | -10.813 | 1.986 | 1.00 | 0.00 |
| | ATOM | 306 | CD2 | HIS | 215 | -9.008 | -10.551 | 3.911 | 1.00 | 0.00 |
| 20 | ATOM | 307 | CE1 | HIS | 215 | -8.191 | -12.034 | 2.484 | 1.00 | 0.00 |
| | ATOM | 308 | NE2 | HIS | 215 | -8.847 | -11.916 | 3.650 | 1.00 | 0.00 |
| | ATOM | 309 | HD1 | HIS | 215 | -7.427 | -10.617 | 1.132 | 1.00 | 0.00 |
| | ATOM | 310 | H | HIS | 215 | -10.287 | -6.869 | 3.322 | 1.00 | 0.00 |
| | ATOM | 311 | N | PRO | 216 | -6.370 | -7.505 | 5.266 | 1.00 | 0.00 |
| | ATOM | 312 | CA | PRO | 216 | -5.386 | -6.857 | 6.114 | 1.00 | 0.00 |
| | ATOM | 313 | C | PRO | 216 | -4.201 | -6.246 | 5.364 | 1.00 | 0.00 |
| 25 | ATOM | 314 | O | PRO | 216 | -3.053 | -6.618 | 5.600 | 1.00 | 0.00 |
| | ATOM | 315 | CB | PRO | 216 | -4.934 | -7.895 | 7.142 | 1.00 | 0.00 |
| | ATOM | 316 | CG | PRO | 216 | -5.591 | -9.218 | 6.747 | 1.00 | 0.00 |
| | ATOM | 317 | CD | PRO | 216 | -6.440 | -8.931 | 5.512 | 1.00 | 0.00 |
| | ATOM | 318 | N | GLY | 217 | -4.478 | -5.253 | 4.515 | 1.00 | 0.00 |
| | ATOM | 319 | CA | GLY | 217 | -3.469 | -4.342 | 4.013 | 1.00 | 0.00 |
| | ATOM | 320 | C | GLY | 217 | -3.693 | -2.993 | 4.682 | 1.00 | 0.00 |
| 30 | ATOM | 321 | O | GLY | 217 | -4.251 | -2.062 | 4.072 | 1.00 | 0.00 |
| | ATOM | 322 | H | GLY | 217 | -5.444 | -5.019 | 4.336 | 1.00 | 0.00 |
| | ATOM | 323 | N | CYS | 218 | -3.297 | -2.887 | 5.954 | 1.00 | 0.00 |
| | ATOM | 324 | CA | CYS | 218 | -3.632 | -1.738 | 6.770 | 1.00 | 0.00 |
| | ATOM | 325 | C | CYS | 218 | -2.423 | -0.837 | 6.986 | 1.00 | 0.00 |
| | ATOM | 326 | O | CYS | 218 | -1.573 | -1.116 | 7.830 | 1.00 | 0.00 |
| | ATOM | 327 | CB | CYS | 218 | -4.308 | -2.206 | 8.058 | 1.00 | 0.00 |
| 35 | ATOM | 328 | SG | CYS | 218 | -5.957 | -1.493 | 8.271 | 1.00 | 0.00 |
| | ATOM | 329 | LPG1 | CYS | 218 | -5.764 | -0.855 | 8.315 | 1.00 | 0.00 |
| | ATOM | 330 | LPG2 | CYS | 218 | -6.271 | -2.082 | 8.448 | 1.00 | 0.00 |
| | ATOM | 331 | H | CYS | 218 | -2.835 | -3.667 | 6.401 | 1.00 | 0.00 |
| | ATOM | 332 | N | LEU | 219 | -2.341 | 0.235 | 6.191 | 1.00 | 0.00 |
| | ATOM | 333 | CA | LEU | 219 | -1.176 | 1.102 | 6.159 | 1.00 | 0.00 |
| | ATOM | 334 | C | LEU | 219 | -1.561 | 2.570 | 6.260 | 1.00 | 0.00 |
| | ATOM | 335 | O | LEU | 219 | -1.534 | 3.316 | 5.282 | 1.00 | 0.00 |
| 40 | ATOM | 336 | CB | LEU | 219 | -0.280 | 0.795 | 4.959 | 1.00 | 0.00 |
| | ATOM | 337 | CG | LEU | 219 | -1.073 | 0.663 | 3.661 | 1.00 | 0.00 |
| | ATOM | 338 | CD1 | LEU | 219 | -0.315 | 1.376 | 2.546 | 1.00 | 0.00 |
| | ATOM | 339 | CD2 | LEU | 219 | -1.201 | -0.817 | 3.311 | 1.00 | 0.00 |
| | ATOM | 340 | H | LEU | 219 | -3.099 | 0.434 | 5.552 | 1.00 | 0.00 |
| | ATOM | 341 | N | PHE | 220 | -1.910 | 2.970 | 7.480 | 1.00 | 0.00 |
| | ATOM | 342 | CA | PHE | 220 | -2.361 | 4.301 | 7.790 | 1.00 | 0.00 |
| | ATOM | 343 | C | PHE | 220 | -1.193 | 5.293 | 7.873 | 1.00 | 0.00 |
| 45 | ATOM | 344 | O | PHE | 220 | -0.508 | 5.363 | 8.893 | 1.00 | 0.00 |
| | ATOM | 345 | CB | PHE | 220 | -3.141 | 4.184 | 9.094 | 1.00 | 0.00 |
| | ATOM | 346 | CG | PHE | 220 | -4.114 | 5.295 | 9.331 | 1.00 | 0.00 |
| | ATOM | 347 | CD1 | PHE | 220 | -5.252 | 5.059 | 10.129 | 1.00 | 0.00 |
| | ATOM | 348 | CD2 | PHE | 220 | -3.661 | 6.612 | 9.141 | 1.00 | 0.00 |
| | ATOM | 349 | CE1 | PHE | 220 | -5.906 | 6.138 | 10.745 | 1.00 | 0.00 |
| | ATOM | 350 | CE2 | PHE | 220 | -6.191 | 7.650 | 9.901 | 1.00 | 0.00 |
| 50 | ATOM | 351 | CZ | PHE | 220 | -5.335 | 7.418 | 10.703 | 1.00 | 0.00 |
| | ATOM | 352 | H | PHE | 220 | -1.949 | 2.287 | 8.223 | 1.00 | 0.00 |

-42-

| | | | | | | | | | | |
|----|------|-----|-----|-----|-----|--------|--------|---------|------|------|
| | ATOM | 353 | N | PHE | 221 | -0.984 | 6.084 | 6.811 | 1.00 | 0.00 |
| | ATOM | 354 | CA | PHE | 221 | -0.011 | 7.166 | 6.841 | 1.00 | 0.00 |
| | ATOM | 355 | C | PHE | 221 | -0.485 | 8.407 | 6.093 | 1.00 | 0.00 |
| | ATOM | 356 | O | PHE | 221 | -0.776 | 9.419 | 6.728 | 1.00 | 0.00 |
| | ATOM | 357 | CB | PHE | 221 | 1.377 | 6.703 | 6.405 | 1.00 | 0.00 |
| 5 | ATOM | 358 | CG | PHE | 221 | 2.494 | 7.480 | 7.066 | 1.00 | 0.00 |
| | ATOM | 359 | CD1 | PHE | 221 | 2.567 | 7.536 | 8.469 | 1.00 | 0.00 |
| | ATOM | 360 | CD2 | PHE | 221 | 3.407 | 8.213 | 6.286 | 1.00 | 0.00 |
| | ATOM | 361 | CE1 | PHE | 221 | 3.563 | 8.307 | 9.093 | 1.00 | 0.00 |
| | ATOM | 362 | CE2 | PHE | 221 | 4.408 | 8.979 | 6.911 | 1.00 | 0.00 |
| | ATOM | 363 | CZ | PHE | 221 | 4.486 | 9.026 | 8.314 | 1.00 | 0.00 |
| | ATOM | 364 | H | PHE | 221 | -1.563 | 5.985 | 5.989 | 1.00 | 0.00 |
| | ATOM | 365 | N | THR | 222 | -0.554 | 8.339 | 4.757 | 1.00 | 0.00 |
| 10 | ATOM | 366 | CA | THR | 222 | -0.994 | 9.463 | 3.945 | 1.00 | 0.00 |
| | ATOM | 367 | C | THR | 222 | -0.700 | 9.333 | 2.457 | 1.00 | 0.00 |
| | ATOM | 368 | O | THR | 222 | -1.540 | 9.019 | 1.615 | 1.00 | 0.00 |
| | ATOM | 369 | CB | THR | 222 | -2.375 | 9.984 | 4.304 | 1.00 | 0.00 |
| | ATOM | 370 | OG1 | THR | 222 | -3.297 | 8.934 | 4.164 | 1.00 | 0.00 |
| | ATOM | 371 | CG2 | THR | 222 | -2.740 | 11.154 | 3.389 | 1.00 | 0.00 |
| | ATOM | 372 | HG1 | THR | 222 | -4.159 | 9.317 | 4.001 | 1.00 | 0.00 |
| 15 | ATOM | 373 | H | THR | 222 | -0.240 | 7.504 | 4.283 | 1.00 | 0.00 |
| | ATOM | 374 | N | PHE | 223 | 0.556 | 9.672 | 2.228 | 1.00 | 0.00 |
| | ATOM | 375 | CA | PHE | 223 | 1.299 | 9.979 | 1.030 | 1.00 | 0.00 |
| | ATOM | 376 | C | PHE | 223 | 0.791 | 10.929 | -0.059 | 1.00 | 0.00 |
| | ATOM | 377 | O | PHE | 223 | -0.352 | 11.385 | -0.078 | 1.00 | 0.00 |
| | ATOM | 378 | CB | PHE | 223 | 2.587 | 10.531 | 1.570 | 1.00 | 0.00 |
| | ATOM | 379 | CG | PHE | 223 | 3.748 | 9.665 | 1.232 | 1.00 | 0.00 |
| 20 | ATOM | 380 | CD1 | PHE | 223 | 4.800 | 10.422 | 0.720 | 1.00 | 0.00 |
| | ATOM | 381 | CD2 | PHE | 223 | 4.060 | 8.678 | 2.189 | 1.00 | 0.00 |
| | ATOM | 382 | CE1 | PHE | 223 | 5.803 | 10.798 | 1.626 | 1.00 | 0.00 |
| | ATOM | 383 | CE2 | PHE | 223 | 5.222 | 8.950 | 2.960 | 1.00 | 0.00 |
| | ATOM | 384 | CZ | PHE | 223 | 5.983 | 10.021 | 2.787 | 1.00 | 0.00 |
| | ATOM | 385 | H | PHE | 223 | 1.131 | 9.627 | 3.057 | 1.00 | 0.00 |
| | ATOM | 386 | N | PHE | 224 | 1.736 | 11.194 | -0.977 | 1.00 | 0.00 |
| 25 | ATOM | 387 | CA | PHE | 224 | 1.677 | 12.196 | -2.022 | 1.00 | 0.00 |
| | ATOM | 388 | C | PHE | 224 | 2.947 | 12.157 | -2.894 | 1.00 | 0.00 |
| | ATOM | 389 | O | PHE | 224 | 3.920 | 11.472 | -2.577 | 1.00 | 0.00 |
| | ATOM | 390 | CB | PHE | 224 | 1.520 | 13.545 | -1.328 | 1.00 | 0.00 |
| | ATOM | 391 | CG | PHE | 224 | 0.980 | 14.652 | -2.194 | 1.00 | 0.00 |
| | ATOM | 392 | CD1 | PHE | 224 | -0.406 | 14.859 | -2.296 | 1.00 | 0.00 |
| | ATOM | 393 | CD2 | PHE | 224 | 1.871 | 15.489 | -2.685 | 1.00 | 0.00 |
| | ATOM | 394 | CE1 | PHE | 224 | -0.898 | 15.878 | -3.130 | 1.00 | 0.00 |
| 30 | ATOM | 395 | CE2 | PHE | 224 | 1.378 | 16.445 | -3.787 | 1.00 | 0.00 |
| | ATOM | 396 | CZ | PHE | 224 | -0.008 | 16.646 | -3.903 | 1.00 | 0.00 |
| | ATOM | 397 | H | PHE | 224 | 2.618 | 10.709 | -0.888 | 1.00 | 0.00 |
| | ATOM | 398 | N | SER | 225 | 2.929 | 12.908 | -4.001 | 1.00 | 0.00 |
| | ATOM | 399 | CA | SER | 225 | 4.034 | 13.048 | -4.939 | 1.00 | 0.00 |
| | ATOM | 400 | C | SER | 225 | 3.890 | 12.022 | -6.069 | 1.00 | 0.00 |
| | ATOM | 401 | O | SER | 225 | 3.334 | 10.942 | -5.871 | 1.00 | 0.00 |
| 35 | ATOM | 402 | CB | SER | 225 | 4.036 | 14.498 | -5.449 | 1.00 | 0.00 |
| | ATOM | 403 | OG | SER | 225 | 5.185 | 14.821 | -6.208 | 1.00 | 0.00 |
| | ATOM | 404 | H | SER | 225 | 2.102 | 13.450 | -4.204 | 1.00 | 0.00 |
| | ATOM | 405 | N | GLN | 226 | 4.395 | 12.365 | -7.258 | 1.00 | 0.00 |
| | ATOM | 406 | CA | GLN | 226 | 4.304 | 11.559 | -8.461 | 1.00 | 0.00 |
| | ATOM | 407 | C | GLN | 226 | 5.664 | 10.983 | -8.858 | 1.00 | 0.00 |
| | ATOM | 408 | O | GLN | 226 | 6.674 | 11.245 | -8.206 | 1.00 | 0.00 |
| 40 | ATOM | 409 | CB | GLN | 226 | 3.732 | 12.428 | -9.583 | 1.00 | 0.00 |
| | ATOM | 410 | CG | GLN | 226 | 4.579 | 13.689 | -9.762 | 1.00 | 0.00 |
| | ATOM | 411 | CD | GLN | 226 | 3.722 | 14.880 | -10.166 | 1.00 | 0.00 |
| | ATOM | 412 | OE1 | GLN | 226 | 3.298 | 15.660 | -9.315 | 1.00 | 0.00 |
| | ATOM | 413 | NE2 | GLN | 226 | 3.471 | 15.019 | -11.469 | 1.00 | 0.00 |
| | ATOM | 414 | H | GLN | 226 | 4.835 | 13.270 | -7.347 | 1.00 | 0.00 |
| | ATOM | 415 | N | GLU | 227 | 5.671 | 10.210 | -9.953 | 1.00 | 0.00 |
| 45 | ATOM | 416 | CA | GLU | 227 | 6.859 | 9.634 | -10.569 | 1.00 | 0.00 |
| | ATOM | 417 | C | GLU | 227 | 7.312 | 8.327 | -9.906 | 1.00 | 0.00 |
| | ATOM | 418 | O | GLU | 227 | 7.740 | 8.351 | -8.754 | 1.00 | 0.00 |
| | ATOM | 419 | CB | GLU | 227 | 7.982 | 10.672 | -10.687 | 1.00 | 0.00 |
| | ATOM | 420 | CG | GLU | 227 | 8.413 | 10.865 | -12.142 | 1.00 | 0.00 |
| | ATOM | 421 | CD | GLU | 227 | 9.525 | 11.904 | -12.302 | 1.00 | 0.00 |
| | ATOM | 422 | OE1 | GLU | 227 | 9.931 | 12.466 | -11.272 | 1.00 | 0.00 |
| | ATOM | 423 | OE2 | GLU | 227 | 9.949 | 12.098 | -13.461 | 1.00 | 0.00 |
| 50 | ATOM | 424 | H | GLU | 227 | 4.793 | 10.061 | -10.428 | 1.00 | 0.00 |
| | ATOM | 425 | N | TRP | 228 | 7.228 | 7.216 | -10.673 | 1.00 | 0.00 |

-43-

| | | | | | | | | | | |
|----|------|-----|------|-----|-----|--------|--------|---------|------|------|
| | ATOM | 426 | CA | TRP | 228 | 8.086 | 6.014 | -10.705 | 1.00 | 0.00 |
| | ATOM | 427 | C | TRP | 228 | 7.373 | 4.655 | -10.953 | 1.00 | 0.00 |
| | ATOM | 428 | O | TRP | 228 | 6.137 | 4.643 | -11.001 | 1.00 | 0.00 |
| | ATOM | 429 | CB | TRP | 228 | 9.320 | 6.270 | -11.584 | 1.00 | 0.00 |
| | ATOM | 430 | CG | TRP | 228 | 9.072 | 6.774 | -12.965 | 1.00 | 0.00 |
| | ATOM | 431 | CD1 | TRP | 228 | 8.103 | 7.661 | -13.305 | 1.00 | 0.00 |
| | ATOM | 432 | CD2 | TRP | 228 | 9.815 | 6.503 | -14.187 | 1.00 | 0.00 |
| | ATOM | 433 | NE1 | TRP | 228 | 8.192 | 7.949 | -14.643 | 1.00 | 0.00 |
| 5 | ATOM | 434 | CE2 | TRP | 228 | 9.238 | 7.282 | -15.235 | 1.00 | 0.00 |
| | ATOM | 435 | CE3 | TRP | 228 | 10.925 | 5.702 | -14.521 | 1.00 | 0.00 |
| | ATOM | 436 | CZ2 | TRP | 228 | 9.741 | 7.269 | -16.542 | 1.00 | 0.00 |
| | ATOM | 437 | CZ3 | TRP | 228 | 11.434 | 5.679 | -15.832 | 1.00 | 0.00 |
| | ATOM | 438 | CH2 | TRP | 228 | 10.847 | 6.467 | -16.841 | 1.00 | 0.00 |
| | ATOM | 439 | N | PRO | 229 | 8.111 | 3.502 | -11.044 | 1.00 | 0.00 |
| | ATOM | 440 | CA | PRO | 229 | 7.678 | 2.225 | -10.448 | 1.00 | 0.00 |
| 10 | ATOM | 441 | C | PRO | 229 | 8.021 | 0.815 | -11.000 | 1.00 | 0.00 |
| | ATOM | 442 | O | PRO | 229 | 7.536 | -0.157 | -10.413 | 1.00 | 0.00 |
| | ATOM | 443 | CB | PRO | 229 | 8.625 | 2.128 | -9.275 | 1.00 | 0.00 |
| | ATOM | 444 | CG | PRO | 229 | 9.964 | 2.649 | -9.813 | 1.00 | 0.00 |
| | ATOM | 445 | CD | PRO | 229 | 9.554 | 3.589 | -10.947 | 1.00 | 0.00 |
| | ATOM | 446 | H | LYS | 230 | 9.050 | 0.657 | -11.843 | 1.00 | 0.00 |
| | ATOM | 447 | CA | LYS | 230 | 10.279 | -0.025 | -11.393 | 1.00 | 0.00 |
| | ATOM | 448 | C | LYS | 230 | 11.502 | 0.890 | -11.540 | 1.00 | 0.00 |
| 15 | ATOM | 449 | O | LYS | 230 | 11.469 | 1.845 | -12.310 | 1.00 | 0.00 |
| | ATOM | 450 | CB | LYS | 230 | 10.510 | -1.323 | -12.161 | 1.00 | 0.00 |
| | ATOM | 451 | CG | LYS | 230 | 9.426 | -2.317 | -11.769 | 1.00 | 0.00 |
| | ATOM | 452 | CD | LYS | 230 | 5.711 | -3.653 | -12.442 | 1.00 | 0.00 |
| | ATOM | 453 | CE | LYS | 230 | 9.307 | -3.566 | -13.909 | 1.00 | 0.00 |
| | ATOM | 454 | NZ | LYS | 230 | 9.583 | -4.831 | -14.605 | 1.00 | 0.00 |
| | ATOM | 455 | H | LYS | 230 | 9.184 | 1.324 | -12.586 | 1.00 | 0.00 |
| 20 | ATOM | 456 | H | GLU | 231 | 12.592 | 0.637 | -10.807 | 1.00 | 0.00 |
| | ATOM | 457 | CA | GLU | 231 | 12.722 | -0.424 | -9.848 | 1.00 | 0.00 |
| | ATOM | 458 | C | GLU | 231 | 12.257 | 0.053 | -8.480 | 1.00 | 0.00 |
| | ATOM | 459 | O | GLU | 231 | 11.349 | -0.545 | -7.906 | 1.00 | 0.00 |
| | ATOM | 460 | CB | GLU | 231 | 14.203 | -0.764 | -9.792 | 1.00 | 0.00 |
| | ATOM | 461 | CG | GLU | 231 | 14.336 | -2.243 | -9.506 | 1.00 | 0.00 |
| | ATOM | 462 | CD | GLU | 231 | 14.162 | -2.548 | -8.038 | 1.00 | 0.00 |
| 25 | ATOM | 463 | OE1 | GLU | 231 | 14.048 | -1.611 | -7.215 | 1.00 | 0.00 |
| | ATOM | 464 | OE2 | GLU | 231 | 14.192 | -3.765 | -7.766 | 1.00 | 0.00 |
| | ATOM | 465 | H | GLU | 231 | 13.410 | 1.212 | -10.927 | 1.00 | 0.00 |
| | ATOM | 466 | H | SER | 232 | 12.957 | 1.064 | -7.942 | 1.00 | 0.00 |
| | ATOM | 467 | CA | SER | 232 | 12.908 | 1.459 | -6.541 | 1.00 | 0.00 |
| | ATOM | 468 | C | SER | 232 | 11.648 | 2.237 | -6.206 | 1.00 | 0.00 |
| | ATOM | 469 | O | SER | 232 | 11.737 | 3.367 | -5.777 | 1.00 | 0.00 |
| 30 | ATOM | 470 | CB | SER | 232 | 14.167 | 2.218 | -6.095 | 1.00 | 0.00 |
| | ATOM | 471 | OG | SER | 232 | 15.017 | 2.584 | -7.161 | 1.00 | 0.00 |
| | ATOM | 472 | H | GLN | 233 | 10.492 | 1.580 | -6.381 | 1.00 | 0.00 |
| | ATOM | 473 | CA | GLN | 233 | 9.174 | 2.030 | -5.955 | 1.00 | 0.00 |
| | ATOM | 474 | C | GLN | 233 | 8.279 | 0.824 | -5.701 | 1.00 | 0.00 |
| | ATOM | 475 | O | GLN | 233 | 7.794 | 0.675 | -4.583 | 1.00 | 0.00 |
| | ATOM | 476 | CB | GLN | 233 | 8.559 | 3.081 | -6.882 | 1.00 | 0.00 |
| | ATOM | 477 | CG | GLN | 233 | 9.741 | 3.929 | -7.344 | 1.00 | 0.00 |
| 35 | ATOM | 478 | CD | GLN | 233 | 9.442 | 5.152 | -6.153 | 1.00 | 0.00 |
| | ATOM | 479 | OE1 | GLN | 233 | 10.307 | 5.642 | -8.874 | 1.00 | 0.00 |
| | ATOM | 480 | NE2 | GLN | 233 | 8.221 | 5.637 | -8.019 | 1.00 | 0.00 |
| | ATOM | 481 | H | GLN | 233 | 10.549 | 0.640 | -6.746 | 1.00 | 0.00 |
| | ATOM | 482 | H | ARG | 234 | 8.088 | -0.057 | -6.695 | 1.00 | 0.00 |
| | ATOM | 483 | CA | ARG | 234 | 7.367 | -1.307 | -6.485 | 1.00 | 0.00 |
| | ATOM | 484 | C | ARG | 234 | 5.845 | -1.090 | -6.342 | 1.00 | 0.00 |
| 40 | ATOM | 485 | O | ARG | 234 | 5.330 | -0.049 | -6.748 | 1.00 | 0.00 |
| | ATOM | 486 | CB | ARG | 234 | 7.730 | -2.318 | -7.576 | 1.00 | 0.00 |
| | ATOM | 487 | CG | ARG | 234 | 9.048 | -3.037 | -7.283 | 1.00 | 0.00 |
| | ATOM | 488 | CD | ARG | 234 | 9.002 | -4.416 | -7.944 | 1.00 | 0.00 |
| | ATOM | 489 | NE | ARG | 234 | 9.937 | -4.505 | -9.070 | 1.00 | 0.00 |
| | ATOM | 490 | CZ | ARG | 234 | 11.263 | -4.566 | -8.900 | 1.00 | 0.00 |
| | ATOM | 491 | NH1 | ARG | 234 | 11.751 | -4.685 | -7.661 | 1.00 | 0.00 |
| 45 | ATOM | 492 | NH2 | ARG | 234 | 12.089 | -4.487 | -9.954 | 1.00 | 0.00 |
| | ATOM | 493 | HE | ARG | 234 | 9.565 | -4.416 | -10.004 | 1.00 | 0.00 |
| | ATOM | 494 | HH21 | ARG | 234 | 11.710 | -4.427 | -10.888 | 1.00 | 0.00 |
| | ATOM | 495 | HH22 | ARG | 234 | 13.091 | -4.466 | -9.818 | 1.00 | 0.00 |
| | ATOM | 496 | HH11 | ARG | 234 | 11.129 | -4.814 | -6.879 | 1.00 | 0.00 |
| | ATOM | 497 | HH12 | ARG | 234 | 12.739 | -4.556 | -7.494 | 1.00 | 0.00 |
| | ATOM | 498 | H | ARG | 234 | 8.479 | 0.112 | -7.613 | 1.00 | 0.00 |

50

-44-

| | | | | | | | | | | |
|----|------|-----|------|-----|-----|--------|--------|--------|------|------|
| | ATOM | 499 | N | ASN | 235 | 5.153 | -2.065 | -5.727 | 1.00 | 0.00 |
| | ATOM | 500 | CA | ASN | 235 | 3.753 | -2.045 | -5.267 | 1.00 | 0.00 |
| | ATOM | 501 | C | ASN | 235 | 2.712 | -1.332 | -6.154 | 1.00 | 0.00 |
| | ATOM | 502 | O | ASN | 235 | 2.665 | -1.690 | -7.322 | 1.00 | 0.00 |
| 5 | ATOM | 503 | CB | ASN | 235 | 3.661 | -1.706 | -3.803 | 1.00 | 0.00 |
| | ATOM | 504 | CG | ASN | 235 | 4.364 | -2.678 | -2.871 | 1.00 | 0.00 |
| | ATOM | 505 | OD1 | ASN | 235 | 4.952 | -3.669 | -3.296 | 1.00 | 0.00 |
| | ATOM | 506 | ND2 | ASN | 235 | 4.312 | -2.367 | -1.577 | 1.00 | 0.00 |
| | ATOM | 507 | H | ASN | 235 | 5.693 | -2.873 | -5.446 | 1.00 | 0.00 |
| | ATOM | 508 | N | LEU | 236 | 1.834 | -0.377 | -5.772 | 1.00 | 0.00 |
| | ATOM | 509 | CA | LEU | 236 | 1.578 | 0.489 | -4.609 | 1.00 | 0.00 |
| | ATOM | 510 | C | LEU | 236 | 0.908 | -0.029 | -3.260 | 1.00 | 0.00 |
| 10 | ATOM | 511 | O | LEU | 236 | 1.598 | -0.823 | -2.649 | 1.00 | 0.00 |
| | ATOM | 512 | CB | LEU | 236 | 2.193 | 1.891 | -4.870 | 1.00 | 0.00 |
| | ATOM | 513 | CG | LEU | 236 | 3.308 | 2.518 | -4.023 | 1.00 | 0.00 |
| | ATOM | 514 | CD1 | LEU | 236 | 3.104 | 4.023 | -4.239 | 1.00 | 0.00 |
| | ATOM | 515 | CD2 | LEU | 236 | 3.079 | 2.194 | -2.547 | 1.00 | 0.00 |
| | ATOM | 516 | H | LEU | 236 | 1.373 | 0.020 | -6.586 | 1.00 | 0.00 |
| | ATOM | 517 | N | CYS | 237 | -0.298 | 0.334 | -2.711 | 1.00 | 0.00 |
| 15 | ATOM | 518 | CA | CYS | 237 | -1.183 | -0.729 | -2.136 | 1.00 | 0.00 |
| | ATOM | 519 | C | CYS | 237 | -0.433 | -1.750 | -1.296 | 1.00 | 0.00 |
| | ATOM | 520 | O | CYS | 237 | -0.024 | -1.471 | -0.170 | 1.00 | 0.00 |
| | ATOM | 521 | CB | CYS | 237 | -2.279 | -0.236 | -1.191 | 1.00 | 0.00 |
| | ATOM | 522 | SG | CYS | 237 | -3.968 | 0.155 | -1.674 | 1.00 | 0.00 |
| | ATOM | 523 | LPG1 | CYS | 237 | -3.841 | 0.387 | -2.269 | 1.00 | 0.00 |
| | ATOM | 524 | LPG2 | CYS | 237 | -3.841 | 0.387 | -2.269 | 1.00 | 0.00 |
| | ATOM | 525 | H | CYS | 237 | -0.351 | 1.183 | -2.124 | 1.00 | 0.00 |
| 20 | ATOM | 526 | N | LEU | 238 | -0.242 | -2.918 | -1.897 | 1.00 | 0.00 |
| | ATOM | 527 | CA | LEU | 238 | 0.655 | -3.954 | -1.427 | 1.00 | 0.00 |
| | ATOM | 528 | C | LEU | 238 | 1.163 | -4.755 | -2.625 | 1.00 | 0.00 |
| | ATOM | 529 | O | LEU | 238 | 0.506 | -4.831 | -3.664 | 1.00 | 0.00 |
| | ATOM | 530 | CB | LEU | 238 | -0.036 | -4.897 | -0.433 | 1.00 | 0.00 |
| | ATOM | 531 | CG | LEU | 238 | -0.169 | -4.294 | 0.966 | 1.00 | 0.00 |
| | ATOM | 532 | CD1 | LEU | 238 | -0.868 | -5.287 | 1.891 | 1.00 | 0.00 |
| 25 | ATOM | 533 | CD2 | LEU | 238 | 1.199 | -3.946 | 1.550 | 1.00 | 0.00 |
| | ATOM | 534 | H | LEU | 239 | -0.618 | -3.035 | -2.824 | 1.00 | 0.00 |
| | ATOM | 535 | N | LEU | 239 | 2.327 | -5.384 | -2.440 | 1.00 | 0.00 |
| | ATOM | 536 | CA | LEU | 239 | 2.617 | -6.483 | -3.258 | 1.00 | 0.00 |
| | ATOM | 537 | C | LEU | 239 | 3.628 | -6.080 | -4.461 | 1.00 | 0.00 |
| | ATOM | 538 | O | LEU | 239 | 3.171 | -5.321 | -5.334 | 1.00 | 0.00 |
| | ATOM | 539 | CB | LEU | 239 | 1.740 | -7.528 | -3.528 | 1.00 | 0.00 |
| 30 | ATOM | 540 | CG | LEU | 239 | 1.908 | -8.639 | -2.496 | 1.00 | 0.00 |
| | ATOM | 541 | CD1 | LEU | 239 | 0.601 | -8.863 | -1.742 | 1.00 | 0.00 |
| | ATOM | 542 | CD2 | LEU | 239 | 2.335 | -9.924 | -3.198 | 1.00 | 0.00 |
| | ATOM | 543 | H | LEU | 239 | 2.824 | -5.198 | -1.582 | 1.00 | 0.00 |
| | ATOM | 544 | N | LYS | 240 | 4.851 | -6.614 | -4.534 | 1.00 | 0.00 |
| | ATOM | 545 | CA | LYS | 240 | 5.799 | -6.378 | -5.605 | 1.00 | 0.00 |
| | ATOM | 546 | C | LYS | 240 | 6.949 | -5.529 | -5.069 | 1.00 | 0.00 |
| 35 | ATOM | 547 | O | LYS | 240 | 6.976 | -4.318 | -5.266 | 1.00 | 0.00 |
| | ATOM | 548 | CB | LYS | 240 | 6.283 | -7.734 | -6.123 | 1.00 | 0.00 |
| | ATOM | 549 | CG | LYS | 240 | 7.251 | -7.571 | -7.291 | 1.00 | 0.00 |
| | ATOM | 550 | CD | LYS | 240 | 6.006 | -8.882 | -7.496 | 1.00 | 0.00 |
| | ATOM | 551 | CE | LYS | 240 | 9.512 | -8.635 | -7.487 | 1.00 | 0.00 |
| | ATOM | 552 | NZ | LYS | 240 | 9.987 | -8.297 | -6.138 | 1.00 | 0.00 |
| | ATOM | 553 | HZ3 | LYS | 240 | 9.271 | -8.512 | -5.459 | 1.00 | 0.00 |
| | ATOM | 554 | HZ2 | LYS | 240 | 10.186 | -7.306 | -6.096 | 1.00 | 0.00 |
| 40 | ATOM | 555 | HZ1 | LYS | 240 | 10.828 | -8.611 | -5.921 | 1.00 | 0.00 |
| | ATOM | 556 | H | LYS | 240 | 5.139 | -7.224 | -3.782 | 1.00 | 0.00 |
| | ATOM | 557 | N | THR | 241 | 7.881 | -6.176 | -4.366 | 1.00 | 0.00 |
| | ATOM | 558 | CA | THR | 241 | 8.935 | -5.530 | -3.608 | 1.00 | 0.00 |
| | ATOM | 559 | C | THR | 241 | 10.061 | -5.017 | -4.495 | 1.00 | 0.00 |
| | ATOM | 560 | O | THR | 241 | 10.511 | -5.705 | -5.403 | 1.00 | 0.00 |
| | ATOM | 561 | CB | THR | 241 | 9.467 | -6.512 | -2.564 | 1.00 | 0.00 |
| 45 | ATOM | 562 | OG1 | THR | 241 | 9.808 | -7.739 | -3.172 | 1.00 | 0.00 |
| | ATOM | 563 | CG2 | THR | 241 | 9.408 | -6.763 | -1.494 | 1.00 | 0.00 |
| | ATOM | 564 | H | THR | 241 | 7.811 | -7.179 | -4.275 | 1.00 | 0.00 |
| | ATOM | 565 | N | SER | 242 | 10.543 | -3.815 | -4.189 | 1.00 | 0.00 |
| | ATOM | 566 | CA | SER | 242 | 11.665 | -3.203 | -4.845 | 1.00 | 0.00 |
| | ATOM | 567 | C | SER | 242 | 13.018 | -3.825 | -4.400 | 1.00 | 0.00 |
| | ATOM | 568 | O | SER | 242 | 13.061 | -4.651 | -3.491 | 1.00 | 0.00 |
| | ATOM | 569 | CB | SER | 242 | 11.633 | -1.679 | -4.677 | 1.00 | 0.00 |
| 50 | ATOM | 570 | OG | SER | 242 | 10.927 | -1.314 | -3.500 | 1.00 | 0.00 |
| | ATOM | 571 | HG | SER | 242 | 10.536 | -0.451 | -3.629 | 1.00 | 0.00 |

-45-

| | | | | | | | | | | |
|----|------|-----|---------|-----|-------|--------|--------|--------|------|------|
| 5 | ATOM | 572 | H | SER | 242 | 10.121 | -3.301 | -3.433 | 1.00 | 0.00 |
| | ATOM | 573 | N | GLU | 243 | 14.096 | -3.421 | -5.074 | 1.00 | 0.00 |
| | ATOM | 574 | CA | GLU | 243 | 15.463 | -3.924 | -4.930 | 1.00 | 0.00 |
| | ATOM | 575 | C | GLU | 243 | 16.173 | -3.201 | -3.819 | 1.00 | 0.00 |
| | ATOM | 576 | O | GLU | 243 | 17.025 | -3.805 | -3.167 | 1.00 | 0.00 |
| | ATOM | 577 | CB | GLU | 243 | 16.306 | -3.729 | -6.198 | 1.00 | 0.00 |
| | ATOM | 578 | CG | GLU | 243 | 16.667 | -2.254 | -6.432 | 1.00 | 0.00 |
| | ATOM | 579 | CD | GLU | 243 | 17.429 | -2.016 | -7.735 | 1.00 | 0.00 |
| | ATOM | 580 | OE1 | GLU | 243 | 17.705 | -2.999 | -8.435 | 1.00 | 0.00 |
| | ATOM | 581 | OE2 | GLU | 243 | 17.722 | -0.822 | -7.998 | 1.00 | 0.00 |
| 10 | ATOM | 582 | H | GLU | 243 | 13.959 | -2.682 | -5.745 | 1.00 | 0.00 |
| | ATOM | 583 | N | SER | 244 | 15.801 | -1.922 | -3.628 | 1.00 | 0.00 |
| | ATOM | 584 | CA | SER | 244 | 16.148 | -1.114 | -2.482 | 1.00 | 0.00 |
| | ATOM | 585 | C | SER | 244 | 16.136 | -1.999 | -1.243 | 1.00 | 0.00 |
| | ATOM | 586 | O | SER | 244 | 15.318 | -2.927 | -1.188 | 1.00 | 0.00 |
| | ATOM | 587 | CB | SER | 244 | 17.486 | -0.419 | -2.691 | 1.00 | 0.00 |
| | ATOM | 588 | OG | SER | 244 | 17.231 | 0.796 | -3.344 | 1.00 | 0.00 |
| | ATOM | 589 | H | SER | 244 | 15.093 | -1.533 | -4.228 | 1.00 | 0.00 |
| | ATOM | 590 | N | GLY | 245 | 17.069 | -1.682 | -0.312 | 1.00 | 0.00 |
| | ATOM | 591 | CA | GLY | 245 | 17.209 | -1.988 | 1.058 | 1.00 | 0.00 |
| 15 | ATOM | 592 | C | GLY | 245 | 15.841 | -1.550 | 1.463 | 1.00 | 0.00 |
| | ATOM | 593 | O | GLY | 245 | 15.488 | -0.435 | 1.794 | 1.00 | 0.00 |
| | ATOM | 594 | H | GLY | 245 | 17.629 | -0.865 | -0.435 | 1.00 | 0.00 |
| | ATOM | 595 | N | LEU | 246 | 15.062 | -2.443 | 1.395 | 1.00 | 0.00 |
| | ATOM | 596 | CA | LEU | 246 | 14.257 | -2.565 | 2.458 | 1.00 | 0.00 |
| | ATOM | 597 | C | LEU | 246 | 14.830 | -3.936 | 3.399 | 1.00 | 0.00 |
| | ATOM | 598 | O | LEU | 246 | 14.218 | -4.569 | 4.406 | 1.00 | 0.00 |
| | ATOM | 599 | CB | LEU | 246 | 13.130 | -2.566 | 1.278 | 1.00 | 0.00 |
| | ATOM | 600 | CG | LEU | 246 | 11.823 | -1.707 | 1.266 | 1.00 | 0.00 |
| | ATOM | 601 | CD1 | LEU | 246 | 11.202 | -1.722 | -0.173 | 1.00 | 0.00 |
| 20 | ATOM | 602 | CD2 | LEU | 246 | 12.335 | -0.380 | 1.719 | 1.00 | 0.00 |
| | ATOM | 603 | N | PRO | 247 | 14.743 | -4.728 | 2.392 | 1.00 | 0.00 |
| | ATOM | 604 | CA | PRO | 247 | 13.223 | -4.611 | 2.461 | 1.00 | 0.00 |
| | ATOM | 605 | C | PRO | 247 | 12.240 | -3.626 | 3.441 | 1.00 | 0.00 |
| | ATOM | 606 | O | PRO | 247 | 12.824 | -2.914 | 4.273 | 1.00 | 0.00 |
| | ATOM | 607 | CB | PRO | 247 | 13.957 | -2.569 | 2.914 | 1.00 | 0.00 |
| | ATOM | 608 | CG | PRO | 247 | 15.449 | -2.497 | 2.631 | 1.00 | 0.00 |
| | ATOM | 609 | CD | PRO | 247 | 15.939 | -3.910 | 2.357 | 1.00 | 0.00 |
| | ATOM | 610 | N | SER | 248 | 11.028 | -3.341 | 3.436 | 1.00 | 0.00 |
| | ATOM | 611 | CA | SER | 248 | 10.344 | -2.880 | 4.671 | 1.00 | 0.00 |
| 30 | ATOM | 612 | C | SER | 248 | 9.981 | -1.419 | 4.798 | 1.00 | 0.00 |
| | ATOM | 613 | O | SER | 248 | 10.806 | -0.559 | 5.081 | 1.00 | 0.00 |
| | ATOM | 614 | CB | SER | 248 | 10.815 | -3.586 | 5.956 | 1.00 | 0.00 |
| | ATOM | 615 | OG | SER | 248 | 10.762 | -5.004 | 5.836 | 1.00 | 0.00 |
| | ATOM | 616 | H | SER | 248 | 10.629 | -3.796 | 2.628 | 1.00 | 0.00 |
| | ATOM | 617 | N | THR | 249 | 8.696 | -1.185 | 4.570 | 1.00 | 0.00 |
| | ATOM | 618 | CA | THR | 249 | 8.012 | 0.046 | 4.865 | 1.00 | 0.00 |
| | ATOM | 619 | C | THR | 249 | 8.031 | 0.271 | 6.375 | 1.00 | 0.00 |
| | ATOM | 620 | O | THR | 249 | 8.026 | -0.677 | 7.165 | 1.00 | 0.00 |
| | ATOM | 621 | CB | THR | 249 | 6.567 | -0.150 | 4.372 | 1.00 | 0.00 |
| 35 | ATOM | 622 | OG1 | THR | 249 | 6.491 | -1.540 | 4.064 | 1.00 | 0.00 |
| | ATOM | 623 | CG2 | THR | 249 | 6.305 | 0.543 | 3.033 | 1.00 | 0.00 |
| | ATOM | 624 | N | ARG | 250 | 8.054 | 1.544 | 6.762 | 1.00 | 0.00 |
| | ATOM | 625 | CA | ARG | 250 | 7.984 | 1.926 | 8.154 | 1.00 | 0.00 |
| | ATOM | 626 | C | ARG | 250 | 6.561 | 1.756 | 8.672 | 1.00 | 0.00 |
| | ATOM | 627 | O | ARG | 250 | 5.629 | 2.364 | 8.147 | 1.00 | 0.00 |
| | ATOM | 628 | CB | ARG | 250 | 8.467 | 3.362 | 8.303 | 1.00 | 0.00 |
| | ATOM | 629 | CG | ARG | 250 | 8.586 | 3.702 | 9.783 | 1.00 | 0.00 |
| | ATOM | 630 | CD | ARG | 250 | 8.666 | 5.217 | 9.900 | 1.00 | 0.00 |
| | ATOM | 631 | NE | ARG | 250 | 8.423 | 5.667 | 11.271 | 1.00 | 0.00 |
| 40 | ATOM | 632 | CZ | ARG | 250 | 8.737 | 6.903 | 11.688 | 1.00 | 0.00 |
| | ATOM | 633 | NH1 | ARG | 250 | 9.277 | 7.782 | 10.830 | 1.00 | 0.00 |
| | ATOM | 634 | NH2 | ARG | 250 | 8.512 | 7.257 | 12.961 | 1.00 | 0.00 |
| | ATOM | 635 | HE | ARG | 250 | 7.996 | 5.016 | 11.914 | 1.00 | 0.00 |
| | ATOM | 636 | HH21ARG | 250 | 8.104 | 6.595 | 13.605 | 1.00 | 0.00 | |
| | ATOM | 637 | HH22ARG | 250 | 8.753 | 8.185 | 13.278 | 1.00 | 0.00 | |
| | ATOM | 638 | HH11ARG | 250 | 9.436 | 7.510 | 9.871 | 1.00 | 0.00 | |
| | ATOM | 639 | HH12ARG | 250 | 9.518 | 8.713 | 11.136 | 1.00 | 0.00 | |
| | ATOM | 640 | H | ARG | 250 | 8.073 | 2.267 | 8.059 | 1.00 | 0.00 |
| | ATOM | 641 | N | ILE | 251 | 6.402 | 0.928 | 8.708 | 1.00 | 0.00 |
| 50 | ATOM | 642 | CA | ILE | 251 | 5.102 | 0.701 | 10.311 | 1.00 | 0.00 |
| | ATOM | 643 | C | ILE | 251 | 5.175 | 0.642 | 11.836 | 1.00 | 0.00 |
| | ATOM | 644 | O | ILE | 251 | 4.756 | 1.589 | 12.499 | 1.00 | 0.00 |

-46-

| | | | | | | | | | | |
|----|------|-----|-----|-----|-----|--------|---------|--------|------|------|
| | ATOM | 645 | CB | ILE | 251 | 4.382 | -0.492 | 9.656 | 1.00 | 0.00 |
| | ATOM | 646 | CG1 | ILE | 251 | 5.248 | -1.752 | 9.708 | 1.00 | 0.00 |
| | ATOM | 647 | CG2 | ILE | 251 | 3.948 | -0.154 | 8.228 | 1.00 | 0.00 |
| | ATOM | 648 | CD1 | ILE | 251 | 4.532 | -2.938 | 9.057 | 1.00 | 0.00 |
| | ATOM | 649 | H | ILE | 251 | 7.202 | 0.448 | 10.094 | 1.00 | 0.00 |
| 5 | ATOM | 650 | N | LYS | 252 | 5.683 | -0.463 | 12.392 | 1.00 | 0.00 |
| | ATOM | 651 | CA | LYS | 252 | 5.685 | -0.680 | 13.627 | 1.00 | 0.00 |
| | ATOM | 652 | C | LYS | 252 | 6.616 | -1.829 | 14.190 | 1.00 | 0.00 |
| | ATOM | 653 | O | LYS | 252 | 7.587 | -1.625 | 14.918 | 1.00 | 0.00 |
| | ATOM | 654 | CB | LYS | 252 | 4.248 | -0.953 | 14.311 | 1.00 | 0.00 |
| | ATOM | 655 | CG | LYS | 252 | 4.137 | -0.776 | 15.826 | 1.00 | 0.00 |
| | ATOM | 656 | CD | LYS | 252 | 5.522 | -0.659 | 16.468 | 1.00 | 0.00 |
| 10 | ATOM | 657 | CE | LYS | 252 | 5.410 | -0.482 | 17.983 | 1.00 | 0.00 |
| | ATOM | 658 | NZ | LYS | 252 | 6.747 | -0.371 | 18.589 | 1.00 | 0.00 |
| | ATOM | 659 | H | LYS | 252 | 6.036 | -1.202 | 11.802 | 1.00 | 0.00 |
| | ATOM | 660 | N | LYS | 253 | 6.313 | -3.031 | 13.686 | 1.00 | 0.00 |
| | ATOM | 661 | CA | LYS | 253 | 7.107 | -4.220 | 13.938 | 1.00 | 0.00 |
| | ATOM | 662 | C | LYS | 253 | 8.538 | -4.066 | 13.435 | 1.00 | 0.00 |
| | ATOM | 663 | O | LYS | 253 | 8.793 | -3.355 | 12.463 | 1.00 | 0.00 |
| 15 | ATOM | 664 | CB | LYS | 253 | 6.424 | -5.451 | 13.314 | 1.00 | 0.00 |
| | ATOM | 665 | CG | LYS | 253 | 5.153 | -5.821 | 14.082 | 1.00 | 0.00 |
| | ATOM | 666 | CD | LYS | 253 | 4.555 | -7.128 | 13.556 | 1.00 | 0.00 |
| | ATOM | 667 | CE | LYS | 253 | 4.137 | -8.042 | 14.709 | 1.00 | 0.00 |
| | ATOM | 668 | NZ | LYS | 253 | 3.415 | -9.219 | 14.197 | 1.00 | 0.00 |
| | ATOM | 669 | H | LYS | 253 | 5.491 | -3.129 | 13.107 | 1.00 | 0.00 |
| | ATOM | 670 | N | SER | 254 | 9.467 | -4.730 | 14.130 | 1.00 | 0.00 |
| 20 | ATOM | 671 | CA | SER | 254 | 10.893 | -4.649 | 13.865 | 1.00 | 0.00 |
| | ATOM | 672 | C | SER | 254 | 11.248 | -5.052 | 12.437 | 1.00 | 0.00 |
| | ATOM | 673 | O | SER | 254 | 10.779 | -6.071 | 11.932 | 1.00 | 0.00 |
| | ATOM | 674 | CB | SER | 254 | 11.663 | -5.458 | 14.925 | 1.00 | 0.00 |
| | ATOM | 675 | OG | SER | 254 | 12.165 | -4.629 | 15.969 | 1.00 | 0.00 |
| | ATOM | 676 | H | SER | 254 | 9.172 | -5.289 | 14.918 | 1.00 | 0.00 |
| | ATOM | 677 | N | LYS | 255 | 12.115 | -4.250 | 11.812 | 1.00 | 0.00 |
| 25 | ATOM | 678 | CA | LYS | 255 | 12.760 | -4.621 | 10.569 | 1.00 | 0.00 |
| | ATOM | 679 | C | LYS | 255 | 13.918 | -5.557 | 10.892 | 1.00 | 0.00 |
| | ATOM | 680 | O | LYS | 255 | 14.866 | -5.167 | 11.572 | 1.00 | 0.00 |
| | ATOM | 681 | CB | LYS | 255 | 13.250 | -3.358 | 9.836 | 1.00 | 0.00 |
| | ATOM | 682 | CG | LYS | 255 | 13.936 | -3.721 | 8.518 | 1.00 | 0.00 |
| | ATOM | 683 | CD | LYS | 255 | 14.422 | -2.466 | 7.789 | 1.00 | 0.00 |
| | ATOM | 684 | CE | LYS | 255 | 15.109 | -2.829 | 6.471 | 1.00 | 0.00 |
| | ATOM | 685 | NZ | LYS | 255 | 15.572 | -1.615 | 5.780 | 1.00 | 0.00 |
| 30 | ATOM | 686 | H | LYS | 255 | 12.446 | -3.420 | 12.284 | 1.00 | 0.00 |
| | ATOM | 687 | N | ALA | 256 | 13.817 | -6.806 | 10.431 | 1.00 | 0.00 |
| | ATOM | 688 | CA | ALA | 256 | 14.802 | -7.828 | 10.729 | 1.00 | 0.00 |
| | ATOM | 689 | C | ALA | 256 | 15.023 | -8.716 | 9.514 | 1.00 | 0.00 |
| | ATOM | 690 | O | ALA | 256 | 14.057 | -9.139 | 8.878 | 1.00 | 0.00 |
| | ATOM | 691 | CB | ALA | 256 | 14.345 | -8.652 | 11.929 | 1.00 | 0.00 |
| | ATOM | 692 | H | ALA | 256 | 13.017 | -7.064 | 9.870 | 1.00 | 0.00 |
| 35 | ATOM | 693 | N | LEU | 257 | 16.299 | -8.981 | 9.199 | 1.00 | 0.00 |
| | ATOM | 694 | CA | LEU | 257 | 16.736 | -9.736 | 8.029 | 1.00 | 0.00 |
| | ATOM | 695 | C | LEU | 257 | 16.594 | -8.912 | 6.759 | 1.00 | 0.00 |
| | ATOM | 696 | O | LEU | 257 | 17.580 | -8.601 | 6.093 | 1.00 | 0.00 |
| | ATOM | 697 | CB | LEU | 257 | 16.061 | -11.118 | 7.947 | 1.00 | 0.00 |
| | ATOM | 698 | CG | LEU | 257 | 16.351 | -12.076 | 9.105 | 1.00 | 0.00 |
| | ATOM | 699 | CD1 | LEU | 257 | 15.160 | -12.154 | 10.062 | 1.00 | 0.00 |
| | ATOM | 700 | CD2 | LEU | 257 | 16.761 | -13.455 | 8.585 | 1.00 | 0.00 |
| 40 | ATOM | 701 | H | LEU | 257 | 17.024 | -8.606 | 9.794 | 1.00 | 0.00 |
| | ATOM | 702 | N | SER | 258 | 15.363 | -8.505 | 6.460 | 1.00 | 0.00 |
| | ATOM | 703 | CA | SER | 258 | 15.095 | -7.393 | 5.595 | 1.00 | 0.00 |
| | ATOM | 704 | C | SER | 258 | 15.858 | -6.159 | 6.163 | 1.00 | 0.00 |
| | ATOM | 705 | O | SER | 258 | 15.989 | -5.994 | 7.392 | 1.00 | 0.00 |
| | ATOM | 706 | CE | SER | 258 | 13.554 | -7.327 | 5.494 | 1.00 | 0.00 |
| | ATOM | 707 | OG | SER | 258 | 12.953 | -8.569 | 5.075 | 1.00 | 0.00 |
| 45 | ATOM | 708 | HG | SER | 258 | 12.045 | -8.389 | 4.799 | 1.00 | 0.00 |
| | ATOM | 709 | H | SER | 258 | 14.581 | -8.797 | 7.031 | 1.00 | 0.00 |
| | ATOM | 710 | N | GLY | 259 | 16.428 | -5.338 | 5.234 | 1.00 | 0.00 |
| | ATOM | 711 | CA | GLY | 259 | 16.803 | -3.904 | 5.425 | 1.00 | 0.00 |
| | ATOM | 712 | C | GLY | 259 | 15.798 | -2.862 | 5.997 | 1.00 | 0.00 |
| | ATOM | 713 | O | GLY | 259 | 14.832 | -3.188 | 6.682 | 1.00 | 0.00 |
| | ATOM | 714 | H | GLY | 259 | 15.961 | -5.509 | 4.368 | 1.00 | 0.00 |
| | ATOM | 715 | N | PHE | 260 | 16.125 | -1.593 | 5.737 | 1.00 | 0.00 |
| 50 | ATOM | 716 | CA | PHE | 260 | 15.508 | -0.436 | 6.360 | 1.00 | 0.00 |
| | ATOM | 717 | C | PHE | 260 | 16.089 | 0.638 | 5.752 | 1.00 | 0.00 |

| | | | | | | | | | | |
|----|------|-----|-----|-----|-----|--------|--------|--------|------|------|
| 5 | ATOM | 716 | O | PHE | 260 | 17.202 | 1.238 | 6.092 | 1.00 | 0.00 |
| | ATOM | 719 | CB | PHE | 260 | 15.745 | -0.484 | 7.881 | 1.00 | 0.00 |
| | ATOM | 720 | CG | PHE | 260 | 15.177 | 0.700 | 8.651 | 1.00 | 0.00 |
| | ATOM | 721 | CD1 | PHE | 260 | 13.792 | 0.984 | 8.606 | 1.00 | 0.00 |
| | ATOM | 722 | CD2 | PHE | 260 | 16.035 | 1.529 | 9.410 | 1.00 | 0.00 |
| | ATOM | 723 | CE1 | PHE | 260 | 13.270 | 2.085 | 9.318 | 1.00 | 0.00 |
| | ATOM | 724 | CE2 | PHE | 260 | 15.512 | 2.630 | 10.121 | 1.00 | 0.00 |
| | ATOM | 725 | CZ | PHE | 260 | 14.130 | 2.908 | 10.075 | 1.00 | 0.00 |
| | ATOM | 726 | H | PHE | 260 | 16.923 | -1.427 | 5.137 | 1.00 | 0.00 |
| | ATOM | 727 | N | SER | 261 | 15.320 | 1.476 | 4.864 | 1.00 | 0.00 |
| | ATOM | 728 | CA | SER | 261 | 15.673 | 2.780 | 4.327 | 1.00 | 0.00 |
| | ATOM | 729 | C | SER | 261 | 14.470 | 3.530 | 3.751 | 1.00 | 0.00 |
| 10 | ATOM | 730 | O | SER | 261 | 13.329 | 3.093 | 3.896 | 1.00 | 0.00 |
| | ATOM | 731 | CB | SER | 261 | 16.871 | 2.703 | 3.376 | 1.00 | 0.00 |
| | ATOM | 732 | OG | SER | 261 | 16.596 | 1.901 | 2.252 | 1.00 | 0.00 |
| | ATOM | 733 | HG | SER | 261 | 16.853 | 0.997 | 2.454 | 1.00 | 0.00 |
| | ATOM | 734 | H | SER | 261 | 14.420 | 1.088 | 4.620 | 1.00 | 0.00 |
| | ATOM | 735 | N | LEU | 262 | 14.733 | 4.683 | 3.125 | 1.00 | 0.00 |
| | ATOM | 736 | CA | LEU | 262 | 13.699 | 5.605 | 2.692 | 1.00 | 0.00 |
| | ATOM | 737 | C | LEU | 262 | 13.023 | 5.163 | 1.402 | 1.00 | 0.00 |
| 15 | ATOM | 738 | O | LEU | 262 | 13.624 | 5.222 | 0.331 | 1.00 | 0.00 |
| | ATOM | 739 | CB | LEU | 262 | 14.302 | 7.014 | 2.505 | 1.00 | 0.00 |
| | ATOM | 740 | CG | LEU | 262 | 14.632 | 7.779 | 3.788 | 1.00 | 0.00 |
| | ATOM | 741 | CD1 | LEU | 262 | 13.483 | 8.708 | 4.183 | 1.00 | 0.00 |
| | ATOM | 742 | CD2 | LEU | 262 | 15.007 | 6.818 | 4.918 | 1.00 | 0.00 |
| | ATOM | 743 | H | LEU | 262 | 15.692 | 4.980 | 3.028 | 1.00 | 0.00 |
| | ATOM | 744 | N | GLN | 263 | 11.746 | 4.782 | 1.502 | 1.00 | 0.00 |
| 20 | ATOM | 745 | CA | GLN | 263 | 10.901 | 4.646 | 0.330 | 1.00 | 0.00 |
| | ATOM | 746 | C | GLN | 263 | 10.115 | 5.935 | 0.106 | 1.00 | 0.00 |
| | ATOM | 747 | O | GLN | 263 | 9.526 | 6.480 | 1.039 | 1.00 | 0.00 |
| | ATOM | 748 | CB | GLN | 263 | 9.996 | 3.405 | 0.441 | 1.00 | 0.00 |
| | ATOM | 749 | CG | GLN | 263 | 9.007 | 3.550 | 1.600 | 1.00 | 0.00 |
| | ATOM | 750 | CD | GLN | 263 | 8.396 | 2.197 | 1.972 | 1.00 | 0.00 |
| | ATOM | 751 | OE1 | GLN | 263 | 7.313 | 2.107 | 2.526 | 1.00 | 0.00 |
| 25 | ATOM | 752 | NE2 | GLN | 263 | 9.149 | 1.153 | 1.637 | 1.00 | 0.00 |
| | ATOM | 753 | H | GLN | 263 | 11.308 | 4.731 | 2.410 | 1.00 | 0.00 |
| | ATOM | 754 | N | SER | 264 | 10.122 | 6.431 | -1.134 | 1.00 | 0.00 |
| | ATOM | 755 | CA | SER | 264 | 9.404 | 7.642 | -1.482 | 1.00 | 0.00 |
| | ATOM | 756 | C | SER | 264 | 8.655 | 7.466 | -2.800 | 1.00 | 0.00 |
| | ATOM | 757 | O | SER | 264 | 9.186 | 6.936 | -3.764 | 1.00 | 0.00 |
| | ATOM | 758 | CB | SER | 264 | 10.364 | 8.846 | -1.515 | 1.00 | 0.00 |
| | ATOM | 759 | CG | SER | 264 | 10.310 | 9.605 | -0.310 | 1.00 | 0.00 |
| 30 | ATOM | 760 | H | SER | 264 | 10.627 | 5.946 | -1.864 | 1.00 | 0.00 |
| | ATOM | 761 | N | CYS | 265 | 7.423 | 8.013 | -2.829 | 1.00 | 0.00 |
| | ATOM | 762 | | | | | | | | |

-48-

APPENDIX 2

Factor XI Heavy Chain Domain A1

| | | | | | | |
|----|------|---------|-----|---|---------|----------------|
| 5 | | | | | | |
| | ATOM | 1 N | GLU | 1 | 155.502 | 3.466 -12.472 |
| | ATOM | 2 HN | GLU | 1 | 156.178 | 4.244 -12.172 |
| | ATOM | 3 HN | GLU | 1 | 155.722 | 3.318 -13.473 |
| | ATOM | 4 HN | GLU | 1 | 154.618 | 3.718 -12.305 |
| 10 | ATOM | 5 CA | GLU | 1 | 155.885 | 2.210 -11.762 |
| | ATOM | 6 C | GLU | 1 | 156.562 | 2.369 -10.453 |
| | ATOM | 7 O | GLU | 1 | 157.713 | 1.882 -10.388 |
| | ATOM | 8 CB | GLU | 1 | 154.648 | 1.284 -11.743 |
| | ATOM | 9 CG | GLU | 1 | 154.949 | -0.199 -11.441 |
| | ATOM | 10 CD | GLU | 1 | 153.782 | -1.021 -11.086 |
| | ATOM | 11 OE1 | GLU | 1 | 153.604 | -1.365 -0.898 |
| 15 | ATOM | 12 OE2 | GLU | 1 | 152.955 | -1.359 -11.974 |
| | ATOM | 13 N | CYS | 2 | 155.118 | 2.949 -9.335 |
| | ATOM | 14 HN | CYS | 2 | 156.695 | 2.937 -8.596 |
| | ATOM | 15 CA | CYS | 2 | 154.884 | 3.576 -9.172 |
| | ATOM | 16 C | CYS | 2 | 153.796 | 2.787 -8.544 |
| | ATOM | 17 O | CYS | 2 | 153.948 | 2.209 -7.446 |
| 20 | ATOM | 18 CB | CYS | 2 | 155.075 | 4.997 -8.614 |
| | ATOM | 19 SG | CYS | 2 | 155.135 | 5.111 -5.849 |
| | ATOM | 20 N | VAL | 3 | 152.578 | 2.596 -9.016 |
| | ATOM | 21 HN | VAL | 3 | 152.002 | 2.129 -8.439 |
| | ATOM | 22 CA | VAL | 3 | 152.016 | 2.970 -10.231 |
| | ATOM | 23 C | VAL | 3 | 152.287 | 4.239 -10.846 |
| | ATOM | 24 O | VAL | 3 | 152.731 | 4.208 -12.015 |
| 25 | ATOM | 25 CB | VAL | 3 | 150.650 | 2.274 -10.451 |
| | ATOM | 26 CG1 | VAL | 3 | 149.381 | 3.139 -10.483 |
| | ATOM | 27 CG2 | VAL | 3 | 150.658 | 1.399 -11.710 |
| | ATOM | 28 N | THR | 4 | 152.193 | 5.638 -10.410 |
| | ATOM | 29 HN | THR | 4 | 152.282 | 6.174 -11.095 |
| | ATOM | 30 CA | THR | 4 | 151.998 | 6.118 -9.146 |
| | ATOM | 31 C | THR | 4 | 151.164 | 5.502 -8.090 |
| 30 | ATOM | 32 O | THR | 4 | 149.913 | 5.459 -8.245 |
| | ATOM | 33 CB | THR | 4 | 151.882 | 7.651 -5.355 |
| | ATOM | 34 OG1 | THR | 4 | 152.452 | 6.394 -8.291 |
| | ATOM | 35 HOG1 | THR | 4 | 151.971 | 8.213 -7.456 |
| | ATOM | 36 CG2 | THR | 4 | 150.512 | 8.250 -9.703 |
| | ATOM | 37 N | GLN | 5 | 151.782 | 5.013 -7.605 |
| | ATOM | 38 HN | GLN | 5 | 152.719 | 5.098 -6.564 |
| 35 | ATOM | 39 CA | GLN | 5 | 151.136 | 4.400 -5.925 |
| | ATOM | 40 C | GLN | 5 | 151.342 | 4.870 -4.534 |
| | ATOM | 41 O | GLN | 5 | 152.411 | 5.374 -4.099 |
| | ATOM | 42 CB | GLN | 5 | 151.002 | 2.855 -6.084 |
| | ATOM | 43 CG | GLN | 5 | 149.616 | 2.421 -6.502 |
| | ATOM | 44 CD | GLN | 5 | 148.423 | 3.029 -5.991 |
| | ATOM | 45 OE1 | GLN | 5 | 148.212 | 3.038 -4.756 |
| 40 | ATOM | 46 NE2 | GLN | 5 | 147.525 | 3.602 -6.750 |
| | ATOM | 47 HNE1 | GLN | 5 | 147.520 | 3.544 -7.656 |
| | ATOM | 48 HNE2 | GLN | 5 | 145.827 | 4.079 -6.342 |
| | ATOM | 49 N | LEU | 6 | 150.251 | 4.705 -5.762 |
| | ATOM | 50 HN | LEU | 6 | 149.592 | 4.193 -4.143 |
| | ATOM | 51 CA | LEU | 6 | 149.977 | 5.145 -2.479 |
| | ATOM | 52 C | LEU | 6 | 148.624 | 5.753 -2.402 |
| | ATOM | 53 O | LEU | 6 | 148.551 | 6.765 -1.665 |
| 45 | ATOM | 54 CB | LEU | 6 | 150.051 | 3.938 -1.525 |
| | ATOM | 55 CG | LEU | 6 | 151.098 | 4.158 -0.401 |
| | ATOM | 56 CD1 | LEU | 6 | 150.408 | 4.034 0.960 |
| | ATOM | 57 CD2 | LEU | 6 | 152.198 | 3.105 0.450 |
| | ATOM | 58 N | LEU | 7 | 147.555 | 5.761 2.057 |
| 50 | | | | | | |

-49-

| | | | | | | | |
|----|------|---------|-----|----|---------|--------|--------|
| 5 | ATOM | 59 HN | LEU | 7 | 147.772 | 4.532 | -3.620 |
| | ATOM | 60 CA | LEU | 7 | 146.195 | 5.609 | -3.102 |
| | ATOM | 61 C | LEU | 7 | 145.476 | 4.882 | -4.182 |
| | ATOM | 62 O | LEU | 7 | 145.529 | 5.277 | -5.385 |
| | ATOM | 63 CB | LEU | 7 | 145.787 | 7.101 | -2.951 |
| 10 | ATOM | 64 CG | LEU | 7 | 146.325 | 0.072 | -4.016 |
| | ATOM | 65 CD1 | LEU | 7 | 145.169 | 0.619 | -4.959 |
| | ATOM | 66 CD2 | LEU | 7 | 147.021 | 9.261 | -3.351 |
| | ATOM | 67 N | LYS | 8 | 144.765 | 3.799 | -3.866 |
| | ATOM | 68 HN | LYS | 8 | 144.763 | 3.509 | -2.374 |
| 15 | ATOM | 69 CA | LYS | 8 | 143.893 | 3.023 | -4.739 |
| | ATOM | 70 C | LYS | 8 | 144.410 | 1.608 | -4.382 |
| | ATOM | 71 O | LYS | 8 | 144.485 | 0.852 | -3.374 |
| | ATOM | 72 CB | LYS | 8 | 142.513 | 3.214 | -4.344 |
| | ATOM | 73 CG | LYS | 8 | 141.465 | 2.712 | -5.371 |
| 20 | ATOM | 74 CD | LYS | 8 | 140.991 | 1.325 | -4.346 |
| | ATOM | 75 CE | LYS | 8 | 140.023 | 0.708 | -5.960 |
| | ATOM | 76 NZ | LYS | 8 | 140.186 | -0.739 | -5.676 |
| | ATOM | 77 HN21 | LYS | 8 | 139.435 | -1.221 | -6.371 |
| | ATOM | 78 HN22 | LYS | 8 | 140.189 | -0.578 | -4.664 |
| 25 | ATOM | 79 HN23 | LYS | 8 | 141.094 | -0.557 | -6.265 |
| | ATOM | 80 N | ASP | 9 | 144.672 | 1.200 | -6.124 |
| | ATOM | 81 HN | ASP | 9 | 144.709 | 1.881 | -5.772 |
| | ATOM | 82 CA | ASP | 9 | 144.891 | -0.101 | -6.603 |
| | ATOM | 83 C | ASP | 9 | 143.845 | -1.107 | -6.287 |
| 30 | ATOM | 84 O | ASP | 9 | 142.831 | -1.146 | -7.034 |
| | ATOM | 85 CB | ASP | 9 | 146.376 | -0.532 | -5.713 |
| | ATOM | 86 CG | ASP | 9 | 147.134 | -0.760 | -5.465 |
| | ATOM | 87 OD1 | ASP | 9 | 146.805 | -1.655 | -4.683 |
| | ATOM | 88 OD2 | ASP | 9 | 148.133 | -0.072 | -5.245 |
| 35 | ATOM | 89 N | THR | 10 | 143.988 | -1.917 | -5.243 |
| | ATOM | 90 HN | THR | 10 | 144.876 | -1.939 | -4.942 |
| | ATOM | 91 CA | THR | 10 | 143.038 | -2.694 | -4.854 |
| | ATOM | 92 C | THR | 10 | 142.222 | -3.760 | -5.165 |
| | ATOM | 93 O | THR | 10 | 140.588 | -3.693 | -4.955 |
| 40 | ATOM | 94 CB | THR | 10 | 143.281 | -2.906 | -3.943 |
| | ATOM | 95 OG1 | THR | 10 | 143.021 | -1.708 | -2.823 |
| | ATOM | 96 HOG1 | THR | 10 | 142.094 | -1.453 | -2.869 |
| | ATOM | 97 CG2 | THR | 10 | 144.589 | -3.580 | -2.603 |
| | ATOM | 98 N | CYS | 11 | 142.534 | -4.782 | -5.671 |
| 45 | ATOM | 99 HN | CYS | 11 | 141.780 | -5.203 | -6.355 |
| | ATOM | 100 CA | CYS | 11 | 143.754 | 5.367 | -5.327 |
| | ATOM | 101 C | CYS | 11 | 144.168 | 6.599 | -5.532 |
| | ATOM | 102 O | CYS | 11 | 144.496 | 7.569 | -6.201 |
| | ATOM | 103 CB | CYS | 11 | 144.945 | -4.506 | -6.741 |
| 50 | ATOM | 104 SG | CYS | 11 | 145.271 | -4.699 | -6.511 |
| | ATOM | 105 HSG | CYS | 11 | 145.380 | 3.913 | -6.569 |
| | ATOM | 106 N | PHE | 12 | 144.192 | -6.621 | -4.262 |
| | ATOM | 107 HN | PHE | 12 | 143.821 | -5.978 | -3.818 |
| | ATOM | 108 CA | PHE | 12 | 144.726 | -7.637 | -3.453 |
| | ATOM | 109 C | PHE | 12 | 143.768 | -8.156 | -2.864 |
| | ATOM | 110 O | PHE | 12 | 143.307 | -7.402 | -1.501 |
| | ATOM | 111 CB | PHE | 12 | 146.072 | -7.196 | -2.846 |
| | ATOM | 112 CG | PHE | 12 | 147.138 | 6.762 | -3.712 |
| | ATOM | 113 CD1 | PHE | 12 | 147.545 | -5.403 | -3.718 |
| | ATOM | 114 CD2 | PHE | 12 | 147.754 | 7.575 | -4.619 |
| | ATOM | 115 CE1 | PHE | 12 | 148.577 | -4.953 | -4.516 |
| | ATOM | 116 CE2 | PHE | 12 | 148.732 | -7.229 | -5.514 |
| | ATOM | 117 CZ | PHE | 12 | 149.197 | -5.373 | -5.869 |
| | ATOM | 118 N | GLU | 12 | 143.315 | 9.401 | -2.352 |

-50-

| | | | | | | | |
|----|------|----------|-----|----|---------|---------|--------|
| 5 | ATOM | 119 HN | GLU | 13 | 142.620 | -9.571 | -1.772 |
| | ATOM | 120 CA | GLU | 13 | 143.776 | -10.489 | -3.121 |
| | ATOM | 121 C | GLU | 13 | 142.862 | -10.880 | -4.288 |
| | ATOM | 122 O | GLU | 13 | 141.863 | -11.490 | -4.144 |
| | ATOM | 123 CB | GLU | 13 | 144.145 | -11.635 | -2.161 |
| 10 | ATOM | 124 CG | GLU | 13 | 145.433 | -12.354 | -2.592 |
| | ATOM | 125 CD | GLU | 13 | 146.631 | -11.528 | -2.433 |
| | ATOM | 126 OE1 | GLU | 13 | 147.331 | -11.595 | -1.401 |
| | ATOM | 127 OE2 | GLU | 13 | 146.980 | -10.728 | -3.324 |
| | ATOM | 128 N | GLY | 14 | 143.486 | -10.540 | -5.461 |
| 15 | ATOM | 129 HN | GLY | 14 | 144.265 | -10.016 | -5.433 |
| | ATOM | 130 CA | GLY | 14 | 143.018 | -10.858 | -6.738 |
| | ATOM | 131 C | GLY | 14 | 141.920 | -10.013 | -7.226 |
| | ATOM | 132 O | GLY | 14 | 140.812 | -10.594 | -7.395 |
| | ATOM | 133 N | GLY | 15 | 142.145 | -8.716 | -7.456 |
| 20 | ATOM | 134 HN | GLY | 15 | 142.963 | -8.373 | -7.148 |
| | ATOM | 135 CA | GLY | 15 | 141.294 | -7.807 | -8.051 |
| | ATOM | 136 C | GLY | 15 | 140.238 | -7.233 | -7.247 |
| | ATOM | 137 O | GLY | 15 | 140.177 | -5.981 | -7.166 |
| | ATOM | 138 N | ASP | 16 | 139.419 | -8.069 | -6.628 |
| 25 | ATOM | 139 HN | ASP | 16 | 139.671 | -8.967 | -6.720 |
| | ATOM | 140 CA | ASP | 16 | 138.206 | -7.734 | -5.897 |
| | ATOM | 141 C | ASP | 16 | 138.375 | -7.886 | -4.426 |
| | ATOM | 142 O | ASP | 16 | 138.640 | -8.581 | -3.859 |
| | ATOM | 143 CB | ASP | 16 | 137.033 | -8.351 | -6.540 |
| 30 | ATOM | 144 CG | ASP | 16 | 136.512 | -7.501 | -7.612 |
| | ATOM | 145 OD1 | ASP | 16 | 135.536 | -6.754 | -7.389 |
| | ATOM | 146 OD2 | ASP | 16 | 137.031 | -7.514 | -5.752 |
| | ATOM | 147 N | ILE | 17 | 138.180 | -5.896 | -3.569 |
| | ATOM | 148 HN | ILE | 17 | 138.170 | -7.190 | -2.677 |
| 35 | ATOM | 149 CA | ILE | 17 | 137.890 | -5.526 | -3.826 |
| | ATOM | 150 C | ILE | 17 | 138.187 | -4.673 | -2.626 |
| | ATOM | 151 O | ILE | 17 | 137.389 | -4.773 | -1.666 |
| | ATOM | 152 CB | ILE | 17 | 136.758 | -5.173 | -4.715 |
| | ATOM | 153 CG1 | ILE | 17 | 136.766 | -3.743 | -5.260 |
| 40 | ATOM | 154 CG2 | ILE | 17 | 135.364 | -5.486 | -4.140 |
| | ATOM | 155 CD1 | ILE | 17 | 137.529 | -3.639 | -6.606 |
| | ATOM | 156 N | THR | 18 | 139.202 | -3.814 | -2.630 |
| | ATOM | 157 HN | THR | 18 | 139.785 | -3.808 | -3.368 |
| | ATOM | 158 CA | THR | 18 | 139.468 | -2.898 | -1.596 |
| 45 | ATOM | 159 C | THR | 18 | 139.489 | -1.461 | -2.018 |
| | ATOM | 160 O | THR | 18 | 140.263 | -1.089 | -2.921 |
| | ATOM | 161 CB | THR | 18 | 140.520 | -3.227 | -0.515 |
| | ATOM | 162 OG1 | THR | 18 | 141.493 | 4.220 | -0.807 |
| | ATOM | 163 HOG1 | THR | 18 | 142.251 | -4.068 | -0.205 |
| 50 | ATOM | 164 CG2 | THR | 18 | 139.844 | -3.581 | 0.811 |
| | ATOM | 165 N | THR | 19 | 138.734 | -0.517 | -1.517 |
| | ATOM | 166 HN | THR | 19 | 138.733 | 0.297 | -1.987 |
| | ATOM | 167 CA | THR | 19 | 137.943 | -0.551 | -0.364 |
| | ATOM | 168 C | THR | 19 | 136.796 | -1.486 | -0.274 |
| | ATOM | 169 O | THR | 19 | 136.739 | -2.160 | 0.783 |
| | ATOM | 170 CB | THR | 19 | 137.722 | 0.911 | 0.100 |
| | ATOM | 171 OG1 | THR | 19 | 137.773 | 1.050 | 1.510 |
| | ATOM | 172 HOG1 | THR | 19 | 138.467 | 0.460 | 1.896 |
| | ATOM | 173 CG2 | THR | 19 | 136.504 | 1.684 | -0.436 |
| | ATOM | 174 N | VAL | 20 | 135.808 | -1.577 | -1.263 |
| | ATOM | 175 HN | VAL | 20 | 136.213 | -1.292 | -2.166 |
| | ATOM | 176 CA | VAL | 20 | 134.578 | -2.011 | -1.260 |
| | ATOM | 177 C | VAL | 20 | 134.128 | -3.255 | -0.517 |
| | ATOM | 178 O | VAL | 20 | 133.012 | -3.129 | 0.026 |

-51-

| | | | | | | | | |
|----|------|-----|------|-----|----|---------|---------|--------|
| | ATOM | 179 | CB | VAL | 20 | 133.843 | -1.507 | -2.488 |
| | ATOM | 180 | CG1 | VAL | 20 | 133.315 | -2.553 | -3.402 |
| | ATOM | 181 | CG2 | VAL | 20 | 132.723 | -0.523 | -2.126 |
| | ATOM | 182 | N | PHE | 21 | 134.805 | -4.408 | -0.526 |
| | ATOM | 183 | HN | PHE | 21 | 135.640 | -4.462 | -0.955 |
| 5 | ATOM | 184 | CA | PHE | 21 | 134.384 | -5.587 | 0.103 |
| | ATOM | 185 | C | PHE | 21 | 134.597 | -5.542 | 1.564 |
| | ATOM | 186 | O | PHE | 21 | 135.725 | -5.770 | 2.091 |
| | ATOM | 187 | CB | PHE | 21 | 134.873 | -6.843 | -0.645 |
| | ATOM | 188 | CG | PHE | 21 | 134.191 | -8.072 | -0.223 |
| | ATOM | 189 | CD1 | PHE | 21 | 134.845 | -8.955 | 0.677 |
| | ATOM | 190 | CD2 | PHE | 21 | 132.892 | -8.372 | -0.711 |
| 10 | ATOM | 191 | CE1 | PHE | 21 | 134.194 | -10.138 | 1.101 |
| | ATOM | 192 | CE2 | PHE | 21 | 132.237 | -9.554 | -0.269 |
| | ATOM | 193 | CZ | PHE | 21 | 132.893 | -10.425 | 0.618 |
| | ATOM | 194 | N | THR | 22 | 133.509 | -5.233 | 2.266 |
| | ATOM | 195 | HN | THR | 22 | 132.701 | -5.247 | 1.787 |
| | ATOM | 196 | CA | THR | 22 | 133.421 | -4.877 | 3.625 |
| | ATOM | 197 | C | THR | 22 | 134.192 | -3.629 | 3.890 |
| 15 | ATOM | 198 | O | THR | 22 | 155.285 | -3.771 | 4.487 |
| | ATOM | 199 | CB | THR | 22 | 133.503 | -6.007 | 4.667 |
| | ATOM | 200 | OG1 | THR | 22 | 134.546 | -6.947 | 4.452 |
| | ATOM | 201 | HOG1 | THR | 22 | 135.012 | -6.623 | 3.653 |
| | ATOM | 202 | CG2 | THR | 22 | 132.165 | -6.722 | 4.907 |
| | ATOM | 203 | N | PRO | 23 | 133.765 | 2.399 | 3.514 |
| | ATOM | 204 | CA | PRO | 23 | 134.593 | -1.332 | 3.113 |
| 20 | ATOM | 205 | C | PRO | 23 | 135.732 | -0.944 | 3.972 |
| | ATOM | 206 | O | PRO | 23 | 135.585 | -0.247 | 5.015 |
| | ATOM | 207 | CB | PRO | 23 | 133.700 | -0.181 | 2.627 |
| | ATOM | 208 | CG | PRO | 23 | 132.313 | -0.811 | 2.548 |
| | ATOM | 209 | CD | PRO | 23 | 132.421 | 2.037 | 3.455 |
| | ATOM | 210 | N | SER | 24 | 136.902 | -1.401 | 3.551 |
| 25 | ATOM | 211 | HN | SER | 24 | 135.813 | -1.705 | 2.662 |
| | ATOM | 212 | CA | SER | 24 | 135.078 | 1.473 | 4.295 |
| | ATOM | 213 | C | SER | 24 | 139.055 | 0.462 | 3.856 |
| | ATOM | 214 | O | SER | 24 | 139.760 | -0.548 | 2.819 |
| | ATOM | 215 | CB | SER | 24 | 138.546 | 2.341 | 4.338 |
| | ATOM | 216 | OG | SER | 24 | 139.344 | -3.226 | 5.480 |
| | ATOM | 217 | HOG | SER | 24 | 140.275 | 2.389 | 5.287 |
| 30 | ATOM | 218 | N | ALA | 25 | 139.136 | 0.634 | 4.605 |
| | ATOM | 219 | HN | ALA | 25 | 138.555 | 0.671 | 5.353 |
| | ATOM | 220 | CA | ALA | 25 | 139.980 | 1.735 | 4.397 |
| | ATOM | 221 | C | ALA | 25 | 141.412 | 1.429 | 4.639 |
| | ATOM | 222 | O | ALA | 25 | 141.761 | 0.838 | 5.690 |
| | ATOM | 223 | CB | ALA | 25 | 139.451 | 2.961 | 5.156 |
| | ATOM | 224 | N | LYS | 26 | 142.447 | 1.688 | 3.846 |
| | ATOM | 225 | HN | LYS | 26 | 143.189 | 1.166 | 4.085 |
| 35 | ATOM | 226 | CA | LYS | 26 | 142.617 | 2.564 | 2.755 |
| | ATOM | 227 | C | LYS | 26 | 143.994 | 2.592 | 2.175 |
| | ATOM | 228 | O | LYS | 26 | 144.755 | 1.583 | 2.226 |
| | ATOM | 229 | CB | LYS | 26 | 141.479 | 2.526 | 1.690 |
| | ATOM | 230 | CG | LYS | 26 | 141.699 | 1.804 | 0.343 |
| | ATOM | 231 | CD | LYS | 26 | 141.577 | 0.275 | 0.407 |
| | ATOM | 232 | CE | LYS | 26 | 142.849 | 0.423 | 0.901 |
| 40 | ATOM | 233 | NZ | LYS | 26 | 142.572 | 1.187 | 2.116 |
| | ATOM | 234 | HNZ1 | LYS | 26 | 143.161 | 0.889 | 2.094 |
| | ATOM | 235 | HNZ2 | LYS | 26 | 142.811 | 2.144 | 1.860 |
| | ATOM | 236 | HNZ3 | LYS | 26 | 141.589 | 1.079 | 2.364 |
| | ATOM | 237 | N | TYR | 27 | 144.383 | 3.723 | 1.582 |
| | ATOM | 238 | HN | TYR | 27 | 143.807 | 4.485 | 1.806 |

45

50

-52-

| | | | | | | | | |
|----|------|-----|------|-----|----|---------|--------|--------|
| | ATOM | 239 | CA | TYR | 27 | 145.424 | 3.914 | 0.651 |
| | ATOM | 240 | C | TYR | 27 | 145.539 | 2.643 | -0.377 |
| | ATOM | 241 | O | TYR | 27 | 144.584 | 2.778 | -1.194 |
| | ATOM | 242 | CB | TYR | 27 | 146.716 | 4.460 | 1.294 |
| 5 | ATOM | 243 | CG | TYR | 27 | 146.658 | 5.870 | 1.720 |
| | ATOM | 244 | CD1 | TYR | 27 | 146.711 | 6.147 | 3.109 |
| | ATOM | 245 | CD2 | TYR | 27 | 146.656 | 6.912 | 0.763 |
| | ATOM | 246 | CE1 | TYR | 27 | 146.676 | 7.487 | 3.551 |
| | ATOM | 247 | CE2 | TYR | 27 | 146.521 | 8.254 | 1.201 |
| | ATOM | 248 | CZ | TYR | 27 | 146.586 | 8.523 | 2.589 |
| | ATOM | 249 | OH | TYR | 27 | 146.583 | 9.805 | 3.007 |
| | ATOM | 250 | HOH | TYR | 27 | 146.502 | 10.533 | 2.353 |
| 10 | ATOM | 251 | N | CYS | 28 | 146.569 | 1.997 | -0.436 |
| | ATOM | 252 | HN | CYS | 28 | 147.335 | 2.232 | 0.057 |
| | ATOM | 253 | CA | CYS | 28 | 146.621 | 0.705 | -1.141 |
| | ATOM | 254 | C | CYS | 28 | 146.545 | -0.467 | -0.328 |
| | ATOM | 255 | O | CYS | 28 | 146.570 | -1.589 | -0.893 |
| | ATOM | 256 | CB | CYS | 28 | 147.780 | 0.882 | -2.157 |
| | ATOM | 257 | SG | CYS | 28 | 149.356 | 0.252 | -1.533 |
| 15 | ATOM | 258 | N | GLN | 29 | 146.445 | -0.446 | 0.994 |
| | ATOM | 259 | HN | GLN | 29 | 145.835 | 0.253 | 1.364 |
| | ATOM | 260 | CA | GLN | 29 | 147.012 | -1.321 | 1.930 |
| | ATOM | 261 | C | GLN | 29 | 147.597 | -0.543 | 3.057 |
| | ATOM | 262 | O | GLN | 29 | 148.735 | -0.869 | 3.471 |
| | ATOM | 263 | CB | GLN | 29 | 146.026 | -2.422 | 2.361 |
| 20 | ATOM | 264 | CG | GLN | 29 | 145.955 | -3.704 | 1.514 |
| | ATOM | 265 | CD | GLN | 29 | 144.673 | -4.326 | 1.285 |
| | ATOM | 266 | CE1 | GLN | 29 | 143.661 | -3.659 | 0.968 |
| | ATOM | 267 | NE2 | GLN | 29 | 144.454 | -5.612 | 1.388 |
| | ATOM | 268 | HNE1 | GLN | 29 | 145.114 | -6.231 | 1.638 |
| | ATOM | 269 | HNE2 | GLN | 29 | 143.588 | -5.927 | 1.200 |
| | ATOM | 270 | N | VAL | 30 | 146.950 | 0.481 | 3.623 |
| 25 | ATOM | 271 | HN | VAL | 30 | 146.194 | 0.778 | 3.152 |
| | ATOM | 272 | CA | VAL | 30 | 147.169 | 1.211 | 4.788 |
| | ATOM | 273 | C | VAL | 30 | 147.560 | 0.493 | 6.019 |
| | ATOM | 274 | O | VAL | 30 | 148.774 | 0.398 | 6.335 |
| | ATOM | 275 | CB | VAL | 30 | 147.331 | 2.731 | 4.581 |
| | ATOM | 276 | CG1 | VAL | 30 | 145.544 | 3.551 | 5.610 |
| | ATOM | 277 | CG2 | VAL | 30 | 148.761 | 3.258 | 4.437 |
| | ATOM | 278 | N | VAL | 31 | 146.690 | -0.075 | 6.635 |
| 30 | ATOM | 279 | HN | VAL | 31 | 147.035 | -0.549 | 7.570 |
| | ATOM | 280 | CA | VAL | 31 | 145.295 | -0.039 | 6.703 |
| | ATOM | 281 | C | VAL | 31 | 144.733 | -0.991 | 5.709 |
| | ATOM | 282 | O | VAL | 31 | 144.249 | -0.507 | 4.641 |
| | ATOM | 283 | CB | VAL | 31 | 144.656 | 0.185 | 8.098 |
| | ATOM | 284 | CG1 | VAL | 31 | 143.910 | -0.962 | 8.797 |
| | ATOM | 285 | CG2 | VAL | 31 | 143.806 | 1.457 | 8.135 |
| 35 | ATOM | 286 | N | CYS | 32 | 144.767 | -2.300 | 5.964 |
| | ATOM | 287 | HN | CYS | 32 | 145.169 | -2.555 | 6.773 |
| | ATOM | 288 | CA | CYS | 32 | 144.278 | -3.335 | 5.170 |
| | ATOM | 289 | C | CYS | 32 | 142.800 | -3.475 | 5.329 |
| | ATOM | 290 | O | CYS | 32 | 142.004 | -2.555 | 4.978 |
| | ATOM | 291 | CB | CYS | 32 | 145.170 | -4.601 | 5.274 |
| | ATOM | 292 | SG | CYS | 32 | 146.944 | -4.465 | 5.153 |
| 40 | ATOM | 293 | N | THR | 33 | 142.019 | -4.405 | 5.866 |
| | ATOM | 294 | HN | THR | 33 | 141.117 | -4.151 | 5.856 |
| | ATOM | 295 | CA | THR | 33 | 142.344 | 5.653 | 6.401 |
| | ATOM | 296 | C | THR | 33 | 141.269 | -6.670 | 6.263 |
| | ATOM | 297 | O | THR | 33 | 140.400 | -6.800 | 7.157 |
| | ATOM | 298 | CB | THR | 33 | 143.242 | -5.664 | 7.652 |

45

50

-53-

| | | | | | | | |
|----|------|-----|----------|----|---------|---------|--------|
| | ATOM | 299 | OG1 THR | 33 | 144.004 | -6.865 | 7.680 |
| | ATOM | 300 | HOG1 THR | 33 | 144.062 | -7.186 | 6.757 |
| | ATOM | 301 | CG2 THR | 33 | 142.611 | -5.360 | 9.031 |
| 5 | ATOM | 302 | N TYR | 34 | 141.107 | -7.504 | 5.239 |
| | ATOM | 303 | HN TYR | 34 | 140.427 | -8.144 | 5.346 |
| | ATOM | 304 | CA TYR | 34 | 141.788 | -7.562 | 4.021 |
| | ATOM | 305 | C TYR | 34 | 143.201 | -8.032 | 3.980 |
| | ATOM | 306 | O TYR | 34 | 144.022 | -7.724 | 4.890 |
| | ATOM | 307 | CB TYR | 34 | 141.419 | -6.419 | 3.055 |
| | ATOM | 308 | CG TYR | 34 | 140.533 | -6.887 | 1.981 |
| 10 | ATOM | 309 | CD1 TYR | 34 | 141.091 | -7.241 | 0.727 |
| | ATOM | 310 | CD2 TYR | 34 | 139.136 | -6.978 | 2.209 |
| | ATOM | 311 | CE1 TYR | 34 | 140.249 | -7.700 | -0.315 |
| | ATOM | 312 | CE2 TYR | 34 | 138.293 | -7.443 | 1.175 |
| | ATOM | 313 | CZ TYR | 34 | 138.858 | -7.802 | -0.072 |
| | ATOM | 314 | OH TYR | 34 | 138.023 | -8.248 | -1.035 |
| | ATOM | 315 | HOH TYR | 34 | 138.315 | -8.497 | -1.936 |
| 15 | ATOM | 316 | N HIS | 35 | 143.532 | -8.793 | 2.935 |
| | ATOM | 317 | HN HIS | 35 | 142.866 | -8.880 | 2.276 |
| | ATOM | 318 | CA HIS | 35 | 144.721 | -9.486 | 2.677 |
| | ATOM | 319 | C HIS | 35 | 146.027 | -8.793 | 2.862 |
| | ATOM | 320 | O HIS | 35 | 146.259 | -7.775 | 2.137 |
| | ATOM | 321 | CB HIS | 35 | 144.592 | -10.326 | 1.393 |
| | ATOM | 322 | CG HIS | 35 | 144.947 | -11.737 | 1.596 |
| 20 | ATOM | 323 | ND1 HIS | 35 | 145.837 | -12.411 | 0.919 |
| | ATOM | 324 | HND1 HIS | 35 | 146.347 | -12.086 | 0.200 |
| | ATOM | 325 | CD2 HIS | 35 | 144.415 | -12.618 | 2.533 |
| | ATOM | 326 | CE1 HIS | 35 | 145.915 | -13.633 | 1.308 |
| | ATOM | 327 | NE2 HIS | 35 | 145.046 | -13.756 | 2.366 |
| | ATOM | 328 | N PRO | 36 | 146.932 | -9.215 | 3.771 |
| | ATOM | 329 | CA PRO | 36 | 147.939 | -8.415 | 4.322 |
| 25 | ATOM | 330 | C PRO | 36 | 149.034 | -7.931 | 3.464 |
| | ATOM | 331 | O PRO | 36 | 149.762 | -8.716 | 2.794 |
| | ATOM | 332 | CB PRO | 36 | 148.434 | -9.108 | 5.602 |
| | ATOM | 333 | CG PRO | 36 | 147.547 | -10.345 | 5.725 |
| | ATOM | 334 | CD PRO | 36 | 146.989 | -10.501 | 4.311 |
| | ATOM | 335 | N ARG | 37 | 149.166 | -6.613 | 3.479 |
| | ATOM | 336 | HN ARG | 37 | 148.440 | -6.137 | 3.837 |
| 30 | ATOM | 337 | CA ARG | 37 | 150.237 | -5.809 | 3.064 |
| | ATOM | 338 | C ARG | 37 | 149.997 | -4.450 | 3.508 |
| | ATOM | 339 | O ARG | 37 | 149.432 | -3.571 | 2.880 |
| | ATOM | 340 | CB ARG | 37 | 150.786 | -5.948 | 1.621 |
| | ATOM | 341 | CG ARG | 37 | 149.966 | -5.351 | 0.459 |
| | ATOM | 342 | CD ARG | 37 | 148.708 | -6.152 | 0.112 |
| | ATOM | 343 | NE ARG | 37 | 149.045 | -7.173 | -0.769 |
| 35 | ATOM | 344 | HNE ARG | 37 | 149.725 | -6.966 | -1.385 |
| | ATOM | 345 | CZ ARG | 37 | 148.543 | -8.395 | -0.870 |
| | ATOM | 346 | NH1 ARG | 37 | 147.608 | -8.995 | -0.163 |
| | ATOM | 347 | HN11 ARG | 37 | 147.398 | -9.868 | -0.440 |
| | ATOM | 348 | HN12 ARG | 37 | 147.177 | -8.584 | 0.565 |
| | ATOM | 349 | NH2 ARG | 37 | 149.035 | -9.147 | -1.813 |
| | ATOM | 350 | HN21 ARG | 37 | 149.778 | -8.884 | -2.326 |
| 40 | ATOM | 351 | HN22 ARG | 37 | 148.599 | -9.963 | -1.953 |
| | ATOM | 352 | N CYS | 38 | 150.393 | -4.224 | 4.835 |
| | ATOM | 353 | HN CYS | 38 | 150.923 | -4.833 | 5.247 |
| | ATOM | 354 | CA CYS | 38 | 150.079 | -3.037 | 5.590 |
| | ATOM | 355 | C CYS | 38 | 151.246 | -2.207 | 5.686 |
| | ATOM | 356 | O CYS | 38 | 152.178 | -2.400 | 6.527 |
| | ATOM | 357 | CB CYS | 38 | 149.393 | -3.552 | 6.891 |
| 45 | ATOM | 358 | SG CYS | 38 | 147.617 | -3.578 | 6.826 |

-54-

| | | | | | | | | |
|----|------|-----|------|-----|----|---------|--------|--------|
| 5 | ATOM | 359 | N | LEU | 39 | 151.255 | -1.204 | -1.818 |
| | ATOM | 360 | HN | LEU | 39 | 150.464 | -1.683 | -1.325 |
| | ATOM | 361 | CA | LEU | 39 | 152.319 | -0.330 | -1.580 |
| | ATOM | 362 | C | LEU | 39 | 151.856 | 1.092 | 4.691 |
| | ATOM | 363 | O | LEU | 39 | 151.501 | 1.759 | 3.681 |
| | ATOM | 364 | CB | LEU | 39 | 153.273 | -0.752 | 3.436 |
| | ATOM | 365 | CG | LEU | 39 | 152.680 | -0.861 | 2.024 |
| | ATOM | 366 | CD1 | LEU | 39 | 153.605 | -0.150 | 1.034 |
| | ATOM | 367 | CD2 | LEU | 39 | 152.597 | -2.339 | 1.629 |
| | ATOM | 368 | N | LEU | 40 | 152.046 | 1.600 | 5.919 |
| 10 | ATOM | 369 | HN | LEU | 40 | 152.331 | 1.012 | 6.595 |
| | ATOM | 370 | CA | LEU | 40 | 151.767 | 2.911 | 6.306 |
| | ATOM | 371 | C | LEU | 40 | 152.931 | 3.806 | 6.131 |
| | ATOM | 372 | O | LEU | 40 | 153.774 | 4.020 | 7.054 |
| | ATOM | 373 | CB | LEU | 40 | 151.086 | 2.911 | 7.691 |
| | ATOM | 374 | CG | LEU | 40 | 149.858 | 3.830 | 7.756 |
| | ATOM | 375 | CD1 | LEU | 40 | 148.826 | 3.227 | 8.712 |
| | ATOM | 376 | CD2 | LEU | 40 | 150.225 | 5.232 | 8.254 |
| | ATOM | 377 | N | PHE | 41 | 153.022 | 4.354 | 4.924 |
| | ATOM | 378 | HN | PHE | 41 | 152.346 | 4.122 | 4.314 |
| 15 | ATOM | 379 | CA | PHE | 41 | 154.016 | 5.221 | 4.479 |
| | ATOM | 380 | C | PHE | 41 | 153.574 | 5.447 | 3.791 |
| | ATOM | 381 | O | PHE | 41 | 154.021 | 7.504 | 4.314 |
| | ATOM | 382 | CB | PHE | 41 | 155.177 | 4.479 | 3.782 |
| | ATOM | 383 | CG | PHE | 41 | 156.455 | 5.131 | 4.084 |
| | ATOM | 384 | CD1 | PHE | 41 | 157.107 | 4.876 | 5.321 |
| | ATOM | 385 | CD2 | PHE | 41 | 157.028 | 6.010 | 3.134 |
| | ATOM | 386 | CE1 | PHE | 41 | 158.308 | 5.562 | 5.633 |
| | ATOM | 387 | CE2 | PHE | 41 | 158.235 | 6.692 | 3.441 |
| | ATOM | 388 | CZ | PHE | 41 | 158.859 | 6.469 | 4.693 |
| 20 | ATOM | 389 | N | THR | 42 | 152.765 | 6.443 | 2.712 |
| | ATOM | 390 | HN | THR | 42 | 152.440 | 5.615 | 2.430 |
| | ATOM | 391 | CA | THR | 42 | 152.439 | 7.574 | 1.961 |
| | ATOM | 392 | C | THR | 42 | 152.564 | 7.395 | 0.409 |
| | ATOM | 393 | O | THR | 42 | 151.550 | 7.266 | -0.257 |
| | ATOM | 394 | CB | THR | 42 | 151.232 | 8.331 | 2.575 |
| | ATOM | 395 | CG1 | THR | 42 | 150.000 | 7.925 | 1.999 |
| | ATOM | 396 | HOG1 | THR | 42 | 150.310 | 7.654 | 1.112 |
| | ATOM | 397 | CG2 | THR | 42 | 151.397 | 9.847 | 2.407 |
| | ATOM | 398 | N | PHE | 43 | 153.796 | 7.333 | -0.012 |
| 30 | ATOM | 399 | HN | PHE | 43 | 154.504 | 7.468 | 0.601 |
| | ATOM | 400 | CA | PHE | 43 | 154.140 | 7.258 | -1.364 |
| | ATOM | 401 | C | PHE | 43 | 153.727 | 8.395 | -2.212 |
| | ATOM | 402 | O | PHE | 43 | 153.945 | 9.592 | -1.854 |
| | ATOM | 403 | CB | PHE | 43 | 155.634 | 6.913 | -1.546 |
| | ATOM | 404 | CG | PHE | 43 | 156.030 | 5.521 | -1.278 |
| | ATOM | 405 | CD1 | PHE | 43 | 157.152 | 5.310 | -0.437 |
| | ATOM | 406 | CD2 | PHE | 43 | 155.334 | 4.415 | -1.837 |
| | ATOM | 407 | CE1 | PHE | 43 | 157.592 | 3.093 | -0.161 |
| | ATOM | 408 | CE2 | PHE | 43 | 155.759 | 3.095 | -1.548 |
| 35 | ATOM | 409 | CZ | PHE | 43 | 156.691 | 2.895 | -0.719 |
| | ATOM | 410 | N | THR | 44 | 153.128 | 8.067 | -3.357 |
| | ATOM | 411 | HN | THR | 44 | 152.802 | 7.195 | -3.517 |
| | ATOM | 412 | CA | THR | 44 | 152.844 | 8.992 | -4.382 |
| | ATOM | 413 | C | THR | 44 | 153.966 | 9.035 | -5.344 |
| | ATOM | 414 | O | THR | 44 | 154.299 | 8.004 | -5.984 |
| | ATOM | 415 | CB | THR | 44 | 151.384 | 8.215 | -4.882 |
| | ATOM | 416 | OG1 | THR | 44 | 151.103 | 7.905 | 5.840 |
| | ATOM | 417 | OG2 | THR | 44 | 151.103 | 7.905 | 5.840 |
| | ATOM | 418 | OG3 | THR | 44 | 151.103 | 7.905 | 5.840 |
| 40 | ATOM | 419 | OG4 | THR | 44 | 151.103 | 7.905 | 5.840 |
| | ATOM | 420 | OG5 | THR | 44 | 151.103 | 7.905 | 5.840 |
| | ATOM | 421 | OG6 | THR | 44 | 151.103 | 7.905 | 5.840 |
| | ATOM | 422 | OG7 | THR | 44 | 151.103 | 7.905 | 5.840 |
| | ATOM | 423 | OG8 | THR | 44 | 151.103 | 7.905 | 5.840 |
| | ATOM | 424 | OG9 | THR | 44 | 151.103 | 7.905 | 5.840 |
| | ATOM | 425 | OG10 | THR | 44 | 151.103 | 7.905 | 5.840 |
| | ATOM | 426 | OG11 | THR | 44 | 151.103 | 7.905 | 5.840 |
| | ATOM | 427 | OG12 | THR | 44 | 151.103 | 7.905 | 5.840 |
| | ATOM | 428 | OG13 | THR | 44 | 151.103 | 7.905 | 5.840 |

-55-

| | | | | | | | | |
|----|------|-----|-----|-----|----|---------|--------|---------|
| | ATOM | 418 | N | ALA | 45 | 154.567 | 10.204 | -5.467 |
| | ATOM | 420 | HN | ALA | 45 | 154.164 | 10.931 | -5.027 |
| | ATOM | 421 | CA | ALA | 45 | 155.771 | 10.470 | -6.165 |
| | ATOM | 422 | C | ALA | 45 | 155.820 | 10.094 | -7.593 |
| 5 | ATOM | 423 | O | ALA | 45 | 154.937 | 10.524 | -6.393 |
| | ATOM | 424 | CB | ALA | 45 | 156.248 | 11.899 | -5.863 |
| | ATOM | 425 | N | GLU | 46 | 156.834 | 9.291 | -7.831 |
| | ATOM | 426 | HN | GLU | 46 | 157.453 | 9.146 | -7.239 |
| | ATOM | 427 | CA | GLU | 46 | 157.146 | 8.613 | -6.127 |
| | ATOM | 428 | C | GLU | 46 | 158.577 | 8.235 | -9.131 |
| | ATOM | 429 | O | GLU | 46 | 156.456 | 9.051 | -5.449 |
| 10 | ATOM | 430 | CB | GLU | 46 | 156.623 | 8.178 | -10.476 |
| | ATOM | 431 | CG | GLU | 46 | 156.885 | 8.337 | -11.742 |
| | ATOM | 432 | CD | GLU | 46 | 156.366 | 6.969 | -11.737 |
| | ATOM | 433 | OE1 | GLU | 46 | 155.140 | 6.733 | -11.681 |
| | ATOM | 434 | OE2 | GLU | 46 | 157.164 | 5.998 | -11.798 |
| | ATOM | 435 | N | SER | 47 | 158.890 | 7.021 | -6.677 |
| | ATOM | 436 | HN | SER | 47 | 158.209 | 6.512 | -8.776 |
| 15 | ATOM | 437 | CA | SER | 47 | 160.165 | 6.449 | -8.737 |
| | ATOM | 438 | C | SER | 47 | 160.330 | 5.249 | -9.599 |
| | ATOM | 439 | O | SER | 47 | 159.936 | 4.136 | -9.132 |
| | ATOM | 440 | CB | SER | 47 | 160.898 | 6.392 | -7.564 |
| | ATOM | 441 | OG | SER | 47 | 161.224 | 7.685 | -6.665 |
| | ATOM | 442 | HOG | SER | 47 | 160.413 | 8.085 | -6.509 |
| | ATOM | 443 | N | PRO | 48 | 160.886 | 5.331 | -10.330 |
| 20 | ATOM | 444 | CA | PRO | 48 | 161.565 | 4.202 | -11.464 |
| | ATOM | 445 | C | PRO | 48 | 160.789 | 3.147 | -12.022 |
| | ATOM | 446 | O | PRO | 48 | 160.005 | 3.296 | -12.990 |
| | ATOM | 447 | CB | PRO | 48 | 162.535 | 4.926 | -12.455 |
| | ATOM | 448 | CG | PRO | 48 | 162.016 | 6.352 | -12.640 |
| | ATOM | 449 | CD | PRO | 48 | 160.873 | 6.479 | -11.829 |
| | ATOM | 450 | N | SER | 49 | 161.043 | 1.992 | -11.417 |
| 25 | ATOM | 451 | HN | SER | 49 | 161.528 | 2.057 | -10.316 |
| | ATOM | 452 | CA | SER | 49 | 160.736 | 0.657 | -11.716 |
| | ATOM | 453 | C | SER | 49 | 161.964 | -0.158 | -11.593 |
| | ATOM | 454 | O | SER | 49 | 162.263 | -0.471 | -10.411 |
| | ATOM | 455 | CB | SER | 49 | 159.740 | 0.277 | -12.835 |
| | ATOM | 456 | OG | SER | 49 | 158.504 | -0.129 | -12.269 |
| | ATOM | 457 | HOG | SER | 49 | 159.215 | 0.555 | -11.629 |
| 30 | ATOM | 458 | N | GLU | 50 | 162.706 | -0.530 | -12.629 |
| | ATOM | 459 | HN | GLU | 50 | 162.420 | -0.248 | -13.489 |
| | ATOM | 460 | CA | GLU | 50 | 163.871 | -1.306 | -12.593 |
| | ATOM | 461 | C | GLU | 50 | 165.162 | -0.551 | -12.744 |
| | ATOM | 462 | O | GLU | 50 | 155.327 | 0.267 | -13.658 |
| | ATOM | 463 | CB | GLU | 50 | 163.732 | -2.548 | -13.490 |
| | ATOM | 464 | CG | GLU | 50 | 164.418 | -3.740 | -12.805 |
| 35 | ATOM | 465 | CD | GLU | 50 | 163.753 | -5.038 | -12.931 |
| | ATOM | 466 | OE1 | GLU | 50 | 162.591 | -6.256 | -12.535 |
| | ATOM | 467 | OE2 | GLU | 50 | 164.366 | -5.996 | -13.434 |
| | ATOM | 468 | N | ASP | 51 | 166.226 | -0.752 | -11.962 |
| | ATOM | 469 | HN | ASP | 51 | 166.986 | -0.234 | -12.151 |
| | ATOM | 470 | CA | ASP | 51 | 166.310 | -1.635 | -10.885 |
| | ATOM | 471 | C | ASP | 51 | 165.928 | -1.071 | -9.571 |
| 40 | ATOM | 472 | O | ASP | 51 | 164.815 | -1.545 | -9.238 |
| | ATOM | 473 | CB | ASP | 51 | 167.607 | -2.474 | -10.847 |
| | ATOM | 474 | CG | ASP | 51 | 167.487 | -3.736 | -10.209 |
| | ATOM | 475 | OD1 | ASP | 51 | 166.830 | -4.016 | -9.163 |
| | ATOM | 476 | OD2 | ASP | 51 | 168.062 | -4.734 | -10.705 |
| | ATOM | 477 | N | PRO | 52 | 166.614 | -0.156 | -8.794 |
| | ATOM | 478 | CA | PRO | 52 | 165.508 | -0.083 | -7.392 |

45

50

-56-

| | | | | | | | | |
|----|------|-----|------|-----|----|---------|--------|---------|
| | ATOM | 479 | C | PRO | 52 | 165.352 | 0.618 | -6.752 |
| | ATOM | 480 | O | PRO | 52 | 165.448 | 1.512 | -5.065 |
| | ATOM | 481 | CB | PRO | 52 | 167.919 | 0.332 | -6.945 |
| 5 | ATOM | 482 | CG | PRO | 52 | 168.592 | 0.900 | -8.193 |
| | ATOM | 483 | CD | PRO | 52 | 167.553 | 0.702 | -9.296 |
| | ATOM | 484 | N | THR | 53 | 164.176 | 0.216 | -7.187 |
| | ATOM | 485 | HN | THR | 53 | 164.269 | -0.303 | -7.905 |
| | ATOM | 486 | CA | THR | 53 | 162.873 | 0.505 | -6.777 |
| | ATOM | 487 | C | THR | 53 | 162.120 | -0.765 | -6.685 |
| | ATOM | 488 | O | THR | 53 | 161.903 | -1.183 | -5.513 |
| 10 | ATOM | 489 | CB | THR | 53 | 162.141 | 1.680 | -7.481 |
| | ATOM | 490 | OG1 | THR | 53 | 162.479 | 1.944 | -6.845 |
| | ATOM | 491 | HOG1 | THR | 53 | 162.400 | 1.124 | -9.375 |
| | ATOM | 492 | CG2 | THR | 53 | 162.307 | 2.981 | -6.685 |
| | ATOM | 493 | N | ARG | 54 | 161.717 | -1.415 | -7.780 |
| | ATOM | 494 | HN | ARG | 54 | 161.919 | -1.024 | -8.610 |
| | ATOM | 495 | CA | ARG | 54 | 161.021 | -2.626 | -7.805 |
| 15 | ATOM | 496 | C | ARG | 54 | 159.542 | -2.502 | -7.912 |
| | ATOM | 497 | O | ARG | 54 | 158.964 | -1.455 | -8.306 |
| | ATOM | 498 | CB | ARG | 54 | 161.509 | -3.413 | -9.132 |
| | ATOM | 499 | CG | ARG | 54 | 162.917 | -4.016 | -9.027 |
| | ATOM | 500 | CD | ARG | 54 | 162.942 | -5.547 | -9.016 |
| | ATOM | 501 | NE | ARG | 54 | 163.846 | -5.970 | -9.966 |
| | ATOM | 502 | HNE | ARG | 54 | 163.561 | -5.793 | -10.651 |
| 20 | ATOM | 503 | CZ | ARG | 54 | 165.028 | -6.572 | -9.858 |
| | ATOM | 504 | NH1 | ARG | 54 | 165.641 | -7.004 | -8.771 |
| | ATOM | 505 | NH11 | ARG | 54 | 166.526 | -7.314 | -8.833 |
| | ATOM | 506 | NH12 | ARG | 54 | 165.202 | -7.011 | -7.940 |
| | ATOM | 507 | NH2 | ARG | 54 | 165.680 | -6.780 | -10.971 |
| | ATOM | 508 | NH21 | ARG | 54 | 166.528 | -7.187 | -10.965 |
| | ATOM | 509 | NH22 | ARG | 54 | 165.281 | -6.519 | -11.761 |
| 25 | ATOM | 510 | N | TRP | 55 | 158.851 | -3.555 | -7.494 |
| | ATOM | 511 | HN | TRP | 55 | 159.382 | -4.310 | -7.317 |
| | ATOM | 512 | CA | TRP | 55 | 157.478 | -3.743 | -7.261 |
| | ATOM | 513 | C | TRP | 55 | 156.468 | -3.115 | -8.155 |
| | ATOM | 514 | O | TRP | 55 | 156.280 | -3.713 | -8.241 |
| | ATOM | 515 | CB | TRP | 55 | 157.074 | -4.016 | -5.706 |
| | ATOM | 516 | CG | TRP | 55 | 158.068 | -3.773 | -4.740 |
| 30 | ATOM | 517 | CD1 | TRP | 55 | 159.068 | -4.606 | -4.395 |
| | ATOM | 518 | CD2 | TRP | 55 | 158.231 | -2.565 | -3.985 |
| | ATOM | 519 | NE1 | TRP | 55 | 159.831 | -3.906 | -3.450 |
| | ATOM | 520 | HNE1 | TRP | 55 | 160.582 | -4.378 | -3.041 |
| | ATOM | 521 | CE2 | TRP | 55 | 159.395 | -2.768 | -3.235 |
| | ATOM | 522 | CE3 | TRP | 55 | 157.484 | -1.368 | -3.866 |
| | ATOM | 523 | CZ2 | TRP | 55 | 159.922 | -1.753 | -2.413 |
| 35 | ATOM | 524 | CZ3 | TRP | 55 | 157.981 | -0.361 | -3.022 |
| | ATOM | 525 | CH2 | TRP | 55 | 159.196 | -0.540 | -2.312 |
| | ATOM | 526 | N | PHE | 56 | 155.735 | -2.016 | -7.972 |
| | ATOM | 527 | HN | PHE | 56 | 155.092 | -1.810 | -8.625 |
| | ATOM | 528 | CA | PHE | 56 | 155.830 | -1.139 | -6.890 |
| | ATOM | 529 | C | PHE | 56 | 154.634 | -1.166 | -6.014 |
| | ATOM | 530 | O | PHE | 56 | 154.605 | -2.128 | -5.210 |
| 40 | ATOM | 531 | CB | PHE | 56 | 156.355 | 0.216 | -7.402 |
| | ATOM | 532 | CG | PHE | 56 | 157.088 | 1.044 | -6.423 |
| | ATOM | 533 | CD1 | PHE | 56 | 156.350 | 1.765 | -5.447 |
| | ATOM | 534 | CD2 | PHE | 56 | 158.485 | 1.104 | -6.455 |
| | ATOM | 535 | CE1 | PHE | 56 | 157.049 | 2.595 | -4.522 |
| | ATOM | 536 | CE2 | PHE | 56 | 159.186 | 1.913 | -5.539 |
| | ATOM | 537 | CZ | PHE | 56 | 158.463 | 2.650 | -4.578 |
| 45 | ATOM | 538 | N | THR | 57 | 153.645 | -0.269 | -6.023 |

-57-

| | | | | | | | | |
|----|------|-----|------|-----|----|---------|---------|--------|
| | ATOM | 539 | HN | THR | 57 | 153.776 | 0.499 | -6.558 |
| | ATOM | 540 | CA | THR | 57 | 152.406 | -0.308 | -5.359 |
| | ATOM | 541 | C | THR | 57 | 152.501 | 0.032 | -2.912 |
| | ATOM | 542 | O | THR | 57 | 152.636 | 1.241 | -3.603 |
| 5 | ATOM | 543 | CB | THR | 57 | 151.360 | -1.364 | -5.823 |
| | ATOM | 544 | OG1 | THR | 57 | 151.850 | -2.704 | -5.814 |
| | ATOM | 545 | HOG1 | THR | 57 | 152.803 | -2.518 | -5.611 |
| | ATOM | 546 | CG2 | THR | 57 | 150.763 | -1.072 | -7.208 |
| | ATOM | 547 | N | CYS | 56 | 152.460 | -0.756 | -2.844 |
| | ATOM | 548 | HN | CYS | 56 | 152.713 | -0.355 | -2.030 |
| 10 | ATOM | 549 | CA | CYS | 56 | 152.106 | -2.105 | -2.762 |
| | ATOM | 550 | C | CYS | 56 | 153.191 | -3.080 | -2.532 |
| | ATOM | 551 | O | CYS | 56 | 153.990 | -2.880 | -1.581 |
| | ATOM | 552 | CB | CYS | 56 | 150.955 | -2.295 | -1.773 |
| | ATOM | 553 | SG | CYS | 56 | 149.409 | -1.635 | -2.332 |
| | ATOM | 554 | N | VAL | 59 | 153.272 | -4.153 | -3.325 |
| | ATOM | 555 | HN | VAL | 59 | 152.772 | -4.095 | -4.117 |
| 15 | ATOM | 556 | CA | VAL | 59 | 154.021 | -5.333 | -3.079 |
| | ATOM | 557 | C | VAL | 59 | 154.544 | -6.131 | -4.219 |
| | ATOM | 558 | O | VAL | 59 | 153.894 | -6.255 | -5.290 |
| | ATOM | 559 | CB | VAL | 59 | 153.408 | -6.343 | -2.064 |
| | ATOM | 560 | CG1 | VAL | 59 | 153.619 | -6.012 | -0.562 |
| | ATOM | 561 | CG2 | VAL | 59 | 151.999 | -6.891 | -2.343 |
| 20 | ATOM | 562 | N | LEU | 60 | 155.728 | -6.725 | -4.031 |
| | ATOM | 563 | HN | LEU | 60 | 156.246 | -6.374 | -3.329 |
| | ATOM | 564 | CA | LEU | 60 | 156.301 | -7.611 | -4.717 |
| | ATOM | 565 | C | LEU | 60 | 157.046 | -7.597 | -5.972 |
| | ATOM | 566 | O | LEU | 60 | 156.476 | -7.150 | -5.998 |
| | ATOM | 567 | CB | LEU | 60 | 155.451 | -9.009 | -4.715 |
| | ATOM | 568 | CG | LEU | 60 | 155.883 | -10.058 | -3.600 |
| | ATOM | 569 | CD1 | LEU | 60 | 154.768 | -10.176 | -2.556 |
| 25 | ATOM | 570 | CD2 | LEU | 60 | 156.161 | -11.436 | -4.204 |
| | ATOM | 571 | N | LYS | 61 | 158.336 | -7.919 | -5.940 |
| | ATOM | 572 | HN | LYS | 61 | 158.657 | -8.253 | -5.125 |
| | ATOM | 573 | CA | LYS | 61 | 159.271 | -7.807 | -5.976 |
| | ATOM | 574 | C | LYS | 61 | 160.421 | -8.938 | -6.516 |
| | ATOM | 575 | O | LYS | 61 | 160.480 | -5.632 | -5.991 |
| | ATOM | 576 | CB | LYS | 61 | 159.530 | -9.201 | -7.594 |
| 30 | ATOM | 577 | CG | LYS | 61 | 160.803 | -9.360 | -8.452 |
| | ATOM | 578 | CD | LYS | 61 | 161.761 | -10.283 | -7.629 |
| | ATOM | 579 | CE | LYS | 61 | 163.214 | -10.141 | -8.145 |
| | ATOM | 580 | NZ | LYS | 61 | 164.075 | -10.101 | -6.963 |
| | ATOM | 581 | HNZ1 | LYS | 61 | 164.146 | -9.131 | -6.656 |
| | ATOM | 582 | HNZ2 | LYS | 61 | 165.002 | -10.453 | -7.202 |
| | ATOM | 583 | HNZ3 | LYS | 61 | 163.670 | -10.671 | -6.221 |
| 35 | ATOM | 584 | N | ASP | 62 | 161.329 | -7.463 | -5.660 |
| | ATOM | 585 | HN | ASP | 62 | 161.324 | -3.386 | -5.491 |
| | ATOM | 586 | CA | ASP | 62 | 162.276 | -6.701 | -4.962 |
| | ATOM | 587 | C | ASP | 62 | 163.557 | -5.402 | -5.655 |
| | ATOM | 588 | O | ASP | 62 | 164.261 | -7.305 | -6.188 |
| | ATOM | 589 | CB | ASP | 62 | 162.385 | -7.242 | -3.549 |
| | ATOM | 590 | CG | ASP | 62 | 162.823 | -6.169 | -2.665 |
| 40 | ATOM | 591 | OD1 | ASP | 62 | 162.041 | -5.317 | -2.202 |
| | ATOM | 592 | OD2 | ASP | 62 | 164.021 | -6.083 | -2.356 |
| | ATOM | 593 | N | SER | 63 | 163.901 | -5.122 | -5.650 |
| | ATOM | 594 | HN | SER | 63 | 163.280 | -4.535 | -5.246 |
| | ATOM | 595 | CA | SER | 63 | 165.063 | -4.524 | -6.162 |
| | ATOM | 596 | C | SER | 63 | 166.383 | -4.976 | -5.661 |
| | ATOM | 597 | O | SER | 63 | 166.510 | -5.420 | -4.492 |
| 45 | ATOM | 598 | CB | SER | 63 | 164.929 | -2.965 | -6.200 |

50

-58-

| | | | | | | |
|----|------|--------------|----|---------|--------|--------|
| | ATOM | 599 OG SER | 63 | 164.546 | -2.318 | -4.999 |
| | ATOM | 600 HOG SER | 63 | 163.659 | -1.927 | -5.141 |
| | ATOM | 601 N VAL | 64 | 167.415 | -4.875 | -6.502 |
| | ATOM | 602 HN VAL | 64 | 167.207 | -4.606 | -7.376 |
| 5 | ATOM | 603 CA VAL | 64 | 169.779 | -5.105 | -6.251 |
| | ATOM | 604 C VAL | 64 | 169.333 | -4.466 | -5.032 |
| | ATOM | 605 O VAL | 64 | 169.980 | -5.217 | -4.262 |
| | ATOM | 606 CB VAL | 64 | 169.609 | -5.042 | -7.558 |
| | ATOM | 607 CG1 VAL | 64 | 170.281 | -3.711 | -7.938 |
| | ATOM | 608 CG2 VAL | 64 | 170.642 | -6.172 | -7.628 |
| | ATOM | 609 N THR | 65 | 169.116 | -3.169 | -4.789 |
| 10 | ATOM | 610 HN THR | 65 | 168.818 | -2.645 | -5.510 |
| | ATOM | 611 CA THR | 65 | 169.270 | -2.513 | -3.566 |
| | ATOM | 612 C THR | 65 | 168.220 | -2.934 | -2.604 |
| | ATOM | 613 O THR | 65 | 167.001 | -2.720 | -2.808 |
| | ATOM | 614 CB THR | 65 | 169.555 | -1.009 | -3.763 |
| | ATOM | 615 OG1 THR | 65 | 166.442 | -0.125 | -3.654 |
| | ATOM | 616 HOG1 THR | 65 | 168.267 | 0.112 | -2.719 |
| 15 | ATOM | 617 CG2 THR | 65 | 170.691 | -0.543 | -2.847 |
| | ATOM | 618 N GLU | 66 | 168.711 | -3.549 | -1.538 |
| | ATOM | 619 HN GLU | 66 | 169.616 | -3.365 | -1.358 |
| | ATOM | 620 CA GLU | 66 | 168.111 | -4.445 | -0.646 |
| | ATOM | 621 C GLU | 66 | 166.698 | -4.417 | -0.197 |
| | ATOM | 622 O GLU | 66 | 166.049 | -3.352 | -0.041 |
| | ATOM | 623 CB GLU | 66 | 169.140 | -4.806 | 0.442 |
| 20 | ATOM | 624 CG GLU | 66 | 169.894 | -6.095 | 0.079 |
| | ATOM | 625 CD GLU | 66 | 169.133 | -7.345 | 0.212 |
| | ATOM | 626 OE1 GLU | 66 | 168.176 | -7.652 | -0.507 |
| | ATOM | 627 OE2 GLU | 66 | 169.445 | -8.151 | 1.105 |
| | ATOM | 628 N THR | 67 | 166.165 | -5.618 | 0.020 |
| | ATOM | 629 HN THR | 67 | 166.812 | -6.302 | -0.126 |
| | ATOM | 630 CA THR | 67 | 154.922 | -6.077 | 0.411 |
| 25 | ATOM | 631 C THR | 67 | 163.890 | -5.259 | 1.094 |
| | ATOM | 632 O THR | 67 | 164.174 | -4.601 | 0.119 |
| | ATOM | 633 CB THR | 67 | 165.150 | -7.522 | 0.902 |
| | ATOM | 634 OG1 THR | 67 | 165.274 | -7.723 | 0.304 |
| | ATOM | 635 HOG1 THR | 67 | 165.609 | -6.934 | 0.776 |
| | ATOM | 636 CG2 THR | 67 | 164.131 | -8.517 | 0.333 |
| | ATOM | 637 N LEU | 68 | 162.655 | -5.252 | 0.594 |
| 30 | ATOM | 638 HN LEU | 68 | 162.584 | -5.438 | -0.302 |
| | ATOM | 639 CA LEU | 68 | 161.410 | -5.005 | 1.205 |
| | ATOM | 640 C LEU | 68 | 160.682 | -3.750 | 0.662 |
| | ATOM | 641 O LEU | 68 | 161.322 | -2.678 | 1.095 |
| | ATOM | 642 CB LEU | 68 | 161.169 | -5.430 | 2.650 |
| | ATOM | 643 CG LEU | 68 | 159.783 | -6.132 | 2.806 |
| | ATOM | 644 CD1 LEU | 68 | 159.902 | -7.624 | 3.124 |
| 35 | ATOM | 645 CD2 LEU | 68 | 158.977 | -5.419 | 3.885 |
| | ATOM | 646 N PRO | 69 | 159.407 | -3.723 | 0.402 |
| | ATOM | 647 CA PRO | 69 | 158.548 | -2.605 | 0.371 |
| | ATOM | 648 C PRO | 69 | 158.589 | -1.652 | 1.458 |
| | ATOM | 649 O PRO | 69 | 156.385 | -2.050 | 2.682 |
| | ATOM | 650 CB PRO | 69 | 157.131 | -3.031 | 0.037 |
| | ATOM | 651 CG PRO | 69 | 157.376 | -4.426 | -0.654 |
| 40 | ATOM | 652 CD PRO | 69 | 158.758 | -4.857 | -0.144 |
| | ATOM | 653 N ARG | 70 | 158.863 | -0.386 | 1.161 |
| | ATOM | 654 HN ARG | 70 | 158.855 | 0.183 | 0.246 |
| | ATOM | 655 CA ARG | 70 | 159.173 | 0.638 | 2.040 |
| | ATOM | 656 C ARG | 70 | 158.077 | 1.109 | 2.908 |
| | ATOM | 657 O ARG | 70 | 157.055 | 1.657 | 2.467 |
| | ATOM | 658 CB ARG | 70 | 160.015 | 1.730 | 1.355 |
| 45 | | | | | | |
| 50 | | | | | | |

-59-

| | | | | | | |
|----|------|--------------|----|---------|--------|--------|
| | ATOM | 659 CG ARG | 70 | 161.102 | 2.271 | 2.296 |
| | ATOM | 660 CD ARG | 70 | 160.640 | 3.576 | 2.956 |
| | ATOM | 661 NE ARG | 70 | 160.851 | 3.570 | 4.336 |
| | ATOM | 662 HNE ARG | 70 | 160.416 | 2.916 | 4.853 |
| 5 | ATOM | 663 CZ ARG | 70 | 161.592 | 4.377 | 5.090 |
| | ATOM | 664 NH1 ARG | 70 | 162.327 | 5.415 | 4.731 |
| | ATOM | 665 HN11 ARG | 70 | 162.349 | 5.675 | 3.828 |
| | ATOM | 666 HN12 ARG | 70 | 162.822 | 5.869 | 5.374 |
| | ATOM | 667 NH2 ARG | 70 | 161.559 | 4.068 | 6.360 |
| | ATOM | 668 HN21 ARG | 70 | 162.059 | 4.537 | 7.004 |
| | ATOM | 669 HN22 ARG | 70 | 160.958 | 3.348 | 6.581 |
| 10 | ATOM | 670 N VAL | 71 | 158.291 | 0.846 | 4.182 |
| | ATOM | 671 HN VAL | 71 | 159.058 | 0.336 | 4.367 |
| | ATOM | 672 CA VAL | 71 | 157.611 | 1.183 | 5.358 |
| | ATOM | 673 C VAL | 71 | 158.619 | 1.114 | 6.464 |
| | ATOM | 674 O VAL | 71 | 159.638 | 1.867 | 6.373 |
| | ATOM | 675 CB VAL | 71 | 156.227 | 0.475 | 5.473 |
| | ATOM | 676 CG1 VAL | 71 | 156.186 | -1.059 | 5.621 |
| 15 | ATOM | 677 CG2 VAL | 71 | 155.351 | 1.092 | 6.566 |
| | ATOM | 678 N ASN | 72 | 158.501 | 0.299 | 7.512 |
| | ATOM | 679 HN ASN | 72 | 157.682 | -0.150 | 7.617 |
| | ATOM | 680 CA ASN | 72 | 159.484 | 0.043 | 8.478 |
| | ATOM | 681 C ASN | 72 | 159.682 | -1.335 | 8.790 |
| | ATOM | 682 O ASN | 72 | 159.056 | -1.949 | 9.729 |
| | ATOM | 683 CB ASN | 72 | 159.405 | 1.024 | 9.667 |
| 20 | ATOM | 684 CG ASN | 72 | 160.726 | 1.334 | 10.220 |
| | ATOM | 685 OD1 ASN | 72 | 161.568 | 1.991 | 9.556 |
| | ATOM | 686 ND2 ASN | 72 | 161.041 | 0.925 | 11.427 |
| | ATOM | 687 HND1 ASN | 72 | 160.422 | 0.454 | 11.944 |
| | ATOM | 688 HND2 ASN | 72 | 161.890 | 1.133 | 11.775 |
| | ATOM | 689 N ARG | 73 | 160.557 | -2.032 | 6.024 |
| | ATOM | 690 HN ARG | 73 | 160.851 | -1.579 | 7.255 |
| 25 | ATOM | 691 CA ARG | 73 | 161.068 | -3.215 | 8.256 |
| | ATOM | 692 C ARG | 73 | 162.498 | -3.375 | 8.628 |
| | ATOM | 693 O ARG | 73 | 163.383 | -3.802 | 7.936 |
| | ATOM | 694 CB ARG | 73 | 160.696 | -4.255 | 7.103 |
| | ATOM | 695 CG ARG | 73 | 160.647 | -5.729 | 7.573 |
| | ATOM | 696 CD ARG | 73 | 161.211 | -6.693 | 6.527 |
| | ATOM | 697 NE ARG | 73 | 162.600 | -6.833 | 6.609 |
| 30 | ATOM | 698 HNE ARG | 73 | 163.006 | -6.651 | 7.441 |
| | ATOM | 699 CZ ARG | 73 | 163.489 | -7.154 | 5.675 |
| | ATOM | 700 NH1 ARG | 73 | 164.681 | -7.156 | 6.204 |
| | ATOM | 701 HN11 ARG | 73 | 165.477 | -7.412 | 5.763 |
| | ATOM | 702 HN12 ARG | 73 | 164.700 | -6.959 | 7.116 |
| | ATOM | 703 NH2 ARG | 73 | 163.286 | -7.411 | 4.401 |
| | ATOM | 704 HN21 ARG | 73 | 162.403 | -7.430 | 4.060 |
| | ATOM | 705 HN22 ARG | 73 | 163.392 | -7.554 | 3.798 |
| 35 | ATOM | 706 N THR | 74 | 162.767 | -4.032 | 5.721 |
| | ATOM | 707 HN THR | 74 | 162.021 | -4.335 | 10.206 |
| | ATOM | 708 CA THR | 74 | 164.022 | -4.439 | 10.235 |
| | ATOM | 709 C THR | 74 | 164.820 | -5.345 | 9.378 |
| | ATOM | 710 O THR | 74 | 164.320 | -6.433 | 8.963 |
| | ATOM | 711 CB THR | 74 | 163.911 | -4.814 | 11.735 |
| 40 | ATOM | 712 OG1 THR | 74 | 165.126 | -4.547 | 12.422 |
| | ATOM | 713 HOG1 THR | 74 | 165.879 | -4.645 | 11.803 |
| | ATOM | 714 CG2 THR | 74 | 163.395 | -6.215 | 12.119 |
| | ATOM | 715 N ALA | 75 | 166.055 | -4.971 | 9.077 |
| | ATOM | 716 HN ALA | 75 | 166.341 | -4.146 | 9.427 |
| | ATOM | 717 CA ALA | 75 | 166.995 | -5.668 | 8.295 |
| | ATOM | 718 C ALA | 75 | 167.758 | -6.715 | 9.019 |

45

50

-60-

| | | | | | | | | |
|----|------|-----|-----|-----|----|---------|---------|--------|
| | ATOM | 719 | O | ALA | 75 | 168.335 | -0.447 | 10.116 |
| | ATOM | 720 | CB | ALA | 75 | 167.877 | -4.666 | 7.534 |
| | ATOM | 721 | N | ALA | 76 | 167.807 | -7.937 | 8.475 |
| | ATOM | 722 | HN | ALA | 76 | 167.513 | -7.996 | 7.585 |
| 5 | ATOM | 723 | CA | ALA | 76 | 168.256 | -9.131 | 9.077 |
| | ATOM | 724 | C | ALA | 76 | 168.486 | -10.202 | 8.084 |
| | ATOM | 725 | O | ALA | 76 | 167.504 | -10.777 | 7.511 |
| | ATOM | 726 | CB | ALA | 76 | 167.438 | -9.589 | 10.307 |
| | ATOM | 727 | N | ILE | 77 | 169.763 | -10.509 | 7.820 |
| | ATOM | 728 | HN | ILE | 77 | 170.407 | -10.142 | 8.398 |
| | ATOM | 729 | CA | ILE | 77 | 170.255 | -11.316 | 8.761 |
| 10 | ATOM | 730 | C | ILE | 77 | 170.114 | -13.636 | 5.440 |
| | ATOM | 731 | O | ILE | 77 | 171.137 | -10.486 | 4.727 |
| | ATOM | 732 | CB | ILE | 77 | 169.867 | -12.030 | 6.818 |
| | ATOM | 733 | CG1 | ILE | 77 | 170.265 | -13.550 | 8.121 |
| | ATOM | 734 | CG2 | ILE | 77 | 170.474 | -13.693 | 5.695 |
| | ATOM | 735 | CD1 | ILE | 77 | 169.052 | -13.862 | 9.010 |
| | ATOM | 736 | N | SER | 78 | 168.911 | -10.211 | 5.085 |
| 15 | ATOM | 737 | HN | SER | 78 | 168.269 | -10.440 | 5.726 |
| | ATOM | 738 | CA | SER | 78 | 168.484 | -9.477 | 3.984 |
| | ATOM | 739 | C | SER | 78 | 168.101 | -8.097 | 4.379 |
| | ATOM | 740 | O | SER | 78 | 167.386 | -7.884 | 5.412 |
| | ATOM | 741 | CB | SER | 78 | 167.487 | -10.290 | 3.139 |
| | ATOM | 742 | OG | SER | 78 | 166.119 | -10.193 | 3.520 |
| | ATOM | 743 | HOG | SER | 78 | 165.782 | -9.358 | 2.133 |
| 20 | ATOM | 744 | N | GLY | 79 | 168.557 | -7.129 | 2.595 |
| | ATOM | 745 | HN | GLY | 79 | 168.905 | -7.425 | 2.775 |
| | ATOM | 746 | CA | GLY | 79 | 168.583 | -5.750 | 3.834 |
| | ATOM | 747 | C | GLY | 79 | 167.334 | -4.969 | 3.804 |
| | ATOM | 748 | O | GLY | 79 | 166.209 | -5.533 | 3.902 |
| | ATOM | 749 | N | TYR | 80 | 167.477 | -3.649 | 3.683 |
| | ATOM | 750 | HN | TYR | 80 | 168.359 | -3.333 | 3.607 |
| 25 | ATOM | 751 | CA | TYR | 80 | 166.460 | -2.685 | 3.660 |
| | ATOM | 752 | C | TYR | 80 | 166.848 | -1.382 | 3.068 |
| | ATOM | 753 | O | TYR | 80 | 167.383 | -0.472 | 3.774 |
| | ATOM | 754 | CB | TYR | 80 | 165.767 | -2.592 | 5.050 |
| | ATOM | 755 | CG | TYR | 80 | 164.430 | -2.046 | 4.999 |
| | ATOM | 756 | CD1 | TYR | 80 | 163.379 | -2.653 | 4.500 |
| | ATOM | 757 | CD2 | TYR | 80 | 164.195 | -0.726 | 5.401 |
| 30 | ATOM | 758 | CE1 | TYR | 80 | 162.067 | -2.346 | 4.473 |
| | ATOM | 759 | CE2 | TYR | 80 | 162.881 | -0.217 | 5.460 |
| | ATOM | 760 | CZ | TYR | 80 | 161.842 | -1.050 | 4.984 |
| | ATOM | 761 | OH | TYR | 80 | 160.576 | -0.618 | 5.019 |
| | ATOM | 762 | HOH | TYR | 80 | 160.330 | 0.238 | 5.427 |
| | ATOM | 763 | N | SER | 81 | 166.609 | -1.196 | 1.772 |
| | ATOM | 764 | HN | SER | 81 | 166.356 | -1.942 | 1.258 |
| 35 | ATOM | 765 | CA | SER | 81 | 166.698 | 0.005 | 1.057 |
| | ATOM | 766 | C | SER | 81 | 165.520 | 0.900 | 1.120 |
| | ATOM | 767 | O | SER | 81 | 164.334 | 0.455 | 1.007 |
| | ATOM | 768 | CB | SER | 81 | 167.093 | -0.343 | -0.364 |
| | ATOM | 769 | OG | SER | 81 | 167.889 | 0.666 | -0.985 |
| | ATOM | 770 | HOG | SER | 81 | 168.094 | 0.397 | -1.904 |
| | ATOM | 771 | N | PHE | 82 | 165.761 | 2.198 | 1.295 |
| 40 | ATOM | 772 | HN | PHE | 82 | 166.686 | 2.443 | 1.347 |
| | ATOM | 773 | CA | PHE | 82 | 164.828 | 3.230 | 1.408 |
| | ATOM | 774 | C | PHE | 82 | 164.275 | 3.726 | 0.113 |
| | ATOM | 775 | O | PHE | 82 | 164.377 | 4.925 | -0.289 |
| | ATOM | 776 | CB | PHE | 82 | 165.226 | 4.288 | 2.469 |
| | ATOM | 777 | CG | PHE | 82 | 165.729 | 3.777 | 0.753 |
| | ATOM | 778 | CD1 | PHE | 82 | 164.672 | 3.097 | 4.660 |

45

50

-61-

| | | | | | | | |
|----|---------|-----|-------------|---------|---------|--------|--------|
| | ATOM | 779 | CD2 PHE | 82 | 167.099 | 3.973 | 4.065 |
| | ATOM | 780 | CE1 PHE | 82 | 165.394 | 2.555 | 5.877 |
| | ATOM | 781 | CE2 PHE | 82 | 167.623 | 3.474 | 5.282 |
| 5 | ATOM | 782 | CZ PHE | 82 | 166.766 | 2.786 | 6.176 |
| | ATOM | 783 | N LYS | 83 | 163.650 | 2.801 | -0.017 |
| | ATOM | 784 | HN LYS | 83 | 163.666 | 1.955 | -0.212 |
| | ATOM | 785 | CA LYS | 83 | 163.018 | 2.949 | -1.860 |
| | ATOM | 786 | C LYS | 83 | 161.679 | 3.560 | -1.861 |
| | ATOM | 787 | O LYS | 83 | 160.609 | 2.941 | -2.059 |
| | ATOM | 788 | CB LYS | 83 | 163.302 | 1.793 | -2.046 |
| 10 | ATOM | 789 | CG LYS | 83 | 162.671 | 0.440 | -2.489 |
| | ATOM | 790 | CD LYS | 83 | 163.767 | -0.564 | -2.185 |
| | ATOM | 791 | CE LYS 83 | 163.143 | -1.841 | -1.578 | |
| | ATOM | 792 | NZ LYS 83 | 163.903 | -3.000 | -2.017 | |
| | ATOM | 793 | HNZ1 LYS 83 | 164.682 | -3.141 | -1.375 | |
| | ATOM | 794 | HNZ2 LYS 83 | 164.231 | -2.810 | -2.964 | |
| | ATOM | 795 | HNZ3 LYS 83 | 163.312 | -3.828 | -2.039 | |
| 15 | ATOM | 796 | N GLN 84 | 161.710 | 4.883 | -1.630 | |
| | ATOM | 797 | HN GLN 84 | 162.552 | 5.165 | -1.326 | |
| | ATOM | 798 | CA GLN 84 | 160.692 | 5.836 | -1.763 | |
| | ATOM | 799 | C GLN 84 | 160.352 | 6.247 | -3.144 | |
| | ATOM | 800 | O GLN 84 | 161.261 | 6.483 | -3.993 | |
| | ATOM | 801 | CB GLN 84 | 161.053 | 7.065 | -0.904 | |
| | ATOM | 802 | CG GLN 84 | 160.515 | 6.948 | | 0.532 |
| 20 | ATOM | 803 | CD GLN 84 | 161.551 | 7.166 | | 1.545 |
| | ATOM | 804 | OE1 GLN 84 | 162.288 | 6.224 | | 1.920 |
| | ATOM | 805 | NE2 GLN 84 | 161.713 | 8.352 | | 2.083 |
| | ATOM | 806 | HNE1 GLN 84 | 161.160 | 9.065 | | 1.017 |
| | ATOM | 807 | HNE2 GLN 84 | 162.375 | 8.489 | | 2.731 |
| | ATOM | 808 | N CYS 85 | 159.052 | 6.352 | -3.419 | |
| | ATOM | 809 | HN CYS 85 | 158.455 | 6.116 | -2.732 | |
| 25 | ATOM | 810 | CA CYS 85 | 159.478 | 6.776 | -4.619 | |
| | ATOM | 811 | C CYS 85 | 158.290 | 8.235 | -4.749 | |
| | ATOM | 812 | O CYS 85 | 158.785 | 8.803 | -5.750 | |
| | ATOM | 813 | CB CYS 85 | 157.168 | 6.018 | -4.876 | |
| | ATOM | 814 | SG CYS 85 | 157.073 | 5.545 | -6.531 | |
| | ATOM | 815 | OXT CYS 85 | 157.660 | 8.941 | -3.919 | |
| 30 | CONNECT | 1 | 5 4 | 2 3 | | | |
| | CONNECT | 2 | 1 | | | | |
| | CONNECT | 3 | 1 | | | | |
| | CONNECT | 4 | 1 | | | | |
| | CONNECT | 5 | 1 8 | 6 | | | |
| | CONNECT | 6 | 7 5 | 13 | | | |
| | CONNECT | 7 | 6 | | | | |
| | CONNECT | 8 | 5 9 | | | | |
| 35 | CONNECT | 9 | 6 10 | | | | |
| | CONNECT | 10 | 9 11 | 12 | | | |
| | CONNECT | 11 | 10 | | | | |
| | CONNECT | 12 | 10 | | | | |
| | CONNECT | 13 | 6 15 | 14 | | | |
| | CONNECT | 14 | 13 | | | | |
| | CONNECT | 15 | 18 13 | 16 | | | |
| 40 | CONNECT | 16 | 17 15 | 20 | | | |
| | CONNECT | 17 | 16 | | | | |
| | CONNECT | 18 | 15 19 | | | | |
| | CONNECT | 19 | 18 214 | | | | |
| | CONNECT | 20 | 16 22 | 21 | | | |
| | CONNECT | 21 | 20 | | | | |
| | CONNECT | 22 | 25 20 | 23 | | | |
| 45 | CONNECT | 23 | 24 22 | 28 | | | |
| 50 | | | | | | | |

-62-

| | | | | | |
|----|---------|----|----|----|-------|
| | CONNECT | 24 | 23 | | |
| | CONNECT | 25 | 22 | 26 | 27 |
| | CONNECT | 26 | 25 | | |
| | CONNECT | 27 | 25 | | |
| 5 | CONNECT | 28 | 23 | 30 | 29 |
| | CONNECT | 29 | 28 | | |
| | CONNECT | 30 | 33 | 28 | 31 |
| | CONNECT | 31 | 32 | 30 | 37 |
| | CONNECT | 32 | 31 | | |
| | CONNECT | 33 | 30 | 34 | 36 |
| | CONNECT | 34 | 33 | 35 | |
| 10 | CONNECT | 35 | 34 | | |
| | CONNECT | 36 | 33 | | |
| | CONNECT | 37 | 31 | 39 | 38 |
| | CONNECT | 38 | 37 | | |
| | CONNECT | 39 | 42 | 37 | 40 |
| | CONNECT | 40 | 41 | 39 | 49 |
| | CONNECT | 41 | 40 | | |
| 15 | CONNECT | 42 | 39 | 43 | |
| | CONNECT | 43 | 42 | 44 | |
| | CONNECT | 44 | 43 | 45 | 46 |
| | CONNECT | 45 | 44 | | |
| | CONNECT | 46 | 44 | 48 | 47 |
| | CONNECT | 47 | 46 | | |
| | CONNECT | 48 | 46 | | |
| 20 | CONNECT | 49 | 40 | 51 | 50 |
| | CONNECT | 50 | 49 | | |
| | CONNECT | 51 | 54 | 49 | 52 |
| | CONNECT | 52 | 53 | 51 | 56 |
| | CONNECT | 53 | 52 | | |
| | CONNECT | 54 | 51 | 55 | |
| | CONNECT | 55 | 54 | 56 | 57 |
| 25 | CONNECT | 56 | 55 | | |
| | CONNECT | 57 | 55 | | |
| | CONNECT | 58 | 52 | 60 | 59 |
| | CONNECT | 59 | 58 | | |
| | CONNECT | 60 | 63 | 58 | 61 |
| | CONNECT | 61 | 62 | 60 | 67 |
| | CONNECT | 62 | 61 | | |
| 30 | CONNECT | 63 | 60 | 64 | |
| | CONNECT | 64 | 63 | 65 | 66 |
| | CONNECT | 65 | 64 | | |
| | CONNECT | 66 | 64 | | |
| | CONNECT | 67 | 61 | 69 | 68 |
| | CONNECT | 68 | 67 | | |
| | CONNECT | 69 | 72 | 67 | 70 |
| 35 | CONNECT | 70 | 71 | 69 | 60 |
| | CONNECT | 71 | 70 | | |
| | CONNECT | 72 | 69 | 73 | |
| | CONNECT | 73 | 72 | 74 | |
| | CONNECT | 74 | 73 | 75 | |
| | CONNECT | 75 | 74 | 76 | |
| | CONNECT | 76 | 75 | 79 | 78 77 |
| 40 | CONNECT | 77 | 76 | | |
| | CONNECT | 78 | 76 | | |
| | CONNECT | 79 | 76 | | |
| | CONNECT | 80 | 70 | 82 | 81 |
| | CONNECT | 81 | 80 | | |
| | CONNECT | 82 | 80 | 83 | 85 |
| | CONNECT | 83 | 84 | 82 | 89 |

45

50

-63-

| | | | | | |
|----|---------|-----|-----|-----|-----|
| | CONNECT | 84 | 83 | | |
| | CONNECT | 85 | 86 | 82 | |
| | CONNECT | 86 | 85 | 87 | 88 |
| 5 | CONNECT | 87 | 86 | | |
| | CONNECT | 88 | 86 | | |
| | CONNECT | 89 | 83 | 91 | 90 |
| | CONNECT | 90 | 89 | | |
| | CONNECT | 91 | 94 | 89 | 92 |
| | CONNECT | 92 | 93 | 91 | 96 |
| | CONNECT | 93 | 92 | | |
| 10 | CONNECT | 94 | 91 | 95 | 97 |
| | CONNECT | 95 | 94 | 96 | |
| | CONNECT | 96 | 95 | | |
| | CONNECT | 97 | 94 | | |
| | CONNECT | 98 | 92 | 100 | 99 |
| | CONNECT | 99 | 98 | | |
| | CONNECT | 100 | 103 | 98 | 101 |
| 15 | CONNECT | 101 | 102 | 100 | 106 |
| | CONNECT | 102 | 101 | | |
| | CONNECT | 103 | 100 | 104 | |
| | CONNECT | 104 | 103 | 105 | |
| | CONNECT | 105 | 104 | | |
| | CONNECT | 106 | 101 | 108 | 107 |
| | CONNECT | 107 | 106 | | |
| 20 | CONNECT | 108 | 111 | 106 | 109 |
| | CONNECT | 109 | 110 | 108 | 118 |
| | CONNECT | 110 | 109 | | |
| | CONNECT | 111 | 106 | 112 | |
| | CONNECT | 112 | 111 | 113 | 114 |
| | CONNECT | 113 | 112 | 115 | |
| | CONNECT | 114 | 112 | 116 | |
| 25 | CONNECT | 115 | 113 | 117 | |
| | CONNECT | 116 | 114 | 117 | |
| | CONNECT | 117 | 115 | 116 | |
| | CONNECT | 118 | 109 | 120 | 119 |
| | CONNECT | 119 | 116 | | |
| | CONNECT | 120 | 123 | 118 | 121 |
| | CONNECT | 121 | 122 | 120 | 126 |
| 30 | CONNECT | 122 | 121 | | |
| | CONNECT | 123 | 120 | 124 | |
| | CONNECT | 124 | 123 | 125 | |
| | CONNECT | 125 | 124 | 126 | 127 |
| | CONNECT | 126 | 125 | | |
| | CONNECT | 127 | 125 | | |
| | CONNECT | 128 | 121 | 130 | 129 |
| 35 | CONNECT | 129 | 128 | | |
| | CONNECT | 130 | 126 | 131 | |
| | CONNECT | 131 | 132 | 130 | 133 |
| | CONNECT | 132 | 131 | | |
| | CONNECT | 133 | 131 | 135 | 134 |
| | CONNECT | 134 | 133 | | |
| | CONNECT | 135 | 133 | 136 | |
| 40 | CONNECT | 136 | 137 | 135 | 138 |
| | CONNECT | 137 | 136 | | |
| | CONNECT | 138 | 136 | 140 | 139 |
| | CONNECT | 139 | 138 | | |
| | CONNECT | 140 | 143 | 138 | 141 |
| | CONNECT | 141 | 142 | 140 | 147 |
| | CONNECT | 142 | 141 | | |
| 45 | CONNECT | 143 | 140 | 144 | |
| 50 | | | | | |

-64-

| | |
|----|-------------------------|
| | CONNECT 144 143 145 146 |
| | CONNECT 145 144 |
| | CONNECT 146 144 |
| | CONNECT 147 141 149 148 |
| 5 | CONNECT 148 147 |
| | CONNECT 149 152 147 150 |
| | CONNECT 150 151 149 156 |
| | CONNECT 151 150 |
| | CONNECT 152 149 153 154 |
| | CONNECT 153 152 155 |
| | CONNECT 154 152 |
| 10 | CONNECT 155 153 |
| | CONNECT 156 150 158 157 |
| | CONNECT 157 156 |
| | CONNECT 158 161 156 159 |
| | CONNECT 159 160 158 165 |
| | CONNECT 160 159 |
| | CONNECT 161 158 162 164 |
| 15 | CONNECT 162 161 163 |
| | CONNECT 163 162 |
| | CONNECT 164 161 |
| | CONNECT 165 159 167 166 |
| | CONNECT 166 165 |
| | CONNECT 167 170 165 166 |
| | CONNECT 168 169 167 174 |
| 20 | CONNECT 169 165 |
| | CONNECT 170 167 171 173 |
| | CONNECT 171 170 172 |
| | CONNECT 172 171 |
| | CONNECT 173 170 |
| | CONNECT 174 168 176 175 |
| | CONNECT 175 174 |
| 25 | CONNECT 176 179 174 177 |
| | CONNECT 177 176 176 182 |
| | CONNECT 178 177 |
| | CONNECT 179 176 180 181 |
| | CONNECT 180 179 |
| | CONNECT 181 179 |
| | CONNECT 182 177 184 183 |
| 30 | CONNECT 183 182 |
| | CONNECT 184 187 182 185 |
| | CONNECT 185 186 184 194 |
| | CONNECT 186 185 |
| | CONNECT 187 184 188 |
| | CONNECT 188 187 189 190 |
| | CONNECT 189 188 191 |
| 35 | CONNECT 190 186 192 |
| | CONNECT 191 189 193 |
| | CONNECT 192 190 193 |
| | CONNECT 193 191 192 |
| | CONNECT 194 185 196 195 |
| | CONNECT 195 194 |
| | CONNECT 196 199 194 197 |
| | CONNECT 197 196 196 203 |
| 40 | CONNECT 198 197 |
| | CONNECT 199 196 200 202 |
| | CONNECT 200 199 201 |
| | CONNECT 201 200 |
| | CONNECT 202 199 |
| | CONNECT 203 209 204 197 |
| 45 | |
| 50 | |

-65-

| | |
|----|-----------------------------|
| | CONNECT 204 207 203 205 |
| | CONNECT 205 206 204 210 |
| | CONNECT 206 205 |
| | CONNECT 207 204 206 |
| 5 | CONNECT 208 207 209 |
| | CONNECT 209 208 203 |
| | CONNECT 210 205 212 211 |
| | CONNECT 211 210 |
| | CONNECT 212 215 210 213 |
| | CONNECT 213 214 212 218 |
| | CONNECT 214 213 |
| 10 | CONNECT 215 212 216 |
| | CONNECT 216 215 217 |
| | CONNECT 217 216 |
| | CONNECT 218 213 220 219 |
| | CONNECT 219 218 |
| | CONNECT 220 223 216 221 |
| | CONNECT 221 222 220 224 |
| 15 | CONNECT 222 221 |
| | CONNECT 223 220 |
| | CONNECT 224 221 226 225 |
| | CONNECT 225 224 |
| | CONNECT 226 229 224 227 |
| | CONNECT 227 228 226 237 |
| | CONNECT 228 227 |
| 20 | CONNECT 229 226 230 |
| | CONNECT 230 229 231 |
| | CONNECT 231 230 232 |
| | CONNECT 232 231 233 |
| | CONNECT 233 232 236 235 234 |
| | CONNECT 234 233 |
| | CONNECT 235 233 |
| 25 | CONNECT 236 233 |
| | CONNECT 237 227 239 238 |
| | CONNECT 238 237 |
| | CONNECT 239 242 237 240 |
| | CONNECT 240 241 239 251 |
| | CONNECT 241 240 |
| | CONNECT 242 239 243 |
| 30 | CONNECT 243 242 244 245 |
| | CONNECT 244 243 246 |
| | CONNECT 245 243 247 |
| | CONNECT 246 244 248 |
| | CONNECT 247 245 248 |
| | CONNECT 248 246 247 249 |
| | CONNECT 249 248 250 |
| 35 | CONNECT 250 249 |
| | CONNECT 251 240 253 252 |
| | CONNECT 252 251 |
| | CONNECT 253 256 251 254 |
| | CONNECT 254 255 253 258 |
| | CONNECT 255 254 |
| | CONNECT 256 253 257 |
| 40 | CONNECT 257 256 253 |
| | CONNECT 258 254 260 259 |
| | CONNECT 259 258 |
| | CONNECT 260 263 258 261 |
| | CONNECT 261 262 260 270 |
| | CONNECT 262 261 |
| 45 | CONNECT 263 260 264 |

-66-

| | |
|----|------------------------|
| | CONECT 264 263 265 |
| | CONECT 265 264 266 267 |
| | CONECT 266 265 |
| | CONECT 267 265 269 268 |
| 5 | CONECT 268 267 |
| | CONECT 269 267 |
| | CONECT 270 261 272 271 |
| | CONECT 271 270 |
| | CONECT 272 275 270 273 |
| | CONECT 273 274 272 278 |
| | CONECT 274 273 |
| 10 | CONECT 275 272 276 277 |
| | CONECT 276 275 |
| | CONECT 277 275 |
| | CONECT 278 273 280 279 |
| | CONECT 279 278 |
| | CONECT 280 283 276 281 |
| | CONECT 281 282 280 286 |
| 15 | CONECT 282 281 |
| | CONECT 283 280 264 285 |
| | CONECT 284 283 |
| | CONECT 285 283 |
| | CONECT 286 281 268 287 |
| | CONECT 287 286 |
| | CONECT 288 291 285 289 |
| 20 | CONECT 289 290 288 293 |
| | CONECT 290 289 |
| | CONECT 291 288 292 |
| | CONECT 292 291 358 |
| | CONECT 293 289 295 294 |
| | CONECT 294 293 |
| | CONECT 295 298 293 295 |
| 25 | CONECT 296 297 295 302 |
| | CONECT 297 296 |
| | CONECT 298 295 299 301 |
| | CONECT 299 298 300 |
| | CONECT 300 299 |
| | CONECT 301 298 |
| | CONECT 302 296 304 303 |
| 30 | CONECT 303 302 |
| | CONECT 304 307 302 305 |
| | CONECT 305 306 304 316 |
| | CONECT 306 305 |
| | CONECT 307 304 308 |
| | CONECT 308 307 309 310 |
| | CONECT 309 308 311 |
| 35 | CONECT 310 308 312 |
| | CONECT 311 309 313 |
| | CONECT 312 310 313 |
| | CONECT 313 311 312 314 |
| | CONECT 314 313 315 |
| | CONECT 315 314 |
| | CONECT 316 305 318 317 |
| 40 | CONECT 317 316 |
| | CONECT 318 321 316 319 |
| | CONECT 319 320 318 328 |
| | CONECT 320 319 |
| | CONECT 321 318 322 |
| | CONECT 322 321 323 325 |
| | CONECT 323 322 326 324 |
| 45 | |
| 50 | |

-67-

| | |
|----|-------------------------|
| | CONNECT 324 323 |
| | CONNECT 325 322 327 |
| | CONNECT 326 323 327 |
| 5 | CONNECT 327 325 326 |
| | CONNECT 328 334 329 319 |
| | CONNECT 329 332 328 330 |
| | CONNECT 330 331 329 335 |
| | CONNECT 331 330 |
| | CONNECT 332 329 333 |
| | CONNECT 333 332 334 |
| 10 | CONNECT 334 333 328 |
| | CONNECT 335 330 337 336 |
| | CONNECT 336 335 |
| | CONNECT 337 340 335 338 |
| | CONNECT 338 339 337 352 |
| | CONNECT 339 338 |
| | CONNECT 340 337 341 |
| | CONNECT 341 340 342 |
| 15 | CONNECT 342 341 343 |
| | CONNECT 343 342 345 344 |
| | CONNECT 344 343 |
| | CONNECT 345 343 346 349 |
| | CONNECT 346 345 348 347 |
| | CONNECT 347 346 |
| | CONNECT 348 346 |
| 20 | CONNECT 349 345 351 350 |
| | CONNECT 350 349 |
| | CONNECT 351 349 |
| | CONNECT 352 338 354 353 |
| | CONNECT 353 352 |
| | CONNECT 354 357 352 355 |
| | CONNECT 355 356 354 359 |
| 25 | CONNECT 356 355 |
| | CONNECT 357 354 358 |
| | CONNECT 358 357 292 |
| | CONNECT 359 355 361 360 |
| | CONNECT 360 359 |
| | CONNECT 361 364 359 362 |
| | CONNECT 362 363 361 362 |
| 30 | CONNECT 363 362 |
| | CONNECT 364 361 365 |
| | CONNECT 365 364 366 367 |
| | CONNECT 366 365 |
| | CONNECT 367 365 |
| | CONNECT 368 362 370 369 |
| | CONNECT 369 368 |
| 35 | CONNECT 370 373 368 371 |
| | CONNECT 371 372 370 377 |
| | CONNECT 372 371 |
| | CONNECT 373 370 374 |
| | CONNECT 374 373 375 376 |
| | CONNECT 375 374 |
| | CONNECT 376 374 |
| 40 | CONNECT 377 371 379 376 |
| | CONNECT 378 377 |
| | CONNECT 379 382 377 380 |
| | CONNECT 380 381 379 369 |
| | CONNECT 381 360 |
| | CONNECT 382 379 383 |
| 45 | CONNECT 383 382 384 385 |
| 50 | |

-68-

5
10
15
20
25
30
35
40
45

CONNECT 384 383 386
CONNECT 385 383 387
CONNECT 386 384 388
CONNECT 387 385 388
CONNECT 388 386 387
CONNECT 389 380 391 390
CONNECT 390 389
CONNECT 391 394 389 392
CONNECT 392 393 391 398
CONNECT 393 392
CONNECT 394 391 395 397
CONNECT 395 394 396
CONNECT 396 395
CONNECT 397 394
CONNECT 398 392 400 399
CONNECT 399 398
CONNECT 400 403 392 401
CONNECT 401 402 400 410
CONNECT 402 401
CONNECT 403 400 404
CONNECT 404 403 405 406
CONNECT 405 404 407
CONNECT 406 404 408
CONNECT 407 405 409
CONNECT 408 406 409
CONNECT 409 407 408
CONNECT 410 401 412 411
CONNECT 411 410
CONNECT 412 415 410 413
CONNECT 413 414 412 419
CONNECT 414 413
CONNECT 415 412 416 418
CONNECT 416 415 417
CONNECT 417 416
CONNECT 418 415
CONNECT 419 413 421 420
CONNECT 420 419
CONNECT 421 424 419 422
CONNECT 422 423 421 425
CONNECT 423 422
CONNECT 424 421
CONNECT 425 422 427 426
CONNECT 426 425
CONNECT 427 430 425 428
CONNECT 428 429 427 435
CONNECT 429 428
CONNECT 430 427 431
CONNECT 431 430 432
CONNECT 432 431 433 434
CONNECT 433 432
CONNECT 434 432
CONNECT 435 428 437 436
CONNECT 436 435
CONNECT 437 440 435 438
CONNECT 438 439 437 443
CONNECT 439 438
CONNECT 440 437 441
CONNECT 441 440 442
CONNECT 442 441
CONNECT 443 449 444 436

-69-

| | |
|----|-------------------------|
| | CONNECT 444 447 443 445 |
| | CONNECT 445 446 444 450 |
| | CONNECT 446 445 |
| 5 | CONNECT 447 444 448 |
| | CONNECT 448 447 449 |
| | CONNECT 449 448 443 |
| | CONNECT 450 445 452 451 |
| | CONNECT 451 450 |
| | CONNECT 452 455 450 453 |
| | CONNECT 453 454 452 458 |
| | CONNECT 454 453 |
| 10 | CONNECT 455 452 456 |
| | CONNECT 456 455 457 |
| | CONNECT 457 456 |
| | CONNECT 458 453 460 459 |
| | CONNECT 459 458 |
| | CONNECT 460 463 458 461 |
| | CONNECT 461 462 460 468 |
| 15 | CONNECT 462 461 |
| | CONNECT 463 460 464 |
| | CONNECT 464 463 465 |
| | CONNECT 465 464 466 467 |
| | CONNECT 466 465 |
| | CONNECT 467 465 |
| | CONNECT 468 461 470 469 |
| 20 | CONNECT 469 468 |
| | CONNECT 470 473 468 471 |
| | CONNECT 471 472 470 477 |
| | CONNECT 472 471 |
| | CONNECT 473 470 474 |
| | CONNECT 474 473 475 476 |
| | CONNECT 475 474 |
| 25 | CONNECT 476 474 |
| | CONNECT 477 483 478 471 |
| | CONNECT 478 481 477 479 |
| | CONNECT 479 480 478 484 |
| | CONNECT 480 479 |
| | CONNECT 481 478 482 |
| | CONNECT 482 481 483 |
| 30 | CONNECT 483 482 477 |
| | CONNECT 484 479 486 485 |
| | CONNECT 485 484 |
| | CONNECT 486 489 484 487 |
| | CONNECT 487 488 486 493 |
| | CONNECT 488 487 |
| | CONNECT 489 486 490 492 |
| 35 | CONNECT 490 489 491 |
| | CONNECT 491 490 |
| | CONNECT 492 489 |
| | CONNECT 493 487 495 494 |
| | CONNECT 494 493 |
| | CONNECT 495 496 493 496 |
| | CONNECT 496 497 495 510 |
| 40 | CONNECT 497 496 |
| | CONNECT 498 495 499 |
| | CONNECT 499 498 500 |
| | CONNECT 500 499 501 |
| | CONNECT 501 500 503 502 |
| | CONNECT 502 501 |
| | CONNECT 503 501 504 507 |
| 45 | |
| 50 | |

-70-

| | |
|----|-------------------------|
| | CONNECT 604 503 506 505 |
| | CONNECT 505 504 |
| | CONNECT 606 504 |
| | CONNECT 507 603 509 508 |
| 5 | CONNECT 608 507 |
| | CONNECT 509 507 |
| | CONNECT 510 496 512 511 |
| | CONNECT 511 610 |
| | CONNECT 512 515 510 513 |
| | CONNECT 513 514 512 526 |
| | CONNECT 614 513 |
| 10 | CONNECT 515 512 516 |
| | CONNECT 516 515 517 518 |
| | CONNECT 617 516 519 |
| | CONNECT 518 516 521 522 |
| | CONNECT 519 517 521 523 |
| | CONNECT 520 519 |
| | CONNECT 521 518 519 523 |
| 15 | CONNECT 522 518 524 |
| | CONNECT 523 521 525 |
| | CONNECT 624 522 525 |
| | CONNECT 525 523 524 |
| | CONNECT 626 513 528 527 |
| | CONNECT 527 526 |
| | CONNECT 528 531 526 529 |
| 20 | CONNECT 529 530 528 536 |
| | CONNECT 530 529 |
| | CONNECT 531 528 532 |
| | CONNECT 532 531 533 534 |
| | CONNECT 533 532 535 |
| | CONNECT 534 532 536 |
| | CONNECT 635 533 537 |
| 25 | CONNECT 536 534 537 |
| | CONNECT 537 535 536 |
| | CONNECT 538 529 540 539 |
| | CONNECT 539 538 |
| | CONNECT 540 543 539 541 |
| | CONNECT 541 542 540 547 |
| | CONNECT 542 541 |
| 30 | CONNECT 543 540 544 545 |
| | CONNECT 544 543 545 |
| | CONNECT 545 544 |
| | CONNECT 546 543 |
| | CONNECT 547 541 549 548 |
| | CONNECT 646 547 |
| | CONNECT 549 552 547 550 |
| | CONNECT 550 551 549 554 |
| 35 | CONNECT 551 550 |
| | CONNECT 552 549 553 |
| | CONNECT 553 552 557 |
| | CONNECT 554 550 556 555 |
| | CONNECT 555 554 |
| | CONNECT 556 559 554 557 |
| 40 | CONNECT 557 558 556 562 |
| | CONNECT 558 557 |
| | CONNECT 559 556 560 561 |
| | CONNECT 560 559 |
| | CONNECT 561 559 |
| | CONNECT 562 557 554 563 |
| | CONNECT 563 552 |
| 45 | |
| 50 | |

-71-

| | |
|----|----------------------------|
| 5 | CONECT 564 567 562 565 |
| | CONECT 565 566 564 571 |
| | CONECT 566 565 |
| | CONECT 567 564 568 |
| | CONECT 568 567 569 570 |
| | CONECT 569 568 |
| | CONECT 570 568 |
| | CONECT 571 565 573 572 |
| | CONECT 572 571 |
| | CONECT 573 576 571 574 |
| | CONECT 574 575 573 584 |
| | CONECT 575 574 |
| 10 | CONECT 576 573 577 |
| | CONECT 577 576 578 |
| | CONECT 578 577 579 |
| | CONECT 579 578 580 |
| | CONECT 580 579 583 582 581 |
| | CONECT 581 580 |
| | CONECT 582 580 |
| 15 | CONECT 583 580 |
| | CONECT 584 574 586 585 |
| | CONECT 585 584 |
| | CONECT 586 589 584 587 |
| | CONECT 587 588 586 593 |
| | CONECT 588 587 |
| | CONECT 589 585 590 |
| 20 | CONECT 590 589 591 592 |
| | CONECT 591 590 |
| | CONECT 592 590 |
| | CONECT 593 587 595 594 |
| | CONECT 594 593 |
| | CONECT 595 598 593 596 |
| | CONECT 596 597 595 601 |
| 25 | CONECT 597 596 |
| | CONECT 598 595 599 |
| | CONECT 599 598 600 |
| | CONECT 600 599 |
| | CONECT 601 595 603 602 |
| | CONECT 602 601 |
| | CONECT 603 606 601 604 |
| 30 | CONECT 604 605 603 609 |
| | CONECT 605 604 |
| | CONECT 606 603 607 608 |
| | CONECT 607 606 |
| | CONECT 608 606 |
| | CONECT 609 604 611 610 |
| | CONECT 610 609 |
| 35 | CONECT 611 614 609 612 |
| | CONECT 612 613 611 618 |
| | CONECT 613 612 |
| | CONECT 614 611 615 617 |
| | CONECT 615 614 616 |
| | CONECT 616 615 |
| | CONECT 617 614 |
| 40 | CONECT 618 612 620 619 |
| | CONECT 619 618 |
| | CONECT 620 623 618 621 |
| | CONECT 621 622 620 629 |
| | CONECT 622 621 |
| | CONECT 623 620 624 |
| 45 | |
| 50 | |

-72-

| | |
|----|-------------------------|
| | CONNECT 624 623 625 |
| | CONNECT 625 624 626 627 |
| | CONNECT 626 625 |
| | CONNECT 627 625 |
| 5 | CONNECT 628 621 630 629 |
| | CONNECT 629 628 |
| | CONNECT 630 633 628 631 |
| | CONNECT 631 632 630 637 |
| | CONNECT 632 631 |
| | CONNECT 633 630 634 636 |
| | CONNECT 634 633 635 |
| | CONNECT 635 634 |
| 10 | CONNECT 636 633 |
| | CONNECT 637 631 639 638 |
| | CONNECT 638 637 |
| | CONNECT 639 642 637 640 |
| | CONNECT 640 641 639 646 |
| | CONNECT 641 640 |
| | CONNECT 642 639 643 |
| 15 | CONNECT 643 642 644 645 |
| | CONNECT 644 643 |
| | CONNECT 645 643 |
| | CONNECT 646 652 647 640 |
| | CONNECT 647 650 646 648 |
| | CONNECT 648 649 647 653 |
| | CONNECT 649 648 |
| 20 | CONNECT 650 647 651 |
| | CONNECT 651 650 652 |
| | CONNECT 652 651 646 |
| | CONNECT 653 648 655 654 |
| | CONNECT 654 653 |
| | CONNECT 655 658 653 656 |
| | CONNECT 656 657 655 670 |
| 25 | CONNECT 657 656 |
| | CONNECT 658 655 659 |
| | CONNECT 659 658 660 |
| | CONNECT 660 659 661 |
| | CONNECT 661 660 663 662 |
| | CONNECT 662 661 |
| | CONNECT 663 661 664 667 |
| 30 | CONNECT 664 663 666 665 |
| | CONNECT 665 664 |
| | CONNECT 666 664 |
| | CONNECT 667 663 669 668 |
| | CONNECT 668 667 |
| | CONNECT 669 667 |
| | CONNECT 670 666 672 671 |
| | CONNECT 671 670 |
| 35 | CONNECT 672 675 670 673 |
| | CONNECT 673 674 672 678 |
| | CONNECT 674 673 |
| | CONNECT 675 672 676 677 |
| | CONNECT 676 675 |
| | CONNECT 677 675 |
| | CONNECT 678 673 680 679 |
| 40 | CONNECT 679 678 |
| | CONNECT 680 683 678 681 |
| | CONNECT 681 682 680 689 |
| | CONNECT 682 681 |
| | CONNECT 683 680 684 |
| 45 | |
| 50 | |

-73-

| | |
|----|-------------------------|
| | CONNECT 684 683 685 686 |
| | CONNECT 685 684 |
| | CONNECT 686 684 688 687 |
| | CONNECT 687 686 |
| 5 | CONNECT 688 686 |
| | CONNECT 689 681 691 690 |
| | CONNECT 690 689 |
| | CONNECT 691 694 689 692 |
| | CONNECT 692 693 691 706 |
| | CONNECT 693 692 |
| | CONNECT 694 691 695 |
| 10 | CONNECT 695 694 695 |
| | CONNECT 696 695 697 |
| | CONNECT 697 696 699 698 |
| | CONNECT 698 697 |
| | CONNECT 699 697 700 703 |
| | CONNECT 700 699 702 701 |
| | CONNECT 701 700 |
| | CONNECT 702 700 |
| 15 | CONNECT 703 699 705 704 |
| | CONNECT 704 703 |
| | CONNECT 705 703 |
| | CONNECT 706 692 706 707 |
| | CONNECT 707 706 |
| | CONNECT 708 711 706 709 |
| | CONNECT 709 710 706 715 |
| 20 | CONNECT 710 709 |
| | CONNECT 711 708 712 714 |
| | CONNECT 712 711 713 |
| | CONNECT 713 712 |
| | CONNECT 714 711 |
| | CONNECT 715 709 717 716 |
| | CONNECT 716 715 |
| 25 | CONNECT 717 720 715 718 |
| | CONNECT 718 719 717 721 |
| | CONNECT 719 718 |
| | CONNECT 720 717 |
| | CONNECT 721 718 723 722 |
| | CONNECT 722 721 |
| | CONNECT 723 726 721 724 |
| 30 | CONNECT 724 725 722 727 |
| | CONNECT 725 724 |
| | CONNECT 726 723 |
| | CONNECT 727 724 729 728 |
| | CONNECT 728 727 |
| | CONNECT 729 732 727 730 |
| | CONNECT 730 731 729 736 |
| 35 | CONNECT 731 730 |
| | CONNECT 732 729 733 734 |
| | CONNECT 733 732 735 |
| | CONNECT 734 732 |
| | CONNECT 735 733 |
| | CONNECT 736 730 733 737 |
| | CONNECT 737 736 |
| 40 | CONNECT 738 741 736 739 |
| | CONNECT 739 740 738 744 |
| | CONNECT 740 739 |
| | CONNECT 741 738 742 |
| | CONNECT 742 741 743 |
| | CONNECT 743 742 |
| | CONNECT 744 739 746 745 |
| 45 | CONNECT 745 744 |
| | CONNECT 746 744 747 |
| | CONNECT 747 748 746 749 |
| | CONNECT 748 747 |
| 50 | |

-74-

| | |
|----|----------------------------|
| | CONECT 749 747 751 750 |
| | CONECT 750 749 |
| | CONECT 751 754 749 752 |
| | CONECT 752 753 751 763 |
| 5 | CONECT 753 752 |
| | CONECT 754 751 755 |
| | CONECT 755 754 756 757 |
| | CONECT 756 755 758 |
| | CONECT 757 755 769 |
| | CONECT 758 756 760 |
| | CONECT 759 757 760 |
| 10 | CONECT 760 758 759 761 |
| | CONECT 761 760 762 |
| | CONECT 762 761 |
| | CONECT 763 752 765 764 |
| | CONECT 764 763 |
| | CONECT 765 766 763 766 |
| | CONECT 766 767 765 771 |
| 15 | CONECT 767 766 |
| | CONECT 768 765 769 |
| | CONECT 769 768 770 |
| | CONECT 770 769 |
| | CONECT 771 766 773 772 |
| | CONECT 772 771 |
| | CONECT 773 776 771 774 |
| 20 | CONECT 774 775 773 763 |
| | CONECT 775 774 |
| | CONECT 776 773 777 |
| | CONECT 777 775 778 779 |
| | CONECT 778 777 780 |
| | CONECT 779 777 781 |
| | CONECT 780 778 782 |
| | CONECT 781 779 782 |
| 25 | CONECT 782 780 781 |
| | CONECT 783 774 785 784 |
| | CONECT 784 783 |
| | CONECT 785 786 783 786 |
| | CONECT 786 787 785 795 |
| | CONECT 787 786 |
| 30 | CONECT 788 785 789 |
| | CONECT 789 788 790 |
| | CONECT 790 789 791 |
| | CONECT 791 790 792 |
| | CONECT 792 791 795 794 793 |
| | CONECT 793 792 |
| | CONECT 794 792 |
| | CONECT 795 792 |
| 35 | CONECT 796 786 796 797 |
| | CONECT 797 796 |
| | CONECT 798 801 795 799 |
| | CONECT 799 800 798 808 |
| | CONECT 800 799 |
| | CONECT 801 798 802 |
| | CONECT 802 801 803 |
| 40 | CONECT 803 802 804 805 |
| | CONECT 804 803 |
| | CONECT 805 803 807 806 |
| | CONECT 806 805 |
| | CONECT 807 805 |
| | CONECT 808 799 810 809 |
| | CONECT 809 808 |
| 45 | CONECT 810 813 806 811 |

- 75 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Temple University - Of The Commonwealth System of Higher Education

5 (ii) INVENTORS: Walsh, Peter N., Baglia, Frank A., Jameson, Bradford A.

(iii) TITLE OF INVENTION: PEPTIDE ANALOGS OF THE ACTIVATED PLATELET BINDING SITE ON FACTOR XI

(iv) NUMBER OF SEQUENCES: 23

10 (v) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Seidel, Gonda, Lavorgna & Monaco, P.C.

(B) STREET: Two Penn Center Plaza, Suite 1800

15 (C) CITY: Philadelphia

(D) STATE: Pennsylvania

(E) COUNTRY: U.S.A.

(F) ZIP: 19102

(vi) COMPUTER READABLE FORM:

20 (A) MEDIUM TYPE: Diskette, 3.50 inch, 720 Kb

(B) COMPUTER: IBM PS/2

(C) OPERATING SYSTEM: MS-DOS

(D) SOFTWARE: WordPerfect 5.1

25 (vii) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:

(B) FILING DATE:

(C) CLASSIFICATION:

(viii) PRIOR APPLICATION DATA:

30 (A) APPLICATION NUMBER: 08/172,002

(B) FILING DATE: 22 December 1993

(ix) ATTORNEY/AGENT INFORMATION:

(A) NAME: Monaco, Daniel A.

(B) REGISTRATION NUMBER: 30,480

35 (C) REFERENCE/DOCKET NUMBER: 6056-194PC

(x) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (215) 568-8383

(B) TELEFAX: (215) 568-8383

- 76 -

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 86 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single stranded
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Ala Cys Ile Arg Asp Ile Phe Pro Asn Thr Val Phe Ala Asp Ser
 5 10 15
 10 Asn Ile Asp Ser Val Met Ala Pro Asp Ala Phe Val Cys Gly Arg
 20 25 30
 15 Ile Cys Thr His His Pro Gly Cys Leu Phe Phe Thr Phe Phe Ser
 35 40 45
 Gln Glu Trp Pro Lys Glu Ser Gln Arg Asn Leu Cys Leu Leu Lys
 50 55 60
 20 Thr Ser Glu Ser Gly Leu Pro Ser Thr Arg Ile Lys Lys Ser Lys
 65 70 75
 Ala Leu Ser Gly Phe Ser Leu Gln Ser Cys Arg
 80 85
 25

(3) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- 30 (A) LENGTH: 32 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single stranded
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Asn Leu Cys Leu Leu Lys Thr Ser Glu Ser Gly Leu Pro Ser Thr
 5 10 15
 35 Arg Ile Lys Lys Ser Lys Ala Leu Ser Gly Phe Ser Leu Gln Ser
 20 25 30
 40 Cys Arg

(4) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- 45 (A) LENGTH: 5 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single stranded
 (D) TOPOLOGY: linear

- 77 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Pro Lys Glu Ser Gln
5

5 (5) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single stranded
- (D) TOPOLOGY: linear

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Thr Ser Glu Ser Gly Leu
5

15 (6) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single stranded
- (D) TOPOLOGY: linear

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Ser Thr Arg Ile Lys Lys Ser Lys Ala Leu Ser Gly Phe Ser
5 10

25 (7) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single stranded
- (D) TOPOLOGY: linear

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Thr Ser Glu Ser Gly Leu
5

35 (8) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single stranded

- 78 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Thr Arg Ile Lys Lys Ser Lys Ala Leu Ser Gly Phe
5 10

5 (9) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single stranded
10 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Cys Ser Glu Ser Gly Cys
5

15 (10) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single stranded
20 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Cys Lys Glu Ser Cys
5

25 (11) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single stranded
30 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Cys Thr Arg Ile Lys Gly Cys
5

35 (12) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single stranded
40 (D) TOPOLOGY: linear

Cys Pro Glu Trp Pro Lys Glu Ser Gln Arg Pro Cys
5 10

(13) INFORMATION FOR SEQ ID NO:12:

(A) LENGTH: 8 amino acids

10

(C) **STRANDEDNESS:** single stranded

(D) **TOPOLOGY:** linear

Cys Gly Asp Ser Asp Ile Asp Cys
5

(14) INFORMATION FOR SEQ ID NO:13:

(A) LENGTH: 31 amino acids

20

(B) TYPE: amino acid

(C) **STRANDEDNESS:** single stranded

(D) **TOPOLOGY:** linear

Phe Thr Cys Val Leu Lys Asp Ser Val Thr Glu Thr Leu Pro Arg
5 10 15

25

Val Asn Arg Thr Ala Ala Ile Ser Gly Tyr Ser Phe Lys Gln Cys
20 25 30

(15) INFORMATION FOR SEQ ID NO:14:

35

(A) LENGTH: 43 amino acids

(B) TYPE: amino acid

(C) **STRANDEDNESS:** single stranded

(D) **TOPOLOGY:** linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

40 Ala Thr Arg Gln Phe Pro Ser Leu Glu His Arg Asn Ile Cys Leu
5 10 15

Leu Lys His Thr Gln Thr Gly Thr Pro Thr Arg Ile Thr Lys Leu
20 25 30

45

Asp Lys Val Val Ser Gly Phe Ser Leu Lys Ser Cys Ala
35 40

- 80 -

(16) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 34 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single stranded
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Ala Gln Ala Ser Cys Asn Glu Gly Lys Gly Lys Cys Tyr Leu Lys
5 10 15
10 Leu Ser Ser Asn Gly Ser pro Thr Lys Ile Leu His Gly Arg Gly
20 25 30
15 Gly Ile Ser Gly

(17) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- 20 (A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single stranded
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

25 His Ser Ile Pro Val Phe
5

(18) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- 30 (A) LENGTH: 12 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single stranded
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

35 Val Leu Lys Cys Ser Val Thr Glu Cys Leu Phe Arg
5 10

(19) INFORMATION FOR SEQ ID NO:18:

40 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single stranded
(D) TOPOLOGY: linear

- 81 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Phe Thr Cys Val Leu Lys Asp Ser Val Thr Glu Thr Leu Pro Arg
5 10 15

5 Val

(20) INFORMATION FOR SEQ ID NO:19:

(i) **SEQUENCE CHARACTERISTICS:**

10 (A) **LENGTH:** 15 amino acids
 (B) **TYPE:** amino acid
 (C) **STRANDEDNESS:** single stranded
 (D) **TOPOLOGY:** linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

Asn Arg Thr Ala Ala Ile Ser Gly Tyr Ser Phe Lys Gln Cys Ser
15 5 10 15

(21) INFORMATION FOR SEQ ID NO:20:

20 (i) SEQUENCE CHARACTERISTICS:

(A) **LENGTH:** 14 amino acids
(B) **TYPE:** amino acid
(C) **STRANDEDNESS:** single stranded
(D) **TOPOLOGY:** linear

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20;

Cys Arg Thr Ala Ala Ile Ser Gly Tyr Ser Phe Lys Gln Cys
5 10

(22) INFORMATION FOR SEQ ID NO:21:

30 (i) **SEQUENCE CHARACTERISTICS:**

(A) **LENGTH:** 12 amino acids
(B) **TYPE:** amino acid
(C) **STRANDEDNESS:** single stranded
(D) **TOPOLOGY:** linear

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21;

Asn Arg Thr Cys Ala Ile Ser Cys Tyr Ser Phe Lys
5 10

40 (23) INFORMATION FOR SEQ ID NO:22:

(i) **SEQUENCE CHARACTERISTICS:**

(A) LENGTH 42 ' 3 "

- 82 -

(C) STRANDEDNESS: single stranded

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

| | | | | | | | | | | | | | | | |
|---|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 5 | Thr | Ala | Glu | Ser | Pro | Ser | Glu | Asp | Pro | Thr | Arg | Trp | Phe | Thr | Cys |
| | | | | 5 | | | | | | 10 | | | | | 15 |

| | | | | | | | | | | | | | | | |
|--|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| | Val | Leu | Lys | Asp | Ser | Val | Thr | Glu | Thr | Leu | Pro | Arg | Val | Asn | Arg |
| | | | | 20 | | | | | | 25 | | | | | 30 |

| | | | | | | | | | | | | | |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 10 | Thr | Ala | Ala | Ile | Ser | Gly | Tyr | Ser | Phe | Lys | Gln | Cys | Ser |
| | | | | 35 | | | | | | 40 | | | |

(24) INFORMATION FOR SEQ ID NO:23:

15

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 85 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single stranded

(D) TOPOLOGY: linear

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23

Claims

5

1. A synthetic peptide consisting essentially of an amino acid sequence from at least 5 to about 80 amino acids in length, which sequence corresponds to a portion of the sequence of the platelet binding site on the heavy chain of factor XI or factor XIa, said peptide having an artificially introduced restricted conformation and the ability to inhibit the binding of platelets to factor XI or factor XIa, or a pharmaceutically acceptable salt of said peptide, and wherein said artificially introduced restricted conformation is provided in part by at least one covalent bond other than a cysteine-cysteine disulfide bond when said peptide consists of an amino acid sequence according to SEQ ID NO:2.

20

2. A composition comprising a peptide attached to a linker sequence from about 1 to 100 amino acids in length, which may be further linked to a detectable label, solid matrix, or carrier, wherein said peptide is a peptide according to claim 1.

25

3. A peptide according to claim 1 wherein the peptide is from 5 to about 45 amino acids in length.

4. A peptide according to claim 3 wherein the peptide is from about 5 to about 20 amino acids in length.

30

5. A peptide according to claim 1 selected from the group of peptides having the following amino acid sequences corresponding to the amino acid sequence of the factor XI heavy chain:

35

amino acids 225-266;

- 84 -

amino acids 248-253.

6. A peptide according to claim 1 wherein the
conformation is restricted by means of at least one cyste-
5 ine-cysteine disulfide bond.

7. A peptide according to claim 1 which compris-
es a sequence according to SEQ ID No:7 and at least one
cysteine-cysteine disulfide bond.

10

8. A peptide according to claim 1 wherein the
restricted conformation is determined from the equilibrium
conformation model comprising the set of coordinates and
connect statement of Appendix 1.

15

9. A synthetic peptide consisting essentially
of an amino acid sequence from at least 5 to about 80 amino
acids in length, which sequence corresponds to a portion of
the sequence of the platelet binding site on the heavy chain
20 of factor XI or factor XIa, said peptide having an artifi-
cially introduced restricted conformation and the ability to
inhibit the binding of platelets by factor XI or factor XIa,
or a pharmaceutically acceptable salt of said peptide,

- 85 -

combinations thereof.

11. A peptide according to claim 10 having an amino acid sequence of D-Cys-(SEQ ID NO:7)-Cys.

5

12. A peptide according to claim 9 wherein the restricted conformation is determined from the equilibrium conformation model comprising the set of coordinates and connect statement of Appendix 1.

10

13. A synthetic peptide consisting essentially of an amino acid sequence from at least 5 to about 80 amino acids in length, which sequence corresponds to a portion of the sequence of the platelet binding site on the heavy chain of factor XI or factor XIa, said peptide having an artificially introduced restricted conformation and the ability to inhibit the binding of platelets by factor XI or factor XIa, or a pharmaceutically acceptable salt of said peptide,

15

wherein said restricted conformation is provided at least in part by at least one artificially introduced covalent bond other than a disulfide bond.

20

14. A peptide according to claim 13 wherein the conformation is restricted at least in part by at least one amide bond.

25

15. A peptide according to claim 13 wherein the conformation is restricted at least in part by at least one toluene-2,4-diisocyanate cross-link between two free amino groups of the peptide.

30

16. A peptide according to claim 14 wherein the conformation is restricted at least in part by at least one amide bond formed between side chains of a lysine residue and a glutamic or aspartic acid residue of the peptide.

35

17. A peptide according to claim 13 wherein the peptide comprises a ...

- 86 -

amino acids 225-266;
amino acids 193-199;
amino acids 226-235;
amino acids 229-233;
5 amino acids 241-246;
amino acids 248-261; and
amino acids 248-253.

18. A peptide according to claim 13, wherein a
10 segment of the sequence of said peptide consists of an amino
acid sequence according to SEQ ID NO:7.

19. A peptide according to claim 13 wherein the
restricted conformation is determined from the equilibrium
15 conformation model comprising the set of coordinates and
connect statement of Appendix 1.

20. A method of designing a peptide analog to the
platelet binding site on the factor XI or factor XIa heavy
20 chain comprising:

determining the distance between two parts
of a molecular model including the platelet binding site at
conformational equilibrium;

25 modifying the primary structure of the plate-
let binding site to restrict the distance between said two
parts to the predetermined distance; and

synthesizing a peptide comprising said modi-
fied primary structure.

30 21. The method of claim 20 wherein the step of
modifying the primary structure comprises introducing one or
more cysteine residues to form an intramolecular disulfide
bond.

35 22. The method of claim 20 wherein the step of

- 87 -

23. A method according to claim 20 wherein the the distance between said two parts is restricted to the predetermined distance by forming an amide bond linking two parts of the primary structure of the platelet binding site.

5

24. The method according to claim 22 wherein the step of modifying the primary structure comprises introducing an amino acid selected from the group consisting of lysine, glutamic acid and aspartic acid and reacting side chains of a lysine with a glutamic or aspartic acid residue to form an amide bond to restrict said two parts to the predetermined distance by internally cross-linking said primary structure.

10

25. The method according to claim 20 wherein the step of modifying the primary structure comprises introducing a toluene-2,4-diisocyanate structure to internally cross-link two free amino groups of the peptide.

15

26. The method according to claim 20 wherein the molecular model comprises the set of coordinates and connect statement of Appendix 1.

20

27. A method of producing a peptide having a restricted conformation comprising:

25

providing a peptide having an amino acid sequence corresponding to a portion of the sequence of the platelet binding site on the factor XI or factor XIa heavy chain;

determining the conformational equilibrium of that portion of the factor XI or factor XIa heavy chain; and

30

introducing a covalent modification into the peptide to restrict a distance between two parts of the peptide to a distance between two corresponding parts of the peptide in the equilibrium conformation determined.

35

28. The method of claim 27 wherein the modification comprises one or more cysteine residues capable

- 88 -

of forming an intramolecular cysteine-cysteine disulfide bond.

5 29. The method according to claim 27 wherein the modification comprises an amide bond cross-linking two parts of the peptide.

10 30. The method according to claim 29 wherein the modification comprises an amide bond cross-linking a lysine residue and a glutamic or aspartic acid residue.

15 31. The method according to claim 27 wherein the modification comprises a molecule of toluene-2,4-diisocyanate linking two amino groups.

20 32. The method according to claim 27 wherein the equilibrium conformation is determined according to the set of coordinates and connect statement of Appendix 1.

 33. A pharmaceutical composition comprising one or more peptides of claim 1 and a pharmaceutically acceptable carrier.

25 34. A pharmaceutical composition comprising a peptide of claim 4 and a pharmaceutically acceptable carrier.

30 35. A pharmaceutical composition comprising one or more peptides of claim 8 and a pharmaceutically acceptable carrier.

35 36. A pharmaceutical composition according to claim 33 further comprising a second synthetic peptide having an amino acid sequence from at least 5 to about 50 amino acids in length wherein the amino acid sequence of said peptide corresponds to a portion of the sequence of the binding site for high molecular weight kininogen on the heavy chain of XI, which peptide has an artificially restricted conformation and the ability to inhibit the binding of factor

- 89 -

XI to high molecular weight kininogen, or a pharmaceutically acceptable salt of said peptide.

5 37. A pharmaceutical composition according to claim 36 wherein the restricted conformation of said second peptide is determined from the equilibrium conformation model comprising the set of coordinates and connect statements of Appendix 2.

10 38. A pharmaceutical composition according to claim 36 wherein the restricted conformation of said second peptide is provided at least in part by at least one cysteine-cysteine disulfide bond, wherein at least one of the cysteine residues which form the disulfide bond is not present in the native amino acid sequence of the heavy weight kininogen binding site on the heavy chain of factor XI or factor XIa.

15 39. A pharmaceutical composition according to claim 36 wherein the restricted conformation of said second peptide is provided at least in part by at least one artificially introduced covalent bond other than a disulfide bond.

25 40. A pharmaceutical composition according to claim 39 wherein the conformation of said second peptide is restricted at least in part by at least one amide bond.

30 41. A pharmaceutical composition according to claim 39 wherein the conformation of said second peptide is restricted at least in part by at least one toluene-2,4-diisocyanate cross-link between two free amino groups of said second peptide.

35 42. A pharmaceutical composition according to claim 40 wherein the conformation of said second peptide is restricted at least in part by at least one amide bond formed between side chains of a lysine residue and a glutamic or aspartic acid residue of the peptide.

- 90 -

43. A pharmaceutical composition according to claim 36 wherein said second peptide comprises an amino acid sequence selected from the group consisting of:

5 SEQ ID NO:13;
 SEQ ID NO:17;
 SEQ ID NO:18;
 SEQ ID NO:19;
 SEQ ID NO:20;
 SEQ ID NO:21; and
10 SEQ ID NO:22.

44. A method of inhibiting factor XIa-induced activation of factor IX on the surface of platelets comprising contacting platelets with one or more synthetic peptides
15 comprising an amino acid sequence corresponding to a portion of the sequence of the platelet binding site on the heavy chain of factor XI, said peptide having a restricted conformation and the ability to inhibit the binding of platelets by factor XI or by factor XIa.

20
45. A method according to claim 44 wherein the conformation of said peptide is restricted at least in part by at least one a cysteine-cysteine disulfide bond, wherein at least one of the cysteine residues which form the disulfide bond is not present in the native amino acid sequence
25 of the platelet binding site on the heavy chain of factor XI or factor XIa.

30 46. A method according to claim 44 wherein the restricted conformation of said peptide is provided at least in part by at least one artificially introduced covalent bond other than a cysteine-cysteine disulfide bond.

35 47. A method according to claim 44 wherein the restricted conformation of said the peptide is provided at least in part by at least one artificially introduced amide

- 91 -

48. A method according to claim 44 wherein the peptide is selected from the group of peptides having amino acid sequences selected from the group of sequences consisting of:

5 D-Cys-(SEQ ID NO:7)-Cys;
SEQ ID NO:8;
SEQ ID NO:9;
SEQ ID NO:10;
SEQ ID NO:11;
10 SEQ ID NO:12; and
combinations thereof.

49. A method according to claim 44 further comprising contacting platelets with a second synthetic peptide
15 comprising an amino acid sequence from at least 5 to about 50 amino acids in length wherein the amino acid sequence of said second peptide corresponds to a portion of the sequence of the binding site for high molecular weight kininogen on the heavy chain of XI, which second peptide has an arti-
20 ficially restricted conformation and the ability to inhibit the binding of factor XI to high molecular weight kininogen, or a pharmaceutically acceptable salt of said second peptide.

50. A method according to claim 49 wherein the
25 restricted conformation of said second peptide is determined from the equilibrium conformation model comprising the set of coordinates and connect statements of Appendix 2.

51. A method according to claim 49 wherein the
30 restricted conformation of said second peptide is provided at least in part by at least one artificially introduced covalent bond other than a disulfide bond.

52. A method according to claim 49 wherein the
35 conformation of said second peptide is restricted at least in part by at least one amide bond.

53. A method according to claim 49 wherein the conformation of said second peptide is restricted at least

- 92 -

in part by at least one toluene-2,4-diisocyanate cross-link between two free amino groups of said second peptide.

54. A method according to claim 49 wherein the
5 conformation of said second peptide is restricted at least in part by at least one amide bond formed between side chains of a lysine residue and a glutamic or aspartic acid residue of the peptide.

10 55. A method according to claim 49 wherein said second peptide comprises an amino acid sequence selected from the group consisting of:

SEQ ID NO:13;
SEQ ID NO:17;
15 SEQ ID NO:18;
SEQ ID NO:19;
SEQ ID NO:20;
SEQ ID NO:21; and
SEQ ID NO:22.

20 56. A method of inhibiting the binding of platelets to factor XI or factor XIa comprising contacting platelets with one or more synthetic peptides comprising an amino acid sequence corresponding to a portion of the sequence of
25 the platelet binding site on the heavy chain of factor XI, said peptide having a restricted conformation and the ability to inhibit the binding of platelets to factor XI or to factor XIa.

30 57. A method according to claim 56 wherein the peptide is selected from the group of peptides having amino acid sequences selected from the group of sequences consisting of:

D-Cys-(SEQ ID NO:7)-Cys;
35 SEQ ID NO:8;
SEQ ID NO:9;

- 93 -

combinations thereof.


58. A method according to claim 56 further comprising contacting platelets with a second synthetic peptide comprising an amino acid sequence from at least 5 to about 50 amino acids in length wherein the amino acid sequence of said second peptide corresponds to a portion of the sequence of the binding site for high molecular weight kininogen on the heavy chain of XI, which second peptide has an artificially restricted conformation and the ability to inhibit the binding of factor XI to high molecular weight kininogen, or a pharmaceutically acceptable salt of said second peptide.

59. A method for inhibiting thrombosis comprising administering to a mammal in need of such treatment an effective amount of one or more synthetic peptides comprising an amino acid sequence corresponding to a portion of the sequence of the platelet binding site on the heavy chain of factor XI, said peptide having a restricted conformation and the ability to inhibit the binding of platelets to factor XI or to factor XIa.

60. A method according to claim 59 wherein said synthetic peptide is a peptide according to claim 1.


61. A method according to claim 59 further comprising administering to a mammal in need of such treatment an effective amount of a second synthetic peptide comprising an amino acid sequence from at least 5 to about 50 amino acids in length wherein the amino acid sequence of said second peptide corresponds to a portion of the sequence of the binding site for high molecular weight kininogen on the heavy chain of XI, which second peptide has an artificially restricted conformation and the ability to inhibit the bind-

FIG. 1



2/2

FIG. 2



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/13885

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07K 7/00, 7/06, 7/08, 14/00; A61K 38/08, 38/10, 38/16

US CL : 530/330, 329, 328, 327, 326, 325, 324; 514/12, 13, 14, 15, 16, 17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/330, 329, 328, 327, 326, 325, 324; 514/12, 13, 14, 15, 16, 17

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, CAS ONLINE, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|--|-----------------------|
| A | Blood, Volume 79, No. 2, issued 15 January 1992, R. Rawala-Sheikh, "Role of γ -Carboxyglutamic Acid Residues in the Binding of Factor IXa to Platelets and in Factor-X Activation", pages 398-405, see entire document. | 1-61 |
| A | Biochemistry, Volume 25, issued 1986, A. D. Turner, " p -Amidino Esters as Irreversible Inhibitors of Factors IXa and Xa and Thrombin", pages 4929-4935, see entire document. | 1-61 |



Further documents are listed in the continuation of Box C.



See patent family annex.

| | |
|---|--|
| * Special categories of cited documents: | * later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| *A* document defining the general state of the art which is not considered to be of particular relevance | *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| *E* earlier document published on or after the international filing date | *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | *Z* document member of the same patent family |
| *O* document referring to an oral disclosure, use, exhibition or other means | |
| *P* document published prior to the international filing date but later than the priority date claimed | |

Date of the actual completion of the international search

20 MARCH 1995

Date of mailing of the international search report

30 MAR 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

CAROL A. SALATA

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/13885

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|--|-----------------------|
| A | The Journal of Biological Chemistry, Volume 267, No. 5, issued 15 February 1992, J. Astermark, "Effects of γ -Carboxyglutamic Acid and Epidermal Growth Factor-like Modules of Factor IX on Factor X Activation", pages 3249-3256, see entire document. | 1-61 |
| A | The Journal of Biological Chemistry, Volume 267, No. 12, issued 25 April 1992, S. S. Ahmad, "The Role of the First Growth Factor Domain of Human Factor IXa in Binding to Platelets and in Factor X Activation", pages 8571-8576, see entire document. | 1-61 |
| A | The Journal of Biological Chemistry, Volume 266, No. 35, issued 15 December 1991, F. A. Baglia, "Identification and Chemical Synthesis of a Substrate-binding Site for Factor IX on Coagulation Factor XIa", pages 24190-24197, see entire document. | 1-61 |